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Short Abstract 
 
One of the main goals of the ISISEMD project is to offer innovative ICT services to improve the 
quality of life of elderly persons with cognitive problems or mild dementia and their informal and 
formal caregivers who provide every day care for them. This will be done via integrating intelligent 
scalable ICT services which will be tested for a period of 12 months under realistic conditions. 
Offering the services could not be complete without evaluating quality of life improvement, user 
acceptance and user satisfaction with a representative group of the target user groups. This document 
is devoted to describing important aspects of services evaluation such as: who the test participants will 
be, inclusion and exclusion criterion, selection standards, how the test participants will be recruited, 
ethical considerations, etc. Test methodology, test objectives, evaluation parameters, work plan for the 
tests, test tasks and test scenarios are further presented. 
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Section 1 -  Executive summary  
 
1.1 Description of the deliverable purpose and content  
 
One of the main goals of the ISISEMD project is to offer innovative ICT services to improve the 
quality of life of elderly persons with cognitive problems or mild dementia and their caregivers who 
provide the daily care for them. This will be done via integrating intelligent scalable ICT services to be 
tested for a period of 12 months under realistic conditions with a total of 80 test volunteers in four 
countries in Europe – Denmark, Greece, Finland, and North Ireland. The primary user group of these 
services will be the elderly person with mild cognitive impairments or mild dementia who actually 
will be using the services, a single individual; “the well-being person”. This group directly benefits 
from ISISEMD innovative services by increased quality of life. The secondary users will be persons or 
organisations being in direct contact with the primary end user, such as formal and informal care 
persons, family members, care organisations and their representatives. This group benefits from the 
scalable ISISEMD services directly, when using the services (at a primary end user’s home or 
remotely) and indirectly, when the care needs of primary end users are reduced.  
To work with a representative sample of the primary end-users, the recruitment of ISISEMD trial 
participants for the pilot services will follow strongly defined inclusion and exclusion criteria. The 
World Health Organization (2007) International Classification of Diseases (ICD-10) will be used to 
classify dementia type and level with the aid of the Montreal Cognitive Assessment (MoCA) to 
determine cognitive decline. The main inclusion criterion for the primary users is the stage of disease 
(level of with cognitive decline). More specifically, adults over 60 years of age diagnosed with 
stage two (Age Associated Memory Impairment) to four (Mild Dementia), according to The 
Global Deterioration Scale (GDS), developed by Dr. Barry Reisberg.   
ISISEMD services will be offered in three-level service bundles, which are demand-driven and user-
oriented. They will offer daily technological support to seniors with mild dementia in a way which 
increases their quality of life by allowing them to live safely and independently in their homes and 
decreasing social isolation. Offering the services could not be complete without their evaluation and 
validation. The evaluation parameters concerning the users’ side are assessing cognitive functioning, 
quality of life improvement, user acceptance, ease of use and user satisfaction with a representative 
group of the three target user groups.  
Test objectives will be to evaluate the effects and the efficiency of ISISEMD services, find out how 
success/failure is correlated with a certain group of the users, identify the most successful and most 
preferable service, find out which parameters are most important for user satisfaction/acceptance, and 
find out what should be improved in the services for future application and research.  
ISISEMD will utilize the Quality of Life – Alzheimer’s disease, or QOL-AD, [Logsdon, 2002] 
measurement tool to assess QOL improvement for primary end-users. The QOL-AD is a 13-item 
questionnaire designed to elicit patient and caregiver reports of patient QOL, specific to a home care 
situation.  
Considering that informal caregivers are heavily involved in the daily care of elderly citizens with 
dementia, they experience substantial stress from the care giving tasks they perform. Improving QOL 
of informal caregivers will be measured using Glozman rating scale - Scale of Quality of Life of Care-
Givers (SQLC) [Glozman, 1998]. SQLC evaluates both qualitatively and quantitatively the principal 
levels of the subject’s activities: (a) professional activity of the care-giver, (b) social and leisure 
activities, (c) responsibilities of the care-giver to help the patient in everyday living. Zarit Burden 
Interview (ZBI) for evaluation of the care burden and Caregiver Activity Survey (CAS) for evaluation 
of the time spent by relative for caring for adult with mild dementia will be also used.  
User acceptance, satisfaction and ease of use will be assessed utilizing a proposed method called 
“Triangulation of the three methods”. The test methodology will include questionnaires, 
participation observations, qualitative and quantitative interviews use case description and analysis. To 
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assess the user acceptance and satisfaction with the use assistive technology, specifically designed 
ISISEMD questionnaire will be administered. It is inspired by QUEST 2.0 and ETUQ instruments, 
which has specific focus on daily use of assistive technology and for adults with mild dementia 
[Demers, 2002], [Nygård, 2002], [Rosenberg, 2009].   
Validation of the services will be carried out in two stages – small-scale and large-scale validation. 
The services will be first tested in a smaller scale, with a few end-users at each site for 2 months, in 
order to identify if major problems exist before the large scale testing with all users during the rest of 
the testing period until end of the pilot phase of the project. To allow for iterative evaluation, there will 
be initial, mid-term and final assessment. The work plans for the pilots describe exactly which tests 
will be administered to which group of target users and at what time. Based on assessing QOL 
improvement from the final evaluation, cost-utility analysis for these tele-care services will be carried 
out.  
This report is organised as follows: 
Section 2 describes the profiles of the target test groups – the seniors with cognitive problems or mild 
dementia, the formal and informal care-givers. Section 3 presents inclusion and exclusion criteria for 
the test participants from the three target user groups. Section 4 describes ISISEMD services, service 
scenarios and the equipment to be used. Section 5 provides substantial information about conducting 
the tests – test methodology, test objectives, preparation of the test environment, how support to the 
users will be provided, written material to be presented to the test participants, interview guides for 
collecting user feedback, etc. The report is concluded in Section 6. In the Appendix Section, 
supporting materials for the trial protocol are presented.  
 
1.2 Deviation from objectives 
 
There is no deviation from objectives. However, the following must be noted:  
The preliminary version of the document was submitted in M06 because at that stage of the project 
(M06) the services to be integrated in the ISISEMD system were only selected. The system was not 
yet integrated and installed at the pilot sites. Therefore, complete planning for the testing and 
preparation of the testing material could not be done in M06.  
This is the final version of this report. In this final version detailed test planning was be described, 
such as which services will be tested in each region, tasks to be tested, test scenarios, and necessary 
written test material was be presented.  
 
Specifically, the following updates were done:  
Added 3.1.5.2 – information about demo rooms  
In 5.3.5 – added information about CAS instrument – Caregiver Activity Survey (CAS) 
Added section in 5.4.4 – information about parameters for CAS instrument 
Table 6 was updated, Table 8 was updated 
Added Figure 1- with indicative floor plan of equipment  
Table 9 was updated, Table 13 was updated 
Sect. 5.2 was updated with list of trial hypothesis  
Added Sect. 3.1.8 - Forming of test and control groups by random selection  
Sect. 5.9 – updated text and figure  
Sect. 5.10 – new input, Sect. 5.11 – new input, Sect. 5.12 – new input, Sect. 5.13 – new input 
Section 6 – conclusions was updated 
New appendixes were added with testing instruments, examples of test scenarios, screen shots from 
user guides, Separate consent form for Outdoor Guard service was added in the appendix section.  
 
1.3 If relevant: corrective actions 
N/A  
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Section 2 -  Description of Target User Groups   
 
The goal of this section is to define who the target user groups of ISISEMD services are, to describe 
the profile of the three user groups - their everyday needs, their limitations, and to provide 
information about the stages of dementia for which ISISEMD services will be focused. 
 
Home care is labour-intensive and depends on an assortment of sources to provide a variety of clinical, 
psychological and social services in the home setting. These providers are a combination of 
professional and non-professional personnel, such as volunteers, spouses, dieticians, physicians, social 
workers, therapists, nurses and home care assistants. Historically, home care across all European 
countries has relied heavily on informal care giving. The central networks of family and kin remain a 
uniform theme in all European welfare systems [WHO Europe, 2008]. When services and care are 
brought to the person so that they can continue to live in one place safely, comfortably and 
independently regardless of ability level, it is referred to as Aging in Place (National Aging in Place 
Council, 2008). 
 
In ISISEMD project, we distinguish the following end-user groups: 
 
- Primary end-user - the old person who actually is using service, a single individual, “the well-being 
person”. This group directly benefits from the project by increased quality of life.  
 
- Secondary end-users - persons or organisations directly being in contact with the primary end-user, 
such as formal and informal care persons, family members, friends, care organisations and their 
representatives. This group benefits from project directly when using the services (at a primary end-
user’s home or remote) and indirectly when the care needs of primary end users are reduced.  
As for demand it combines requirements of primary and secondary end-users: old citizens (in general 
and the ones having mild dementia), the closest family members and the professional care-givers. In 
more details they are explained below: 
• Elderly People in general: Generally they need an intelligent system that enables them to 
enjoy comfort, convenient and secure home environment. To prevent their social isolation and 
to help them to maintain their relations with friends and families.  
• Elderly People with mild dementia: Most of these people have difficulty in their everyday 
life which sometimes comes due to cognitive problems and mild dementia. However, these 
people want to be independent from their relatives, to be social and generally enjoy their own 
life. This can be fulfilled by the smart home that facilitates their life and makes them feel 
secure and safe. Additionally, to stop the regression or keeping the brain status at the same 
level, cognitive training could help to delay their situation to become worse.  
• Closest family members (informal care-givers) – very often the closest family members are 
the direct care-givers and supporters in the daily care for the clients. They would like to take 
care of their loved ones in a more efficient way, helping them to reduce their own burden and 
their own stress. They would also like to enjoy their life and maintain their social network.  
• Professional care-givers: They want at any time to have overview of their client’s conditions. 
To be able to send them simple instructions, reminders and alarms.  
 
Based on these main user groups, the test groups with which the functionality of the scalable services 
will be evaluated and validated are divided in test groups.  
The test groups will be  
• Test group EP - of primary end users – elderly people with cognitive problems or mild 
dementia, as well as normal elderly people 
• Test group ICG - of secondary end users – informal care givers. This includes closes 
family members who take care of the senior 
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• Test group FCG - of secondary end users – formal care givers. This test group includes 
home care personnel and specialised dementia care giver personnel  
 
2.1 What is dementia?  
 
In ISISEMD Del 1.1.1 “User & System Requirements” and Del 1.1.2 “User & System Requirements 
updated version”, detailed definition for dementia is presented. The main stages of dementia for which 
ISISEMD services will be offered, have been described. In this section, for the sake of completeness, 
we briefly revisit them again. 
 
Dementia is not a specific disorder or disease. It is a syndrome (group of symptoms) associated with a 
progressive loss of memory and other intellectual functions that is serious enough to interfere with 
performing the tasks of daily life. Dementia can occur to anyone at any age from an injury or from 
oxygen deprivation, although it is most commonly associated with aging. It is the leading cause of 
institutionalization of older adults. Dementia is an overall decline in intellectual function, including 
difficulties with language, simple calculations, planning and judgment, and motor (muscular 
movement) skills as well as loss of memory. 
 
According to the World Health Organization’s International Classification of Diseases 
(http://apps.who.int/classifications/apps/icd/icd10online/), ICD-10, DEMENTIA is evidence of each 
of the following, each of them characterised with a number of stages: 
 
(1) G1 - A decline in memory, which is most evident in the learning of new information, 
although in more severe cases, the recall of previously learned information may be also 
affected. The impairment applies to both verbal and non-verbal material. 
(2) G2 -  A decline in other cognitive abilities characterized by deterioration in judgement and 
thinking, such as planning and organizing, and in the general processing of information  
(3) G3. A decline in emotional control or motivation, or a change in social behaviour, manifest as 
at least one of the following:  
(1) emotional ability; 
(2) irritability; 
(3) apathy; 
(4) coarsening of social behaviour. 
(1) G4. For a confident clinical diagnosis, G1 should have been present for at least six months; if 
the period since the manifest onset is shorter, the diagnosis can only be tentative.  
 
Dementia can be caused by nearly forty different diseases and conditions, ranging from dietary 
deficiencies and metabolic disorders to head injuries and inherited diseases.  
One of the categorisations of dementia is Primary dementia. These dementias are characterized by 
damage to or wasting away of the brain tissue itself. They include Alzheimer's disease (AD), frontal 
lobe dementia (FLD), and Pick's disease.  
 
The information for dementia is found in http://www.who.int/classifications/icd/en/GRNBOOK.pdf. 
Dementia definition starts on page 45 of document, below is pasted from document. 
 
Very general, the severity of the decline is defined as follows: 
 
G1. Evidence of each of the following: 
 
(1) A decline in memory, which is most evident in the learning of new information, although in more 
severe cases, the recall of previously learned information may be also affected. The impairment 
applies to both verbal and non-verbal material. The decline should be objectively verified by obtaining 
a reliable history from an informant, supplemented, if possible, by neuropsychological tests or 
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quantified cognitive assessments. The severity of the decline, with mild impairment as the threshold 
for diagnosis, should be assessed as follows: 
 
Mild: a degree of memory loss sufficient to interfere with everyday activities, though not so severe as 
to be incompatible with independent living (see comment on cultural aspects of "independent living" 
on page 24). The main function affected is the learning of new material. For example, the individual 
has difficulty in registering, storing and recalling elements in daily living, such as where belongings 
have been put, social arrangements, or information recently imparted by family members. 
Moderate: A degree of memory loss which represents a serious handicap to independent living. Only 
highly learned or very familiar material is retained. New information is retained only occasionally and 
very briefly. The individual is unable to recall basic information about where he lives, what he has 
recently been doing, or the names of familiar persons. 
Severe: a degree of memory loss characterized by the complete inability to retain new information. 
Only fragments of previously learned information remain. The subject fails to recognize even close 
relatives. 
 
(2) A decline in other cognitive abilities characterized by deterioration in judgement and thinking, 
such as planning and organizing, and in the general processing of information. Evidence for this 
should be obtained when possible from interviewing an informant, supplemented, if possible, by 
neuropsychological tests or quantified objective assessments. Deterioration from a previously higher 
level of performance should be established. The severity of the decline, with mild impairment as the 
threshold for diagnosis, should be assessed as follows: 
 
Mild. The decline in cognitive abilities causes impaired performance in daily living, but not to a 
degree making the individual dependent on others. More complicated daily tasks or recreational 
activities cannot be undertaken. 
Moderate. The decline in cognitive abilities makes the individual unable to function without the 
assistance of another in daily living, including shopping and handling money. Within the home, only 
simple chores are preserved. Activities are increasingly restricted and poorly sustained. 
Severe. The decline is characterized by an absence, or virtual absence, of intelligible ideation. 
The overall severity of the dementia is best expressed as the level of decline in memory or other 
cognitive abilities, whichever is the more severe (e.g. mild decline in memory and moderate decline in 
cognitive abilities indicate a dementia of moderate severity). 
 
Dementia is specified here as having a minimum duration of six months to avoid confusion with 
reversible states with identical behavioural syndromes, such as traumatic subdural haemorrhage 
(S06.5), normal pressure hydrocephalus (G91.2) and diffuse or focal brain injury (S06.2 and S06.3). 
 
In ICD-10, dementia is classified under  
F00-F09 - Organic, including symptomatic, mental disorders 
 
There are many different types of dementia, presented below: 
F00 Dementia in Alzheimer's disease 
F01Vascular dementia 
F02Dementia in other diseases classified elsewhere 
F03Unspecified dementia 
F04Organic amnesic syndrome, not induced by alcohol and other psychoactive substances 
F05Delirium, not induced by alcohol and other psychoactive substances 
F06Other mental disorders due to brain damage and dysfunction and to physical disease 
F07Personality and behavioural disorders due to brain disease, damage and dysfunction 
F09Unspecified organic or symptomatic mental disorder 
 
Additionally,  
F06.7Mild cognitive disorder 
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The main feature is a decline in cognitive performance. This may include memory impairment, 
learning or concentration difficulties. Objective tests usually indicate abnormality. The symptoms 
are such that a diagnosis of dementia (F00-F03), organic amnesic syndrome (F04) or delirium 
(F05.-) cannot be made. 
 
One important thing to be kept in mind for the services offered by ISISEMD to elderly with 
mild dementia is: 
• Each person with dementia is a unique individual with their own individual experiences of 
life, their own needs and feelings, and their own likes and dislikes. 
• Although some symptoms of dementia are common, dementia affects each person in different 
ways. 
These two very important specifics of the dementia lead to very challenging work for the ISISEMD 
partners w.r.t. the offered services, their acceptance, testing and evaluation.  
 
2.1.1 Symptoms of cognitive problems or mild dementia  
 
In regard to the Primary End User Group, the major symptoms of dementia are: 
 
• Weak memory (forget to eat, drink, take medicine, forget appointments, etc.) 
• Difficulty performing well-known tasks 
• Difficulty creating the structure of the day 
• Confusion 
• Difficulty concentrating  
• Reduced speaking ability  
• Disorientation for time and place  
• Problems with abstract thinking 
• Reduced or poor ability to judge  
• Reduced ability to understand numbers and to calculate  
• Reduced ability to understand senses and feelings  
• Change in mood and behaviour  
• Changed personality and feelings  
• Reduced own initiative 
 
2.1.2 Difficulties experienced by persons with cognitive problems or mild dementia in daily living  
 
The following is based on input from the [Dementia North, 2008]. Problems/ difficulties which elderly 
with cognitive problems or mild dementia experience very often depending on the stage of the illness: 
• Increasingly unstable short-term memory 
• Forget to take medicine (which prescription, amount and time schedule) 
• Forget appointments 
• Forget the names of well-known people 
• Forget what they are looking for  
• Forget wallet when going shopping  
• Forget what to purchase 
• Difficulty maintaining tasks and structure of the day 
• Disorientation for time (day, month, time of the day) 
• Disorientation for place 
• Inability to prepare meals and remember when to eat 
• Decreased personal hygiene 
• Difficulties to unlock the door when returning home 
• Difficulties dressing in clothes (how to dress as well as appropriateness) 
• Difficulties reading and judging time 
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• Difficulties using a normal telephone Mismanagement of finances 
• Forget kitchen equipment switched on 
• Forget past events, details, birthdays  
• Difficulties for orientation in unknown places  
• Socially isolated because of their illness  
• Forget keys for the home before going out 
• Difficulties managing appointments on their own 
• Difficulty reading and comprehending  
 
In the following subsections, more details for the profile of the user groups are presented. 
 
2.2 Profile of Primary end user group  
 
Some preliminary ideas for the profile of the user groups have been drafted in Description of Work. 
They are presented in the Table 1 below: 
 
Table 1: General user profiles for the three test groups 
Range of 
User 
Profile 
Group end-users (EP) Group of informal 
caregivers (ICG) 
Group of formal 
caregivers (FCG) 
Gender Both genders; preferably 50% 
females  
Both genders; statistically 
female 
Statistically female  
Age 60-90 years old Adults over 18 years old. 
However, two main age 
groups: 
• 60-90 years old (if 
partner) 
• 18-45 years old (if 
children or grand 
children)  
No limitation, usually 
20 – 50 years old  
Cognitive 
decline  
Dementia stage 2-4  No No  
Health 
needs 
Very often have another chronic 
disease  
Some of them may also 
have health needs 
N/A 
Care needs - General older adult needs 
- elderly subjects with mild 
dementia  
The care needs – 
- self-care 
- medication self-management  
- meals self-management  
- activity reminders  
- needs to feel safety at home 
- social needs  
Some of them may also 
have care needs 
N/A 
Needed 
type of 
service/ 
technology 
- Self-care  
- Home safety  
- Cognitive training (reminders) 
- Medication self-management  
- Communication with care-givers  
- Social interaction  
-unobtrusive monitoring 
- 2 way Notification 
service 
- 2 way Communication 
service 
- location notification 
service  
- emergency notification 
service  
- unobtrusive 
monitoring  
- 2 way Notification 
service;  
- 2 way 
Communication 
service 
- emergency 
notification service 
- location notification 
service (if permission 
 
 
ISISEMD/WP 3/Del 3.3.2-update/Task 3.3                          CIP-ICT-PSP 238914 ISISEMD
 
 
ID: C:\Documents and 
Settings\kjeld\Dokumenter\ISISEMD\Deliverables\ISISEMD_D3.3.2_NDEU_v.2.doc 
Date:  Sunday, 31 January 2010  
Revision: v 1.3 Security: Confidential 
Last saved by AIM Page 14 of 119 
 
is given by the elderly) 
- re-planning of tasks 
service  
Use of 
technology 
In most of the cases  
- Not very used with everyday 
communication via internet 
and ,  
- No computer literacy  
- Not very used with mobile 
phones  
- Primary means of 
communication is a fixed line 
telephone   
Depending on the age –  
- Either like EP 
- Or like FCG 
Everyday use of  
- Desktop 
Computer 
- Internet 
- Mobile phones 
- PDA 
 
 
2.3 Profile of Secondary user group – informal caregivers ICG  
 
Informal care giving by family and friends serves as the backbone for long-term care. For individuals 
whose conditions have resulted in chronic illness or disability, access to help with daily activities such 
as meal preparation, bathing or transportation involves a considerable amount of time, devotion, 
perseverance and patience. ICG are usually female, family members between the ages of 45 and 65, 
without gainful employment (or with part-time employment) and lower educational and 
socioeconomic levels [Carretero, 2008]. The most common ICG is a middle-aged daughter caring for 
an aging parent; second most common is elderly wives providing assistance to husbands [WHO 
Europe, 2008].  
Care giving is normally delivered in the residence of the dependent person on a continual, intense, 
daily basis ranging from personal safety to psychological support. Total hours of care giving per week 
can easily exceed national standards for full-time employment. Assistance is generally provided by a 
single caregiver and responsibility often lasts for years, with approximate average at 5 years [Family 
Caregiver, 2001].    
The majority of informal care burdens fall upon these persons who do not possess any formal training 
about care and who do not receive any economic retribution for these tasks. As individuals or as a 
society, we cannot afford to pay the costs that informal care giving relieves from paid, formal 
personnel. Socially speaking, ICG often go unnoticed except by those who depend on their care; the 
recipients of informal care giving understand how important their caregiver’s efforts are to their well-
being and that these contributions are invaluable. Due to the chronic nature and indeterminate end 
point that care giving entails, it has been linked to negative trends in physical, psychological and social 
well-being of the ICG [Carretero, 2008]. Considering this, informal care has been conceptualized as a 
critical stress factor, now referred to as caregiver burden.  
 
In the Table 1 above, the group of informal caregivers has been described as both genders, age – from 
40-75 years, some of them might also have specific health needs or care needs.  
Here we extend the description of the informal care-givers since we expect that there will be a 
substantial difference towards ISISEMD services depending on the generation shift and the ability to 
use new technology. This is reflected in the Table 2 below. 
 
ICG could be characterised as two subgroups –  
• ICG-partners - the group of the elderly partner who lives with the patient and is not very 
accustomed to use technology and usually provides care for ADLs 
• ICG-children - the group of the middle-aged children or young grandchildren who also 
provide care to the patient but with different types of tasks, usually related to IADLs   
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Table 2: Profile of informal caregivers (ICG) 
Range of User Profile Group of informal caregivers  
Gender Both genders;  
Age of ICG-partners  60 - 80 years old 
Age of ICG-children - middle-aged 
children or grandchildren  
20-60 years old 
Health needs of ICG-partners Some of them may also have health needs or some long-term 
conditions as hearing, seeing impairments or have chronicle illness  
Care needs of ICG-partners Some of them may also have care needs 
Use of technology – ICG-partners  It is not very common to have knowledge about use of computers. 
It is expected that some of them have and use a mobile phone on 
daily basis. It is to be expected that all of them are very familiar 
with use of a stationary telephone.  
Use of technology -  ICG-children It is very common to have knowledge about use of computers and 
use of internet portals, social internet networks, etc. It is expected 
that most of them have and use a mobile phone on daily basis. It is 
to be expected that all of them are very familiar with use of a 
stationary telephone. 
Needed type of service (in a very 
general aspect) 
- unobtrusive monitoring of the EP 
- 2 way notification service 
- 2 way communication service 
- location notification service  
- emergency notification service  
 
 
2.4 Profile of Secondary user group – formal caregivers FCG 
 
Throughout Europe, many resources are available to support families caring for an older adult, one 
being the availability of formal caregivers. These are paid individuals who are employed full-time or 
part-time, through an agency or hired privately and can provide physical assistance and care to older, 
dependent adults. Formal caregivers are statistically female, middle aged and have a formal education. 
They have experience in working with dementia or general with elderly clients, work well 
independently and can prioritize tasks efficiently, are open, interested and responsible for their work, 
set interdisciplinary cooperation and responsibilities high and enjoy direct patient contact.   
 
There are different types of formal caregivers, depending on the level of services needed.  Examples of 
formal caregivers for in home care are: 
 
House workers – perform basic household duties such as cleaning, cooking, household management, 
some personal care and medication reminding. 
 
Home Health Aides, Certified Nurse Assistants (CNA) and Nurses Aides – often referred to as Home 
Health Care Workers; provide a broad range of services consisting of assisting with therapy, personal 
care, hygiene, transferring, physical exercise, medication administration and many aides have 
additional special training and qualifications. These FCG will typically visit the patient more 
frequently than others. 
 
Registered Nurses (RN), Licensed Practical Nurses (LPN) and Therapists – often referred to as Skilled 
Nursing Care; nurses represent the largest group of professional caregivers (WHO Europe, 2008). 
Nurses evaluate patients, develop care plans, provide skilled nursing care, determine whether services 
are functional and perform duties that cannot be safely performed by other (nonprofessional) care 
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personnel such as wide-ranging medical care (IV injections, tube feeding and cleaning and dressing 
memoir wounds. Physical (PT), occupational (OT) or speech therapists (SP) evaluate therapy needs, 
develop care and rehabilitation plans, assess the home and environment and monitor domain status. 
 
Social Workers and Geriatric Case Managers – often grouped together as Social Care Workers; 
support patients, families and caregivers in finding and receiving access to assistance, navigating 
bureaucracy and financial difficulties, utilizing community and social care programs and providing 
further recommendations for care.  
 
Their daily tasks of more specialised FCG staff usually involve: 
• Participation in searches, determination and diagnosis of patients 
• Guide for patients and caregivers on dementia diseases, treatment and psychosocial support 
• Follow-up of patients in dementia clinic after diagnosis  
• Provide communication to municipality dementia coordinators  
• Contribute to a healthy, coherent patient  
• Participate in dementia clinic other clinical work (e.g. assist in lumbar puncture)  
• Participate in training to relatives of diagnosed patients 
 
Conclusion for Section 2 
This section was devoted to describing the specifics of dementia as illness and the general profile of 
the main end-user groups of ISISEMD services – the elderly persons (EP), the informal caregivers 
(ICG) and the formal caregivers (FCG). Due to dementia, EP have decline in memory or in other 
cognitive ability. Depending on the stage progressing of the illness, they have difficulties to live 
independently or cannot live independently. It is expected that they have very limited knowledge 
about using new technology and it will be difficult for them to learn to use it if the illness has 
progressed. ICG are split in two subgroups- the ICG-partners and ICG-children. ICG-partners are 
statically females and do not have very good knowledge for the new technology either and which 
burden t o care for their ill partner causes a lot of stress and social isolation. ICG-children are usually 
middle-aged and statistically females too, who is expected to use technology on a daily basis.  
FCG are generally females with formal education in care for seniors or in care for dementia patient. It 
is expected that they use PC, mobile phone, etc in their professional tasks.  
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Section 3 -  Criteria for recruiting the test participants 
 
This section describes how the test participants will be approached and found, which 
inclusion/exclusion criteria will be used to find the trial participants for the three user groups. 
Classification standard for dementia will be presented together with rating scales for assessment of 
cognitive decline. The process of selection of test participants will be described and description of the 
test samples will be presented.  
 
Since the study is designed to examine technology as a non-pharmaceutical intervention within the 
home, the ISISEMD consortium agrees that participant samples will include only people who live in 
their home and who have mild cognitive impairments (MCI) to moderate cognitive decline. Detailed 
below are conditions regarding all user groups, inclusion and exclusion criteria and selection 
standards.    
 
3.1 For Primary User Group (EP)  
 
The ISISEMD project is to offer and test services for elderly with cognitive problems or mild 
dementia with a goal of increasing quality of life. The World Health Organization (2007) International 
Classification of Diseases (ICD-10) will be used to classify dementia type and level with the aid of the 
Montreal Cognitive Assessment (MoCA) to determine cognitive decline (see Section 3.1.2 for 
description). Within this framework, the stages correspond to the widely used concepts of mild, 
moderate, moderately severe and severe dementia. It also gives information as to which stages fall 
within the more general divisions of early-stage, mid-stage and late-stage categories.  
 
3.1.1 Classification standard for stages of dementia  
 
This subsections presents which classification standard is taken into account for the stages of 
dementia.  
 
According to The World Health Organization (2007) International Classification of Diseases (ICD-
10), dementia is a syndrome due to disease of the brain, usually of a chronic or progressive nature, in 
which there is disturbance of multiple higher cortical functions, including memory, thinking, 
orientation, comprehension, calculation, learning capacity, language, and judgment. Consciousness is 
not clouded. Impairments of cognitive function are commonly accompanied, and occasionally 
preceded, by deterioration in emotional control, social behaviour, or motivation. This syndrome occurs 
in Alzheimer's disease, in cerebrovascular disease, and in other conditions primarily or secondarily 
affecting the brain.  
Dementia produces an appreciable decline in intellectual functioning, and usually some 
interference with personal activities of daily living, such as washing, dressing, eating, personal 
hygiene, excretory and toilet activities. How such a decline manifests itself will depend largely on 
the social and cultural setting in which the patient lives. Changes in role performance, such as 
lowered ability to keep or find a job, should not be used as criteria of dementia because of the 
large cross-cultural differences that exist in what is appropriate, and because there may be 
frequent, externally imposed changes in the availability of work within a particular culture. 
The primary requirement for diagnosis is demonstration of a decline in both memory and thinking, 
sufficient enough to impair personal activities of daily living (ADLs). The impairment of memory 
typically affects the registration, storage, and retrieval of new information and previously learned and 
familiar material may also be lost, particularly in the later stages. Dementia is also impairment of 
thinking and of reasoning capacity, and a reduction in the flow of ideas. The processing of incoming 
information is marred, and the individual finds it increasingly difficult to focus on more than one 
stimulus at a time (ICD-10).  
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A characteristic of normal cognitive aging is the large inter-individual variance in performance 
[Bäckman, 2003]. Although one participant may have a clinical diagnosis of mild dementia, it is 
entirely possible that their functioning status is lower than that of another participant measured at 
moderate. Despite cognitive deficits being observed years before a clinical diagnosis, empirical 
evidence is unclear regarding the distinctive point from which cognitive impairments become a 
syndrome or disease.  
 
Stages of Dementia  
The Global Deterioration Scale (GDS), developed by Dr. Barry Reisberg, who is Clinical Director of 
the New York University School of Medicine’s Silberstein Aging and Dementia Research Center, 
provides caregivers an overview of the stages of cognitive function for those suffering from a primary 
degenerative dementia such as Alzheimer's disease. It is broken down into 7 different stages. Stages 1-
3 are the pre-dementia stages. Stages 4-7 are the dementia stages. Beginning in stage 5, an 
individual can no longer survive without assistance. Within the GDS, each stage is numbered (1- 
7), given a short title (i.e., Forgetfulness, Early Confusional, etc followed by a brief listing of the 
characteristics for that stage. Caregivers can get a rough idea of where an individual is at in the disease 
process by observing that individual's behavioural characteristics and comparing them to the GDS. 
(From geriatric- resources)  
 
The GDS for Assessment of Primary Degenerative Dementia:  
Level 1 - NO COGNATIVE DECLINE: No subjective complaints of memory deficit. No memory 
deficit evident on clinical interview.  
 
Level 2 - VERY MILD COGNATIVE DECLINE (Age Associated Memory Impairment): 
Subjective complaints of memory deficit, most frequently in following areas: (a) forgetting where one 
has placed familiar objects; (b) forgetting names one formerly knew well. No objective evidence of 
memory deficit on clinical interview. No objective deficits in employment or social situations. 
Appropriate concern with respect to symptopathology.  
 
Level 3 - MILD COGNATIVE DECLINE (Mild Cognitive Impairment): Earliest clear-cut 
deficits. Manifestations in more than one of the following areas: (a) patient may have gotten lost when 
travelling to an unfamiliar location; (b) co-workers become aware of patient's relatively poor 
performance; (c) word and name finding deficit becomes evident to intimates; (d) patient may read a 
passage or a book and retain relatively little material; (e) patient may demonstrate decreased facility in 
remembering names upon introduction to new people; (f) patient may have lost or misplaced an object 
of value; (g) concentration deficit may be evident on clinical testing. Objective evidence of memory 
deficit obtained only with an intensive interview. Decreased performance in demanding employment 
and social settings. Denial begins to become manifest in patient. Mild to moderate anxiety 
accompanies symptoms.  
 
Level 4 - MODERATE COGNITIVE DECLINE (Mild Dementia): Clear-cut deficit on careful 
clinical interview. Deficit manifest in following areas: (a) decreased knowledge of current and recent 
events; (b) may exhibit some deficit in memory of one’s personal history; (c) concentration deficit 
elicited on serial subtractions; (d) decreased ability to travel, handle finances, etc. Frequently no 
deficit in following areas: (a) orientation to time and place; (b) recognition of familiar persons and 
faces; (c) ability to travel to familiar locations. Inability to perform complex tasks. Denial is dominant 
defence mechanism. Flattening of affect and withdrawal from challenging situations frequently occur.  
 
Level 5 - MODERATELY SEVERE COGNITIVE DECLINE (Moderate Dementia): Patient can 
no longer survive without some assistance. Patient is unable during interview to recall a major relevant 
aspect of their current lives, e.g., an address or telephone number of many years, the names of close 
family members (such as grandchildren), the name of the high school or college from which they 
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graduated. Frequently some disorientation to time (date, day of week, season, etc.) or to place. An 
educated person may have difficulty counting back from 40 by 4s or from 20 by 2s. Persons at this 
stage retain knowledge of many major facts regarding themselves and others. They invariably know 
their own names and generally know their spouses' and children's names. They require no assistance 
with toileting and eating, but may have some difficulty choosing the proper clothing to wear.  
 
Level 6 - SEVERE COGNITIVE DECLINE (Moderately Severe Dementia): May occasionally 
forget the name of the spouse upon whom they are entirely dependent for survival. Will be largely 
unaware of all recent events and experiences in their lives. Retain some knowledge of their past lives 
but this is very sketchy. Generally unaware of their surroundings, the year, the season, etc. May have 
difficulty counting from 10, both backward and, sometimes, forward. Will require some assistance 
with activities of daily living, e.g., may become incontinent, will require travel assistance but 
occasionally will be able to travel to familiar locations. Diurnal rhythm frequently disturbed. Almost 
always recall their own name. Frequently continue to be able to distinguish familiar from unfamiliar 
persons in their environment. Personality and emotional changes occur. These are quite variable and 
include: (a) delusional behaviour, e.g., patients may accuse their spouse of being an impostor, may talk 
to imaginary figures in the environment, or to their own reflection in the mirror; (b) obsessive 
symptoms, e.g., person may continually repeat simple cleaning activities; (c) anxiety symptoms, 
agitation, and even previously nonexistent violent behaviour may occur; (d) cognitive abulla, i.e., loss 
of willpower because an individual cannot carry a thought long enough to determine a purposeful 
course of action.  
 
Level 7 - VERY SEVERE COGNITIVE DECLINE (Severe Dementia): All verbal abilities are lost 
over the course of this stage. Frequently there is no speech at all -only unintelligible utterances and 
rare emergence of seemingly forgotten words and phrases. Incontinent of urine, requires assistance 
toileting and feeding. Basic psychomotor skills, e.g., ability to walk, are lost with the progression of 
this stage. The brain appears to no longer be able to tell the body what to do. Generalized rigidity and 
developmental neurologic reflexes are frequently present. 
 
The target primary end-user group of ISISEMD services will be elderly persons with dementia 
2-4 stage and partially 5 stage, since some of 4 stage subjects, in 12-month duration of the test 
project periods, might progress to stage 5. The trial participants will be classified according to 
the above presented standard for stages of dementia.  
 
Functional Assessment 
Since dementia is related to functional decline, below a simplified checklist version of the seven 
dementia stages is presented in the Functional Assessment Staging Test (FAST).  
 
Note that stages 6 and 7 are broken down into smaller steps.  
1 No difficulties, either subjectively or objectively  
2 Complains of forgetting location of objects; subjective word finding difficulties only.  
3 Decreased job functioning evident to co-workers; difficulty in travelling to new locations.  
4 Decreased ability to perform complex tasks (e.g., planning dinner for guests; handling 
finances; marketing).  
5 Requires assistance in choosing proper clothing for the season or occasion.  
6a Difficulty putting clothing on properly without assistance.  
6b Unable to bathe properly; may develop fear of bathing. Will usually require assistance 
adjusting bath water temperature.  
6c Inability to handle mechanics of toileting (i.e., forgets to flush; doesn't wipe properly).  
6d Urinary incontinence, occasional or more frequent.  
6e Faecal incontinence, occasional or more frequent.  
7a Ability to speak limited to about half a dozen words in an average day.  
7b intelligible vocabulary limited to a single word in an average day.  
7c Nonambulatory (unable to walk without assistance).  
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7d Unable to sit up independently.  
7e Unable to smile.  
7f Unable to hold head up. 
 
Since very often when dementia is diagnosed, it is from type of Alzheimer disease, to avoid 
misunderstanding, below we present the mapping between the dementia stages and the Alzheimer 
stages. More information could be obtained from the website of the Alzheimer organization 
http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp.  
 
Table 3: Mapping between the dementia stages and the Alzheimer stages 
Stage Cognitive decline Dementia Alzheimer's disease 
    
Stage 1: No impairment (normal 
function) 
  
Stage 2: Very mild cognitive 
decline 
 
Age Associated Memory 
Impairment 
May be normal age-related 
changes or earliest signs of 
Alzheimer's disease 
Stage 3: Mild cognitive decline 
 
Mild Cognitive 
Impairment (MCI) 
Early-stage Alzheimer's can be 
diagnosed in some, but not all, 
individuals with these 
symptoms 
Stage 4: Moderate cognitive 
decline 
Mild Dementia Mild or early-stage Alzheimer's 
disease 
Stage 5: Moderately severe 
cognitive decline 
Moderate Dementia Moderate or mid-stage 
Alzheimer's disease 
Stage 6: Severe cognitive decline Moderately Severe 
Dementia 
Moderately severe or mid-stage 
Alzheimer's disease 
Stage 7: Very severe cognitive 
decline 
Severe Dementia Severe or late-stage Alzheimer's 
disease 
 
 
Disabilities to be covered by the project as described in the WHO ICF Classification 
 
Since ISISEMD services are is closely related to ADL and IADL, which on their side are linked to 
some disabilities. The objectives of ISISEMD can be explained in the context of improving functional 
status and improving the impact of the environment on the person's functioning (improving the social 
aspects of disability) as outlined in The International Classification of Functioning, Disability and 
Health (ICF).   
 
The International Classification of Functioning, Disability and Health (ICF), known more commonly 
as ICF, are a classification of health and health-related domains. These domains are classified from 
body, individual and societal perspectives by means of two lists: a list of body functions and structure, 
and a list of domains of activity and participation. Since an individual’s functioning and disability 
occurs in a context, the ICF also includes a list of environmental factors. 
The ICF is WHO's framework for measuring health and disability at both individual and population 
levels. (http://www.who.int/classifications/icf/en/) 
 
d ACTIVITIES AND PARTICIPATION 
d199 Learning and applying knowledge, unspecified 
d598 Self-care, other specified 
d599 Self-care, unspecified 
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d630-d649 Household tasks  
d699 Domestic life, unspecified 
 
e1 PRODUCTS AND TECHNOLOGY 
e115 Products and technology for personal use in daily living 
e125 Products and technology for communication 
 
e3 SUPPORT AND RELATIONSHIPS 
e310 Immediate family 
e355 Health professionals 
 
e5 SERVICES, SYSTEMS AND POLICIES 
e5750 general social support services  
e580 Health services, systems and policies 
 
 
3.1.2 Tools for cognitive assessment 
 
This subsection will present two standard tools for cognitive assessment (MoCA and MMSE) and their 
comparison. 
IMMSE and MoCA stands for Mini Mental State Exam and Montreal Cognitive Assessment 
respectively. These are standard rating scales questionnaires for assessing stage of cognitive decline. 
MMSE has been created in 1975. It is 30-pt questionnaire and is administered for 15 Minutes. MoCA 
has been created in 2005. It is 12-section interactive questionnaire/interview (patients not only answer 
questions, but have to draw, recall, think abstractly and draw and is administered in about 10 minutes.  
The specific is that they must be administered by specially trained staff from the care-provider 
organisation for this type of questionnaires. The general training is to ensure that during the interview, 
the interviewer reduces interviewer influence and do not influence the patients’ answers with body 
language, voice, etc.  
The main difference is that MoCA is useful for the mild stages of the cognitive impairment spectrum 
(including MCI and mild AD), and the MMSE is superior for more-advanced stages (AD patients with 
more significant functional impairment). There are currently no other screening tools to quickly and 
reliably distinguish MCI from normal controls.  
 
3.1.2.1 Mini Mental State Exam (MMSE) 
 
The MMSE [http://www.minimental.com/], or Folstein test, [Folstein, 1975] is a 30-point 
questionnaire used to screen for cognitive impairment with lower scores suggestive of greater 
impairment. MMSE is owned by Psychological Assessment Resources (PAR) and official versions 
must be ordered through PAR, although many free versions are available on the Internet. Taking less 
than 15 minutes, MMSE assess functions including arithmetic, memory, repeating lists of words, 
language, comprehension, basic motor skills and orientation. The maximum score on the Mini Mental 
State Exam is 30.  
 
As it is written in MMSE guidelines, in general, scores fall into four categories:  
24 – 30: "normal" range 
20 – 23: mild cognitive impairment or possible early-stage/mild Alzheimer's disease  
10 – 19: middle-stage/moderate Alzheimer's disease  
0 – 9: late-stage/severe Alzheimer's disease  
 
After 1975 trials and studies have adjusted scores from the initial mapping, MMSE is not as sensitive 
as the developers first thought it was in 1975. The updated mapping is the following: 
27-30: no impairment 
20-26: mild cognitive impairment 
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10-19: moderate to severe impairment 
0-10: severe impairment 
 
MMSE is currently a widely used as assessment tool by all end-user partners in Denmark, Greece, 
North Ireland and Finland. Due to its high acceptability but low sensitivity (18%) and specificity, 
MMSE will be used as a secondary cognitive assessment tool.  
For the next version of this report the partners will take decision which mapping will be used in 
ISISEMD.  
 
3.1.2.2 Montreal Cognitive Assessment (MoCA) 
 
The Montreal Cognitive Assessment, or MoCA, [Nasreddine, 2005] was designed as a short screening 
instrument for mild cognitive impairments where participants not only answer questions, but have to 
draw, recall and think abstractly. It assesses 8 different cognitive domains, including attention and 
concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, 
calculations, and orientation. The time to administer MoCA is approximately 10 minutes with a total 
possible score is 30 points. A score of 26 or above is considered normal, so ISISEMD will be using a 
cut-off point of >25. MoCA has been evaluated as being easy to use (by both interviewers and 
interviewees) for any health/social care professional to administer [Olson, 2008]. The measurement 
consists of interactive tasks such as copying figures, naming objects, repeating words and drawing a 
clock. The test can be used free of charge and is standardized in 26 languages (www.mocatest.org).  
 
MoCA is useful for assessing milder stages of cognitive impairment, including MCI and mild 
Alzheimer Disease (AD) where there are currently no other screening tools as quick and accurate to 
distinguish Mild Cognitive Impairments from healthy controls (90% sensitivity). Due to its high 
specificity and sensitivity in detecting MCI, MoCA will be used as the primary cognitive assessment 
tool in determining level of cognitive functioning and changes over the course of the clinical trials. 
 
3.1.2.3 Comparison among MMSE and MoCA rating scales  
 
The MMSE is the most commonly used cognitive screening, but is not most accepted for its 
sensitivity. MMSE is best suited for distinguishing gross cognitive impairment, but not for detecting 
damage to abstract reasoning, executive functioning, and visual perception, which MoCA is. MoCA 
has been shown to have a lesser completion time (by 5 minutes) and 50% more sensitivity towards 
cognitive impairments. Conclusions are that it is well tolerated, accurate, and provides additional 
information over the MMSE [Olson, 2008]. Additionally, MoCA is available in over 25 languages via 
free internet download, without restrictions, and can be administered by any member of the care team. 
Currently MoCA is translated into the four languages of the end-user partners (English, Danish, 
Greek, and Finish).  
Measuring the level of cognitive impairment in dementia is essential to clinical trials testing assistance 
and interventions. In order to produce the most accurate results, as well as gain valuable scientific 
data, a combination of both tests could be used. MoCA scores will be the primary assessment (for 
determining cognitive functioning to provide services) but both tests will provide useful information.  
Where available, MMSE could be administered as well. Administration suggestion to those reasons is 
that tests are randomly administered within the same interview (second test is administered within a 
few hours of the first, but can be in either order and randomized to end users).  
 
 
3.1.2.4 Need for Standardisation 
 
For assessment tools to be validated and widely applicable, they need to be translated and standardized 
depending on the country of use. This entails not only translating the language used in the tool, but 
adjusting the wording used to create the same level of meaning. Additionally, interviewers (the person 
administering the assessment) can influence results and should be trained (or at least familiarized) as 
 
 
ISISEMD/WP 3/Del 3.3.2-update/Task 3.3                          CIP-ICT-PSP 238914 ISISEMD
 
 
ID: C:\Documents and 
Settings\kjeld\Dokumenter\ISISEMD\Deliverables\ISISEMD_D3.3.2_NDEU_v.2.doc 
Date:  Sunday, 31 January 2010  
Revision: v 1.3 Security: Confidential 
Last saved by AIM Page 23 of 119 
 
to how their choice of words, body language, tone of voice, patience, and other non-verbals can 
influence the person answering questions. This is especially true in longer assessments. Fortunately, 
the care personnel from the regional partners that already have access to and use MMSE will have 
already been trained. As MoCA is shorter and easier to administer (designed to be administered by any 
member of the care team) and most interviewers have had training with MMSE, there are no 
foreseeable difficulties in using. Since at the time when ISISEMS partners started discussion about the 
cognitive assessment tools, translation in Finish was not available, the partners contacted the 
developer of MoCA, Dr Z. Nasreddine. Per our request, the developer published finish version of 
MoCA and recommendations/guidelines for translation and standardization.  
 
In the discussion process for the identification of suitable classification standards and standard 
screening tools for cognitive assessment and quality of life questionnaires, ISISEMD partners 
consulted national experts and initiated close fruitful cooperation with representatives from their 
national Alzheimer Associations. The list of contacts is presented below: 
 
Denmark 
Kasper Jørgensen  
Neuropsykologisk fagkonsulent  
Nationalt Videnscenter for Demens Rigshospitalet,  
afsnit 7661  
Blegdamsvej 9,  
2100 København Ø 
www.videnscenterfordemens.dk 
 
For the Ethical application itself for the pilot trial in Denmark, the following expert has been 
associated as a scientific responsible for the trial: 
Anne Stubbe Arndal 
Doctor, National leader for Alzheimer association in Denmark 
 
North Ireland 
Dr David Craig and Dr Ben Knapp 
from Memory Clinic based at the Belfast City Hospital (BCH) 
The clinic is led by the consultants in elderly care who hold Senior Lectureships at the Queen's 
University of Belfast. 
Dr David Craig and Dr Ben Knapp are also involved in other European projects such as COGKNOW 
(STREP project with focus on mild dementia persons), Netwell (under INTERREG programme), 
CAPSIL (Support Action project). 
 
Finland  
Professor Olli-Pekka Ryynänen  
University of Kuopio  
Leading researcher of QOL testing in Finland. 
 
Greece  
Ms Sakka and Ms Areti Efthymiou who is Chairwoman of Athens Association of Alzheimer's Disease.  
They will become external scientific advisors of the partner from Trikala for the project.  
 
3.1.3 Main inclusion/exclusion criteria for primary end-user group (EP) 
 
Inclusion criteria:  
• Age – above 60 years  
• Diagnosed with dementia - diagnose system ICD-10 will be used. Para-clinical data which 
will be used to make the diagnosis is cognitive screening tests.  
 
 
ISISEMD/WP 3/Del 3.3.2-update/Task 3.3                          CIP-ICT-PSP 238914 ISISEMD
 
 
ID: C:\Documents and 
Settings\kjeld\Dokumenter\ISISEMD\Deliverables\ISISEMD_D3.3.2_NDEU_v.2.doc 
Date:  Sunday, 31 January 2010  
Revision: v 1.3 Security: Confidential 
Last saved by AIM Page 24 of 119 
 
• Dementia stages 2 to stage 4 according to GDS (Dr. Barry Reisberg scale), corresponding to 
MoCA or MMSE scores 19-26. 
• Lives in own home; could be supported by home care  
• The dementia diagnoses and stage is defined by a specialist (neurologist, geriatric specialist, 
etc.) 
• Can self understand and give consent to participate in the project trial  
• Have a close relative which is willing to help for the participation to the project trials  
• Open to use new technology in the everyday life  
 
Elderly participants with the following conditions will be excluded from the test group: 
 
Exclusion criteria:  
• Malignant illness  
• Psychological conditions with symptoms which could be wrongly assumed to be dementia, 
especially depression and delirium  
• Present misuse of alcohol or medicine – patients with heavy behaviour disorders and 
psychotically symptoms – for them participation to the project trial will be difficult 
• Participants with dementia which is in the frontal part of the brain since the persons with this 
type of dementia develop sometimes paranoid symptoms and could be aggressive  
• Participants with stage of dementia higher than 5 (moderate and severe dementia) classified 
according to GDS  
• Dementia secondary to head trauma 
• Participants whose dementia is reversible (nutrition deficiencies) 
• Participants with psychological long-term conditions, for example schizophrenia or depression   
• Participants under active treatment (chemotherapy, radiation therapy) for cancer or other 
terminal diagnosis  
• Bedbound (confined to a bed or chair for 20 hours a day for 4 out of 7 days) 
• More than three acute medical hospitalizations in the past year (other than dementia related 
admission) 
• Planned long term care admission in 6 months 
 
These main inclusion/exclusion criteria have been consulted with Bodil Gramkow, chief physician at 
Department of Psychological and Gerontology in Brønderslev, Denmark and Kasper Jørgensen from 
National Knowledge Center for Dementia in Denmark.  
 
3.1.4 Secondary inclusion/exclusion criteria   
 
The project aims to introduce ICT services to senior citizens and at the same time it is observed very 
often some kind of conservatism and resistance to new technology among them. Therefore a 
secondary inclusion criterion for the EP could be that the person is accustomed to use modern 
communication such as mobile phone, eventually computer. Even having a PC at home would be an 
additional advantage.  
 
Because of some cultural differences, both elderly living alone and with a partner will be involved. 
The aim is to have 50% representation of both groups. Also, both genders will be represented. It is a 
general trend that in almost all European countries women live longer. Therefore, when recruiting the 
test subjects, the goal will be to involve at least 50% women.  
 
Due to matters related to budget limitations and costs per pilot, secondary exclusion criteria for the 
persons from the test group will be  
• Participants living in big homes (due to the limitation to buy and install many sensors in their 
homes)  
• Participants who do not have Internet access or for whom there is no possibly to provide such  
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3.1.5 Selection process   
 
3.1.5.1 Channels to find potential test participants  
 
Potential participants will be recruited with the help of general and nurse practitioners, aging and 
cognition specialists, memory and dementia clinics and national and local organizations for aging 
programs and services. Fliers will be posted in their buildings; presentations will take place at 
caregiver education and support groups, and staff communication with potential participants and 
information in local news media that describe the project. In this dissemination material, the contact 
details of the responsible person for the trials in each region will be provided. In this way potential 
participants can call research team members first to express interest. Potential participants will then be 
contacted via telephone by a member of the project research team who will explain the project, answer 
any questions the potential participants have and identify the primary caregiver (the person who is 
most responsible for assisting on a daily basis). During this contact, primary caregivers will complete 
a screening tool to document the characteristics of the caregiver (e.g. occupational status, current use 
of technology, general health status), the individual with dementia (e.g. need for assistance with 
ADLs/IADLs, any challenging behaviours) and the care giving situation (e.g. length of time in role as 
caregiver, hours per day spent care giving, formal assistance received).  
 
From the interviews with informal caregivers during the process of collection of user requirements, it 
became clear that they could play very important role when recruiting the primary end-users. With 
their help it would be easier to find test participants. So another approach to be used by ISISEMD 
partners is to contact the support groups of informal caregivers. The advantage of this approach is that 
when the close relative or partner is positive for the services offered by ISISEMD project, he/she 
could easier convince the primary end-user to take part in the trials.  
 
More specifically for each region, the test participants will be approached using the following 
activities: 
 
Trikala 
1st step - The choice for the patients will be made by the current advisor psychiatrist Mr. Stoforos 
from ISISMED Project in Trikala 
2nd step - The Choice of patients will be made by the rest Psychiatrists in Trikala through our own 
awareness 
3rd step - Announcement in local newspapers in order to search for volunteer patients 
 
Belfast 
To allow for a final group of 20 clients, 20 informal caregivers and 10 formal caregivers to be selected 
and tested in the pilot group, initially a group of 40 potential participants and accompanying informal 
caregivers will be identified by staff from the Community Mental Health teams of the Belfast Trust. 
This will occur at Diagnostic outpatient clinics held in premises of the Belfast Trust. These clinics are 
already held in Belfast for the particular client group addressed by the ISISEMD project. They are led 
by consultants, other professional and Community Mental Health staff, are also in attendance at these 
clinics. The outpatient attendance of the clients at the clinics in Belfast is made by both new referral 
clients and review caseloads. Staff at these clinics presently undertakes the MMSE diagnostic tests 
with clients. Nurse led Memory clinics held in Belfast and attended by those with prior diagnosis, will 
also participate in this initial identification of the potential client group. The clients’ scores will be 
recorded at this point. 
 
Lappeenranta  
The main channel to disseminate the information for testing ISISEMD services will be to use memory 
clinic. All 20 end user, relative and 10 caregivers will be from City of Lappeenranta. 
 
Frederikshavn 
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The main channel to disseminate the information for testing ISISEMD services and to announce for 
the trial activities will be to use the dementia group from Frederikshavn Elderly Care Department. 
Additionally, very good awareness for the project has been already created with the press coverage 
from the kick-off meeting (articles, radio and TV interviews).  
 
3.1.5.2 Process of selection of test participants  
 
As describe in the previous section, participants will need a clinical evaluation by a specialist 
(neurologist, geriatric specialist, etc.) and a rating of cognitive decline. Test participants will be 
seniors over 60 years of age with stage of dementia 2 to 4 and a MoCA or MMSE score 19-26.  
 
Following the evaluation based on the telephone screening, eligible participants will receive a home 
visit by two or more of the research members. It is ideal to have half of the participants living alone in 
their home and half living with a spouse or caregiver. Both genders will be represented as equally as 
possible. The home will be evaluated by an occupational therapist (OT) to determine functionality, 
feasibility and receive professional recommendations. This visit will serve to present both oral and 
written information regarding the research and clinical trial as well as: 
• Obtain informed consent of participants 
• Measure the level of cognitive impairment with MoCA 
• Measure quality of life with QOL-AD 
• Conduct an assessment of each room used by the individual with dementia, documenting 
challenging behaviours that present safety concerns and identifying potential equipment (e.g. 
camera and sensor) placement  
• Ascertain caregivers’ familiarity with computer and cell phone 
• Document caregivers’ feelings of obligation, competence, role satisfaction, etc. 
• Caregivers complete a self-report time budget in which they report length of time spent in 
which care giving activities in the previous 24-hour period 
 
In the next month of the project, the professional staff will identify potential clients which will attempt 
to fulfil mandatory requirements (it must be underlined that they will be only identified, and not 
recruited for the trials before approval from ethical committees is obtained). If there are a large group 
of potential clients to choose from, consideration will also be taken into account of technical access 
i.e. those that have PCs in home and internet access, with a carer/relative willing to participate and 
willing to use technology. The delimitations described in Sections 3.1.3 and 3.1.4 will also be taken 
into account. In general, around 20-23 EP per region will be aimed at. However, some of the regions 
(for example Belfast) would aim to identifying 40 persons with mild dementia. In this case, the 40 
primary end-user group will be those with dementia stages 2- 4 with the aim to target clients with the 
relevant MMSE/MoCA scores for early stage dementia to allow for deterioration. At this stage care 
will be taken not to raise user expectations, any mention of the project pilot to clients will be made in a 
general sense. The reason for this is to have a broader sample of persons, thus allowing later to select 
the exact needed persons based also on some secondary criteria.  
 
As another activity which could help to recruit test subjects, the end-user partners from the ISISEMD 
consortium has decided to organise a demo room in each region during M12-M13. This will be a ready 
ISISEMD platform, installed in a suitable room in the premises of the care-giver partners. The purpose 
of this is four-fold: 
• Demonstration of the systems to potential test participants and their relatives – they will be 
able to see, and experience the system before deciding to join the controlled study and be 
convinced that it is very user friendly and also aesthetically acceptable 
• In this demo rooms, the formal caregivers will be able to try in reality the system and provide 
final feedback to technical partners for usability and functionality and suggestions for 
improvement 
• Introduction seminars and training could be provided to end-users 
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• Personnel from care-giver organisations will gain hands-on experience from installation of the 
system before the pilot installations  
 
The final 20 clients and caregivers chosen will not be recruited before approval from the ethical 
committee is granted. The final group chosen will consist of 10 in a control group i.e. no services 
provided and 3 different groups in the 3 stages of dementia (i.e. stage 2- 4) of 3-4 clients (all in all 10 
test subjects). They will be chosen according to the criteria previously described, with appropriate 
housing requirements/suitability to accommodate the technology inclusion criteria and with a 
carer/relative willing to participate and willing to use technology. Again the delimitations described in 
Sections 3.1.3 and 3.1.4 will also be taken into account. This group will be tested with the relevant 
dementia test (MMSE/MOCA) one month before the pilot is due to begin. A quality of Life 
assessment will also be conducted for the client/informal caregiver groups.  
The eligible participants will have received a home visit to evaluate suitability by the professional 
member of staff and equipment necessary for the pilot. Informal caregivers will also be visited.  
Consent forms and Information leaflets will have been prepared and provided. The consent forms will 
stipulate that the carer is responsible outside normal working hours and contingency arrangements will 
be described. 
 
3.1.6 Number of participants for the evaluation  
 
The targeted number of participants in each user group has been defined in Description of Work. The 
following table summarizes the user involvement per group and per region. 
 
Table 4: Target end-user involvement per group and per region 
Test groups Denmark Greece Finland UK 
 
EP - elderly with cognitive problems from 
MCI to mild dementia 
20 20 20 20 
ICG - informal caregivers 20 20 20 20 
FCG - formal caregivers 10 10 10 10 
 
 
As could be seen from the above table, the goal is to involve 20 primary participants in each region. 
However, it could be expected a small number of some drop outs due to various reasons. Therefore, 
additional 2-3 primary participants per region will be identified and kept as a back-up solution. The 
exact number of the involved ICG will depend on the status of the EP – if he is alone or has a close 
family member living with him/her or close to the home. The exact number of FCG will depend on the 
EP sample too – if most of the EP lives in one area of the city there could be less FCG caring for more 
EP. The number of FCG will depend also on the organisational structure in each region and in general 
on the ratio between the number of carers vs. number of clients. 
Out of the number of 20 primary end users (as back up 22-23 persons), the test group itself will consist 
of half of them. The test group will be offered the ISISEMD services and the system will be installed 
in their homes. 
  
The following Table 5 presents the target characteristics of the sample of EP: 
Table 5: Target characteristics of the test sample of EP 
Characteristics of the sample of EP Comments 
Country of origin Denmark, Finland, North Ireland, Greece 
Geographical distribution  From North, South and Western Europe  
Race  Any race 
Number of test subjects EP 80 
Gender - Female  50% 
Gender - Male  50% 
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Living alone  50% 
Living with a partner  50% 
Stage of dementia stage dementia 2 to 4 
Duration of dementia, y Minimum ½ year 
Age, y >60 y 
Educational level, y No specific  
Type of home Flat or house  
 
 
The sample of EP subjects in ISISEMD will be community type, living in a city.  
 
3.1.7 Control group of primary end-users (EP) 
 
The control EP group will be as characteristically similar to EP group as possible. They will be 
community dwelling, half living alone, with a clinical evaluation by a specialist (neurologist, geriatric 
specialist, etc.) and a rating of MCI to stage 4 moderate cognitive decline following ICD-10 and a 
MoCA score below 26. Participants will also be recruited with the aid of general and nurse 
practitioners, memory and dementia clinics, and regional organizations working with dementia 
populations.  
The control group will consists of approx. 10 subjects from primary end-user group to allow for a 
good comparison. They are going to be involved as the test participants from the beginning months of 
the test period and relevant test will be applied to them too. Control group will also be administered all 
tests for the test group except test user acceptance and user satisfaction because they will not be given 
any technological intervention. For the type of tests to be administered to test and control groups, 
please refer to Section 5.9 and Figure 1. 
 
3.1.8 Statistical considerations and forming of test and control groups by random selection 
 
The overall hypothesis for ISISEMD project is that ICT services can improve QoL among elderly with 
cognitive problems or mild dementia. The end-user partners are not aware of previous research to 
document such a hypothesis with a controlled study. Only references have been found that only 
indicate that there is a relation. According to Logsdon [Logsdon, 2002], it could be expected an 
average score of QoL-AD at approx. 39.5 points (spreading 5,3) among a test group. In ISISEMD 
project, we will try the ICT service for N=97, and MMSE score 17-29.  
We are aiming to be able to measure increased QoL with 6%, spreading 5,3 and p-value of 5% is 
calculated that N=37 persons to be used in the control and test group, in order to prove the hypothesis 
with significance. Because of this reason, the number of test persons will be N=40, meaning 10 
persons in the test group and 10 persons in the control group for each region.  
Additionally, in order to have statically valid test results, the test and control groups of the elderly will 
be randomly selected. This will be done by a small lottery. Some more details are provided in Section 
3.1.5.2. 
 
3.2 For Secondary User Group – informal caregivers (ICG) 
 
ICG will be recruited based on EP recruitment as it is desired to have fifty percent of EP participants 
living with a partner. 
 
3.2.1 Inclusion/Exclusion Criteria for ICG 
 
Inclusion Criteria: 
a. 18 years or older 
b. actively involved caregiver for the care recipient   
c. Must live with the care recipient and/or live separately but provide on average of a couple of 
hours of supervision or direct assistance per day 
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d. Must plan to remain in the area for the duration of the intervention and follow-up 
e. Caregiver role for more than 6 months 
 
Exclusion Criteria: 
a. Active treatment (chemotherapy, radiation therapy) for cancer 
b. Imminent placement of care recipient into a nursing home or with another caregiver (within 
6 months) 
c. Has some stage of dementia  
 
3.3 For Secondary User Group – formal caregivers (FCG) 
 
FCG will be recruited by informing local aging and memory organizations, clinics and support and 
activity groups about the research project. If willing to cooperate, these organizations and groups will 
be asked to identify potential participants and professional caregivers familiar with the potential 
family. Once the potential FCG are identified, they will be contacted via telephone by one of the 
researchers who will further explain the project and answer any questions they may have. Formal 
caregivers will also be asked to identify the care giving situation from their (professional) point of 
view regarding ICG status, EP status and care giving situation.  FCG will complete a screening tool to 
determine their occupational status, current use of technology and role in the care team. Formal 
caregivers are encouraged to participate in the home visit of EP to assess the situation, setting and 
possible solutions.  
 
In determining which kinds of equipment they use, we found that nearly all use a PC, also used are 
PDA, cell phone, fax, internet and some video conferencing. Formal caregivers are also familiar with 
standardized medical equipment (such as IV, respirators, catheter, etc.). Formal caregivers come from 
a variety of professional backgrounds, including: 
• Doctors (general, neurological, psychiatric), nurses, and other health care professionals 
• Gerontologists, Psychologists, Social Workers and other non-medical care professionals 
• Long-Term Care, Care managers, business and administration 
 
3.3.1 Important points to be considered  
 
We would like to mention here that a number of studies have indicated that the formal caregivers are 
quite happy with the good possibilities which use of PDAs gives them. However, we are also aware 
that a recent study among professional care personnel in Denmark using PDAs in their work tasks and 
who are members of FOA (Fag or Arbejde) has shown that only 4 out of 10 caregivers are satisfied 
with the use of PDAs. The study identifies that this is due to technical problems. For example - there 
are often problems with failure, and the person needs to log-in again, small keyboard, slow internet 
connection, the battery cannot hold long, etc. This leads to the perception that PDA uses some of the 
time which they need to spend with the client. Our assumption is that this puts additional stress on the 
professional caregivers [PDA, 2009]. Therefore, it is of utmost importance that the ISISEMD systems 
and services must work properly from the very beginning and this will be taken care of by the 
technical partners. Special attention will be paid during the user acceptability evaluations to also 
assess this aspect of introducing new technology.   
 
Conclusions for Section 3  
This section presented the list of main and secondary inclusion and excision criteria for finding the 
trial participants. As the main inclusion criteria for EP participants is to have mild dementia, first the 
classification standard for dementia stages was presented – namely, the Global Deterioration Scale 
(GDS), developed by Dr. Barry Reisberg. Then the tools for assessing cognitive declined were 
presented – MMSE and MoCA. It was also explained which channels will be used to approach the trial 
participants and how the users will be selected and how many they will be. 
Further, the inclusion and excision criteria for the care-giver groups (formal and informal) were listed.  
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Section 4 -  Description of the ISISEMD services and the equipment  
 
This section presents short overview of the ISISEMD services which will be offered by ISISEMD 
platform and the necessary equipment. List of considerations for the primary end-users is listed to 
highlight some important aspects when introducing the ISISMED system in the people’s homes. It 
further describes how user guides will be prepared and how the support for the end-users will be 
ensured during the 12-month trial period.  
 
4.1 Short Description of the ISISEMD services  
 
The needed services to be provided by ISISEMD platform have been described in Del 1.1.2 “User& 
System Requirements – updated version” in M06. However, during the customisation and adaptation 
work of the integrated services, some deviations happened since M09 from the initially defined 
services to be implemented. The following table 6 is updated based on this outcome.  
 
In Table 6, the “User friendly” names for the services or sub-functions are also presented. The names 
that are marked with the yellow colour indicate where the name is different from the original service 
matrix name from the initial phase of user requirements collection.  
 
Remark: It must be noted, that even though the overall goal of the ISISEMD trial will be to evaluate 
with all end users all the integrated services, some differences are expected among the four trial sites. 
This is due to the fact that for each dyad patient-relative, there will be individual evaluation which 
services to be offered to them based on their individual care needs and dementia level of the primary 
user. It will be also difficult to guarantee for a particular patient that the set of services needed in the 
beginning of the trial period will be the same as in the end of the trial period (after one year). Even 
though the best evaluation will be to have all services tested with all users for the whole test period, 
the test participants cannot be forced to use all of them if they do not like them and moreover, if many 
services are introduced to the primary end-user at once, this might lead to confusion and drop-out from 
the trial.  
All these specifics will be reported in the evaluation report for the services.  
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Table 6: Table of the integrated ISISEMD services for the pilot 
 
User friendly names Service 
Matrix ID 
Service Matrix name Level of 
Implementation 
SERVICES BUNDLE A 
Cooking monitor A1 (A1F1) Home safety\Cooking monitor Full 
Smoke detector – Fire 
alarm 
A1 (A1F2) Home safety\Smoke detector – 
Fire alarm 
Full 
Kitchen water reminder 
and Bathroom water 
reminder 
A1 (A1F3, 
A1F4) 
Home safety\ Kitchen water 
reminder and Bathroom water 
reminder 
Full 
Remember your keys A1 (A1F5) Home safety\Remember your keys Demo only,  
no implementation 
Smart Lock A1 (A1F6) Home safety\Smart lock Full 
Fridge door alarm A1 (A1F7) Home safety\Fridge door alarm Full 
To-do list,  
Calendar, 
Season and clothing 
A2 (A2F1-
A2F4) 
Reminders Full 
Locater of personal 
belongings 
A3 (A3F1) Locater of personal belongings No implementation 
Brain Games A4 (A4F1) Cognitive stimulation Full 
SERVICES BUNDLE B 
Wake up sensor B1 (B1F1) Sleeping activity\In bed for how 
long time 
Full 
Leaving bed during night 
for long time 
B1 (B1F2) Sleeping activity\Leaving bed 
during night for long time 
Full 
Intelligent front door B2 (B2F1, 
B2F2) 
Intelligent front door  Full 
Videophone B3 (3F1) Videophone Full 
Memory Lane B4 (B4F1) Reminiscence Full 
Med Manager B5 (B5F1) Medication Manager No implementation 
SERVICES BUNDLE C 
Outdoor positioning C1 (C1F1) Portable Guard\Outdoor 
positioning 
Full 
Panic button with tracker C1 (C1F2) Portable Guard\Panic button with 
tracker 
Full 
Fall alarm C1 (C1F3) Portable Guard\Fall alarm Full 
Remote Doctor C2 (C2F1) Remote Medical Consultation Full 
Everyday Activity Pattern C3 (C3F1) Lifestyle Pattern Recognition To be implemented 
during the start of 
the 12 month pilot. 
 
ISISEMD scenarios have been described in details in Del 1.1.2 “User & System requirements updated 
version”.  
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4.2 Short description of the equipment to be used  
 
A number of devices can be used to provide ISISEMD services. First of all, a classification of the 
devices is required; two categories can be identified: interactive devices and non-interactive 
devices. 
• The interactive devices are those which exchange contents when decided by the user and 
under user’s control. Examples of interactive devices are mobile phone, PC, etc. 
• The non-interactive devices are those that control some functions but, once programmed, do 
not need any user control. Examples of non interactive devices are home automation 
controllers (flood, fire sensors/actuators). 
 
Non-interactive devices will be chosen by WP2 based on technical and economical criteria and will 
not be a direct subject of evaluation for user satisfaction; it is more the services which they offer will 
be the subject of evaluation. The main focus of the tests with users will be what these devices do, not 
the devices themselves. More technical evaluation, for example number of fault alarms, time if they do 
not function properly, reliability, etc, will be evaluated in the end, as a part of the overall assessment 
of ISISEMD platform.  
 
The possible interactive devices which allow to access and use ISISEMD services are: 
 
Table 7: Generic list of devices to access and use ISISEMD services 
Device Name Device description Services involved in 
PC Any general purpose computer which is 
intended to be operated directly by an end user. 
PCs usually have ready-to-use standard 
software installed. ISISEMD PC should be 
equipped with Web Browser and internet 
connection, features usually available on almost 
all PCs 
A2, A4, B1, B2, B3, 
B4, B5, B6, C2, C3 
PDA Personal Digital Assistant is a handheld 
computer. ISISEMD PDA should be equipped 
with Web Browser and internet connection 
A2, A4, B1, B2, B3, 
B4, B5, C3 
Phone/mobile 
phone 
Standard telephone or GSM/UMTS device that 
allow vocal  communication between two users 
located remotely and can receive SMS 
notification  
A2, B1, B2, B3, B4, 
C3 
Videophone Telephone like previous one, but equipped with 
display to allow video call 
B5 
TV Television is a medium for receiving and 
transmitting moving images 
A2, A4, B6 
Medical devices Devices that are allowed to be used by persons 
in order to measure the value of life parameters 
like blood pressure, Oxygen saturation, etc. 
C2, C3 
Digital Photo frame A display that is a photo and video clip 
container that allow photo slideshow and 
moving  
B6 
Black Boxes Ad hoc solutions to implement specific 
functions (e.g. Outdoor localisation including 
panic button) 
A3, C1 
 
The list of equipment (BoM) to be used by the different user groups is presented in the following 
Table 8. This list was also included in the set of material for the Ethical Committee applications in 
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order to demonstrate that all equipments are with CE label and that ISISEMD platform is not a 
medical device.  
 
Table 8: ISISEMD list of equipment (Bill of material)  
 
 
 
Note2: Because of some considerations for confidentiality, it might be necessary the sections 4.1 and 
4.2 be omitted in the public version of this report which will be uploaded on the project website.  
 
The following Figure 1 presents indicative layout of equipment within a house.  
 
 
 
                                                     
1
 “NO” means that another alternative equipment with the same functionality can be used. “YES” 
means that only the specific product type can be used. 
2
 It must be chosen one of the two models. The most relevant difference for the ISISEMD platform is in 
the screen size. 
Item No. Product Type Must be exactly 
the same1 
Quantity 
1 Cooper M12 
Smoke/fire detector  
NO 1 
2 Bosch Blue Line P1 
Motion detector 
NO 2 
3 CSA Cooper Safety 1450 
Flood detector  
NO 2 
4 Sunwave SD-8561W 
El-magnetic contact for 
door, window NO 3 
5 RAMOS Mini C 
Sensor control module 
YES 3 
6 
Asus PL-X31 
 
Power line Ethernet 
YES 4 
7 Mat Sensor or bed sensor 
Mat Sensor or Bed 
sensor NO 1 
8 
HP TouchSmart 300-1000 
Desktop PC (20’’ screen)  
Or 
HP TouchSmart 600-1000 
Desktop PC (23’’ screen) 
PC with touch screen  
YES2 1 
9 Lommy GPS 
The devise for the GPS 
tracking YES 1 
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Figure 1: Indicative layout of equipment within a house 
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4.3 Important considerations for introducing ISISEMD system to primary end-user  
 
Since the ISISEMD system will be offered to elderly persons who are not very used to operate with 
modern technical devices and in addition, have memory problems and problems to learn new things, 
these limitations for the elderly with mild dementia must be considered when installing the system in 
their homes: 
 
• Elderly with dementia might be even more confused if they are supposed to live interactive 
with relatives via videophone – for the communication service  
• Only one technical help device should be introduced to the elderly at a time 
• The technical device must be placed in place where it is easy to see and known for the person  
• Technical service/device/intervention for only one of their problems/needs do not help so 
much, meaning that a number of technical services/devices should be introduced in order for 
them to feel safe and live independently 
• Sometimes difficult for them even to watch TV because they are not able to turn it on due to 
the impairment that cannot read small print or are confused by buttons  
• Cannot see small print or cannot here very well (typical for elderly persons) 
• May become confused or startled if there are “Speaking” technical devices in their rooms 
• Necessary for them to have enough time to learn how to use technical help devices 
• Help from others (relatives, care persons) is needed to program, adjust, and update information 
in the technical devices 
• Technical help devices must be introduced to them in the early stage of the dementia when 
they still can learn how to use them and foster a feeling of safety and control over their life 
and surroundings 
 
4.4 How the end-user support will be ensured  
 
The end-user support will be provided through the best practices of the IT Infrastructure Library 
paradigm (ITIL) and especially through the IT Service Support action. This action implies the 
distinction of service support into different layers with concrete responsibilities and roles. 
 
In general, there are at least two roles: the first level support and the second level support.  
• The first level support is provided by personnel who are trained and responsible to receive the 
requests from the end-users (whether these requests are questions, complaints, incident 
reporting, etc) and try to resolve them directly through their knowledge, experience, or 
documentation they have available. In case that this cannot be solved, then the request will be 
forwarded to an agent of the second level support who actually has experience and expertise 
on the specific topic. The procedure of forwarding the “ticket” of the request has to be defined 
into detail so as to keep track of its progress and avoid any long workflows that delay the 
whole process.  
• The second level of support will be either technical (on how to upgrade specific versions of 
the software installed, etc) to professional care-giving services as these are going to be offered 
in ISISEMD. For this reason, the Service Support in ISISEMD will be assisted by an IT 
infrastructure, but needs the involvement of all roles that belong to its service chain. 
 
For the purpose of the ISISEMD project, the web portal that will be developed will contain a “Help 
desk” area for supporting the services. This area will contain a form with which the end-user will be 
able to write down the support he would like to receive, along with a classification of the incident. The 
backend of the portal will allow a processing of these incidents in terms of assigning, replying, 
archiving and so on. The help desk will be assisted by a hot line as well to allow a phone 
communication channel. During the project lifetime, the language for this communication will be in 
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English because this is international project. Localisation issues will be handled accordingly by some 
of the technical partners- there will be a person allocated to be involved in the help desk procedures 
and undertake the communication role with people that speak the same language. In general, the Help 
desk of the ISISEMD project will be staffed with personnel from all partners, as all partners are 
involved not only in various technical issues but also in care-giving issues. The role definition and 
responsibilities will be finalized before the start of the pilots.  
The support will be subject to a given Service Level Agreement (SLA), especially as far as it concerns 
the overall time until resolving an issue. The terms of this SLA will be defined however, at the time 
when the Help desk will be setup and based on the various topics that it will cover. In general, the 
response time will be divided into two zones: namely the normal working hours and the non-working 
hours (e.g. Sundays, nights, etc) so that there is a distinction and dimensioning of the Help desk itself.   
The first level support will be provided by a staff from the regional care-provider. Since support is 
needed also out of normal working hours, it is up to the regional care-provider how to organise the 
persons involved. This will depend on the internal organisational model of the service providers (the 
regions).  
It is foreseen that the first level support will be a person who will be trained to have the knowledge as 
a super-user of the ISISEMD system in the respective region – both w.r.t. the web-portal and general 
knowledge about the installations in the clients’ homes. The super-user(s) in the respective region will 
be trained by the technical partners well in advance such as after the installations, he/she will be able 
to provide support. Therefore, the super-user(s) will be able to provide support on local language.  
 
On the other hand, it is foreseen training activities to be carried out in all pilot sites. These training 
activities will target all end-user groups in the form of organisation of workshop and training calendar. 
For this reason, the regions will try to select EP and ICG who live in the same area so it will be easier 
and cheaper for them to travel for this training workshop. There will be demo for ISISEMD platform 
and information for the project. A good period of time for notice would need to be given beforehand to 
coordinate time slots for this.  
Another training workshop will be organised for the FCG too, most probably with more hours for 
training, because they will be using the ISISEMD platform to perform their everyday working tasks 
and will have higher responsibilities.  
 
4.5 Preparation of user guides  
 
For the ISISEMD users, documentation will be provided for all services and equipment as part of the 
deliverables in WP2 for Prototype Integration and Customization. This includes also a user guide and 
description of the specific system/functionality. The documentations and user guides will be used in 
the user training as part of the preparation of each pilot site before start of WP3 – Pilot operation.  
 
The user guides will be provided in local language where this is considered to be necessary – at least 
for the User Guides for functions where the elderly people need to interact. 
 
The ISISEMD platform and portal will be as little interactive as possible (except for example 
cognitive training) for the elderly people with dementia which reduces the risk for difficulties by using 
the system, reading and understand user guides etc. But where interaction and use of devices are 
needed, an instruction will be provided visualising and describing the functionality in a clear and easy 
understandable version. These user guides will be prepared in cooperation with professional caregivers 
or professional educated personal in dementia. 
 
Additionally, short user guides were necessary to be included in the set of materials to be sent together 
with the applications to the Ethical Committees in some of the regions (Frederikshavn for example). 
First versions of the user guides for the ISISEMD portal and the CareBox have been already prepared 
in English. The next step will be to translate them in the other three languages.  
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Some screen shots from the user guides are provided in the Appendix G as a simple example for user 
guides.  
 
Conclusion for Section 4  
This section 4 shortly presented overview of the ISISEMD services to be integrated in a common 
platform and the expected list of equipments, also specifying the list for each user group. Fist and 
second level support will be provided. It further explained how the user support will be ensured and 
what activities are necessary to be organized in order to provide training to all groups. The activities 
foreseen are training of super-users in each region and educational and training workshops in each 
region. User guides will be also prepared, as part of WP2 activities.  
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Section 5 -  Description of the tests  
 
One of the most important aspects of testing ISISEMD services with end-users will be pilot trails in the 
four regions and evaluation of the services. This section describes the ethical consideration for 
carrying out the tests with human participants and the applicable international and national laws and 
acts which will be fulfilled with ISISEMD platform and during the testing. Short information is then 
presented for the applications to the Ethical committees in each country that will be sent before the 
tests start. Further, test objectives and test methodology will be outlined followed by list of parameters 
to be evaluated and quantifiable susses indicators for the pilot sites. In the end of the section, work 
plan for the pilot sites is presented.  
 
5.1 Ethical considerations and applicable laws and acts 
 
As ISISEMD pilot will involve human subjects, a number of ethical and legal considerations will be 
considered. They are briefly summarised below: 
 
• The right to be informed: any participant in the ISISEMD pilot has the right to know the 
purpose of the activity he or she is involved in, the expected duration, procedures, use of 
information collected, the participant’s right as a part of the study and any risks, discomfort, or 
adverse effects. This information should be conveyed during the recruitment process and then 
reiterated at the beginning of the activity when the informed consent form is distributed and 
signed by the participant. The participant signs this form to acknowledge being informed of 
these things and agreeing to participate. 
• Permission to Record: before recording the voice or image of any individual permission will 
be obtained. This will be accomplished with the consent form. 
• Anonymity: Participants have a right to anonymity. Their information will be kept confidential 
and participants name will never associate with his/her data or other personally identifiable 
information. Instead a participants ID will always be used. 
• The right to withdraw: Participants should feel free to withdraw from any activity without 
penalty. 
• Valid and reliable data: In every activity, we will ensure that the data we collect are free from 
bias, accurate, valid and reliable. We will inform stakeholders about the limitations of the 
collected data. 
• Data retention and documentation: collected original data will be retained only for as long as 
it is relevant for the project. 
 
Very important prerequisite for testing ICT services with human subjects is to have approval from 
national and regional Ethical Committees. This is necessary in order to ensure that all ethical rights of 
the citizens will be respected and that the test will be carried out according to the national regulations 
and the privacy of the trial participants and all data related to this, will be ensured. In the following 
paragraphs information is provided for the applications to the Ethical Committees which will be sent 
by each regional partner. Table 9 provides brief overview of the time plan for these applications and 
from which authority’s approval will be sought.  
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Table 9: Calendar of Applications to Ethical Committees (update on 27 January 2010) 
Pilot-site 
(Country 
/Region) 
Activity Need approval?; Name of 
authority  
Start 
date of 
activity 
Period in advance if approval need Supporting Info Needed? 
Denmark Testing of 
ISISEMD 
services in user’s 
home  
Approval is needed from 
Committees for data protection and 
from Regional Ethical Committee  
M12 
March 
2010 
Approval from Committees for data 
protection has been already granted on 
6th of July 2009. 
The journal number is: j.nr. 2009-54-
0750. 
An extension of the application on the 
16th of December 2009 was made, where 
Alcatel was included as host for the data. 
 
Application to Regional Ethical 
Committee was sent on 12 Jan 2010   
 
Provisional approval received on 27 
Jan.  
Final approval is expected beginning of 
Febr 2010.  
 
For Committees for data protection – 
the names of the persons who will have 
access to information about test 
participants and who will conduct 
ISISEMD controlled study  
Detailed application was prepared with 
a number of sections based on a 
template with 14 sections and a lot of 
additional explanation material in 12 
Appendixes.  
Declaration form that ISISEMD 
platform is not a medical device. 
Agreement has been signed by 
Frederikshavn Kommune and Alcatel 
that the personal user data will be 
stored in Alcatel premises according to 
the European rules.  
UK Testing of 
ISISEMD 
services in user’s 
home 
Approval will have to be sought 
from both the Research Governance 
Dept of the BHSCT and the 
Northern Ireland Regional Ethics 
Committee 
http://www.orecni.org.uk/display/h
ome. 
A preliminary meeting has taken 
place with ORECNI on 27th April 
2009 to establish necessary steps.  
M12 
March 
2010 
Approval for both Trust and Regional 
depts. could take approx 4 months. For 
the ORECNI approval alone, before the 
pilot can begin approval will take approx 
38 calendar days 
Ethical applications were sent by 1 Oct 
2009 with any accompanying 
documentation e.g. copies of Client 
Consent forms, Protocol etc. Jill Harpur 
was invited to a meeting to answer 
questions by 13 members of Ethics 
Committee on 17 Dec 09.  
After that, BHSCT received provisional 
approval (opinion) and request for further 
clarifications to be submitted by end of 
Any preliminary interviews (if 
necessary) before the main pilot which 
will involve NHS staff or clients will 
also involve ethical approval 
Detailed application was prepared with 
approx. 80 questions and a lot of 
supporting material in Appendixes. 
Additional supporting information on 
request was submitted by mid Jan 
2010.  
Declaration form that ISISEMD 
platform is not a medical device.  
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Jan 2010.  
BHSCT was asked to fill in declaration 
that ISISEMD platform is not a medical 
device – for MHRA. Final answer is 
expected mid Febr 2010. 
Finland Testing of 
ISISEMD 
services in user’s 
home 
Approval is needed from Regional 
Ethical Committee 
M12 
March 
2010 
Application to Regional Ethical 
Committee was sent by end of Nov 2009.  
Approval for the pilot in Finland has 
been granted on 18 Dec 2009.  
 
Ref.: 
Decision making: 
Lappeenranta, Social and Health Services, 
Ethics Committee 3/12/2009, Case No. 3. 
 
Detailed application was prepared with 
a number of sections with relevant 
information based on material prepared 
in this report –  
- How the data is encrypted 
- where data is stored 
- how long data is stored 
- Description of the ISISEMD service 
- Agreement with end-users.  
- interview forms 
 
Greece Testing of 
ISISEMD 
services in user’s 
home 
Approval is needed only from 
Hellenic Data Protection Authority 
(HDTP). 
M12 
March 
2010 
The notification to the Data Protection 
Authority (DTP) will be submitted in the 
beginning of Febr 2010 immediately after 
the employment of the two psychologists 
that will run the telecare center that will 
monitor the 10 houses.  
 
Just a simple notification is required to 
the DTP, since Trikala will employ 
psychologists as formal care givers in 
the telecare center. 
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5.1.1 Ethical and Legal Framework 
 
The information necessary to be provided in the applications to the Ethical Committees to get approval 
to conduct ISISEMD pilot testing material includes different aspects. A number of details must be 
described, such as short overview of the project and its goal, description of services to be tested, 
duration of the trials, responsible person, involved equipment and its certification, user guides for use 
of the equipment, what type of personal data will be collected, for how long after the trial end it will 
be kept, who will destroy it after that, examples of interview guides and questionnaires, etc. A set of 
written material for the test participants partially describing all these aspects must be prepared, consent 
forms, etc. All this necessary material will be step by step prepared by ISISEMD partners immediately 
after submission of due reports in M06 because in some of the regions it takes some months the 
applications to be processed. In the following subsections the most important parts of these 
applications are presented, namely trial protocol, written material for the trial participants. Some more 
details and different forms are presented in Appendix A and B. 
 
5.1.1.1 Trial protocol 
 
A trial protocol is a document describing the objective, design, methodology, planning, statistical 
considerations, research-ethical considerations, finances, publication and information for participants 
in connection with research project, etc. 
 
The most important documents which must be enclosed with the trial protocol [DK Trial]: 
• Written information for participants 
• Description of procedures for communicating oral information to participants 
• Declaration of consent  
• Advertising material for recruitment of participants 
• Questionnaires 
• Other relevant material like procedures for ensuring security and privacy during and after the 
trials 
 
In the following paragraphs some more information for the necessary information is provided:  
 
1. The purpose of the project, including problem and hypothesis, also supplemented by a short 
review of literature or an actual bibliography. The goal of the description is to enable the 
committee to decide whether there are sufficient grounds for implementing the project, and 
whether the hypothesis of the project is justified; to decide whether the project may be 
justified by the expected therapeutic and public health benefits. 
2. Trial method, including design and planning. Use of control group, randomisation, etc. The 
goal of this information is to enable the committee to assess the research standard of the 
project and ensure that the project contributes to providing new valuable knowledge. Selection 
of a control group shall be accounted for too. It must be also stated who is the monitor on the 
trial. 
3. Information for the data collection - what type of data will be stored and who can have access 
to the data; for how long the data will be stored, etc.  
4. Description of Statistical considerations. They must be sufficient for an evaluation as to 
whether the project can provide answers to the questions made. 
5. Trial subjects, including criteria for inclusion and exclusion. The inclusion and exclusion 
criteria shall be stated. The gender and age of the trial subjects shall be given, including 
whether the subjects included are patients and/or healthy trial subjects. A statistical reason for 
the planned number of trial subjects shall be given.  
6. Side effects, risks and inconveniences for the trial subjects. The description shall cover 
predictable risks, side effects, including known long-term side effects, complications and 
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inconveniences involved in participation in the trial. The trial protocol shall describe any 
safety measures.  
7. Respect for the physical and mental integrity of the trial subjects and for their right of privacy. 
Statement shall be given that data concerning the trial subject are protected under all valid 
Acts on Processing of Personal Data and the Acts on the Health Act.  
8. Where a researcher wishes to use information from patients' records in the research project, 
this shall appear from the protocol. What information is to be used and the intended use hereof 
shall also be stated. The information must be relevant and necessary for the research project. 
Any subsequent contact to the patients concerned shall take place only if the health person 
who has treated the patient allows this 
 
In the trial protocols will be stated that the project is implemented in accordance with the rules of the 
respective Acts on Processing of Personal Data in each of the four countries where the pilot sites are 
established (Denmark, North Ireland, Finland and Greece).  
 
9. Recruitment of participants. A description shall be made of where and how trial subjects are 
recruited. The wording shall be without value-laden expressions and shall not arouse 
unrealistic expectations in the target group of the advertisement. 
10. Availability of information for trial subjects. Indication shall be provided as to how the trial 
subject is guaranteed access to further information on the project, such as reference to a health 
professional who may act as a contact person. 
11. Publication of trial results. The project must publish negative as well as positive trial results. If 
the results cannot be published in a journal, publication must be made in another way. A 
statement shall be provided as to how publication will be made. 
12. Statement of research ethics. The protocol shall include a statement concerning the ethical 
issues raised by the research project, including an argumentation that the project is sound in 
terms of research ethics. 
 
The statement shall include a thorough risk/benefit assessment of the trial. The risk assessment shall 
comprise an evaluation of side effects and risks calculated in absolute figures and in terms of relative 
risk without regard for any other benefits. This shall be followed by an assessment of the project in 
relation to predictable benefits for the trial subjects, for others and for research.  
 
During the trials, of big importance will be the oral information provided to the participants. The 
following paragraphs present the guidelines for oral information for the trial participants.  
 
5.1.1.2 Guidelines for oral information for the trial participants 
 
Guidelines for communication of oral information to participants will be attached to the trial protocol. 
The guidelines will apply to the person who provides the information in practice, i.e. the health 
professional who communicates the information. Basically, the guidelines will describe how to plan 
the information process, but also what is to be included in the information. 
 
As a minimum the guidelines shall consider: 
• Who provides the oral information? 
• How is the first contact to the trial subject made?  
• Through posting or a personal contact? 
• When is the oral information given (e.g. before or after the written information)?  
• How to make sure that the information interview is undisturbed? 
• How to make sure that the trial subject is given the option to have an observer present at the 
information interview? 
• How much time for reflection should be given between the oral/written information and the 
subsequent signature on the declaration of consent? 
• When to ask for consent?  
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One of the most important points of the tests will be the interviews with the trial participants from the 
three end-user groups. There are also guidelines what to be considered during the information 
interview. They are presented below. 
 
5.1.1.3 Guidelines for information interview 
 
During the information interview, the following important points must be considered: 
 
• The interview will be planned so that the trial subjects have sufficient time to read the written 
information, listen to the oral information and ask questions. 
• The interview will contain an understandable presentation of the research project without 
using technical or value-laden terms and communicated considerately adjusted to the 
individual in terms of age, maturity, experience, etc. 
• The information will include details on any predictable risks, side effects, complications and 
inconveniences and state that participation in a biomedical research project may involve 
unpredictable risks and harm. 
• The information will include details on circumstances about which the trial participant is 
believed to be unaware, but which are important to the trial participant's decision. 
 
After the information interview:  
• The trial participant will be informed if, during the implementation of the trial, new 
information becomes available concerning effect, risks, side effects, complications or 
inconveniences.  
• The trial participant who is still actively involved in the trial will be informed if the trial 
design of the research project is significantly altered in relation to the safety of the trial 
subject. 
• The trial participant will be informed if, during the implementation of the research project, 
significant information becomes available on the trial subject's state of health; unless the trial 
subject has expressly stated that he or she does not want this. 
• If it is feasible and the trial participant so wishes, the chief investigator or the health 
professional in charge of information shall, when reporting the research project, inform the 
trial participant of the results achieved and of any consequences for the individual subject. 
 
5.1.1.4 Written information for participants  
 
The trial protocol will also include written information for participants, submitted in paper form or 
electronically.  
 
The most important written information for participants shall include the following:  
• Request regarding participation in a scientific trial at the beginning of the information. 
• Purpose and method and the importance, nature and scope of the research project, including 
the practical arrangement of the project and any clinical trials.  
• Any predictable risks, side effects, including known long-term side effects, complications and 
inconveniences by participating in the research project, and that participation in a research 
project may involve unpredictable risks and harm. 
• How the security and privacy of the collected and communicated data will be ensured. What 
will happen to the communicated and collected data after the termination of the project, will it 
be passed on others outside the respective country? For how long will the data be stored? For 
instance, will it be destroyed after the termination of the project? 
• The possible benefits of the research project. A distinction shall be made between benefits for 
the individual trial subject, for others and for scientific progress. 
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• Circumstances which may result in the involuntary exclusion of the subject concerned from 
the research project as well as circumstances under which the project as a whole may be 
discontinued.  
• Where the trial subject may obtain further information on the research project (e.g. from the 
contact person). 
 
During the trials, declaration of consent will be signed by the trial participants who will be legally 
competent trial participant or be a legally competent representative.  
In a biomedical research project, an informed consent is a decision to participate in a research 
project which has been made upon satisfactory information on the nature, significance, implications 
and risks of the project and receipt of suitable documentation. The decision is made voluntarily by a 
person who is capable of giving his or her consent. The consent shall be in writing, dated and signed 
or provided using an electronic signature. 
 
The trial protocol will be accompanied by a copy of the declaration of consent. 
Original declarations of consent will be stored by the chief investigator, and the trial participant is 
entitled to have a copy of the declaration of consent. ISISEMD Informed consent form for the 
ISISEMD platform is provided in Appendix B1.  
Additionally, declaration of consent for the Outdoor Guard (GPS) service was prepared by the partners 
separately in order to ensure that also this service will be approved by the Ethical Committees in all 
regions. See Appendix B2.  
 
 
5.1.2 Applicable laws and acts 
 
All tests with all user groups in all regions from the consortium partners will comply with the 
applicable European and national laws. As described in Del 1.3.1 “Privacy & Security Analysis 
Report”, building and deploying ISISEMD system and the services will fulfil the national and 
European regulations, rules and laws for collecting and accessing the user’s data and appropriate 
security and privacy protections mechanisms will be implemented. 
 
Below is just a short summary of the applicable laws [Del 1.3.1, 2009]: 
To tackle all the potential ethical issues deriving from the collection and processing of personal data, 
the project partners have agreed in taking concrete action to the thorough examination of the European 
and international regulatory framework on the protection of personal data, respecting the relevant 
legislation, the established case law, the legal doctrine and the opinions and recommendations of the 
Data Protection Working Party of Article 29 of Directive 95/46/EC. 
The aforementioned legislation is the result of various international legislative initiatives which reflect 
the established morals and ethics regarding the protection of privacy and personal data. It follows that 
in order to ensure that all potential ethical concerns with regard to the processing of personal data are 
covered, it is necessary, first and foremost, to ensure that the relevant legislation is respected. More 
specifically, every activity undertaken within the ISISEMD project will be fully compliant to the 
international and European and national privacy and data protection laws. The process of collecting 
the users’ data will be legitimate, in the context of article 7 of Directive 95/46/EC. Additionally, in 
respect with the trans-border transfer: the personal data collected will not be transferred to any third 
county that does not offer adequate protection. In cases where the project results or data regarding the 
evaluation and pilot phase of the project are communicated to the public, they will not include the 
names or other personal data of the users who have been the subject of the activity. 
 
With regard to the willingness of the users (and their informal caregivers) to participate in ISISEMD, 
we underline that every user will be notified in advance and asked to consent specifically for the 
collection and processing of their personal data for the purposes of the project. In addition, their 
consent will be based on thorough and intelligible information on how their personal data will be 
collected and processed, what will be the benefits of such processing and that they can withdraw their 
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consent anytime, after the start of the pilot activities. In the contest form it will also be explained some 
other relevant aspects, such as among others - liability. For example it will be mentioned, that the 
solutions offered by the project aim to enhance the quality of life and not to substitute professional 
medical assistance for the project/trial period. Details about this type of written material for the test 
participants are presented in the Section 5.1.1.4 above and some documents are provided in Appendix 
A and B.  
 
Specific fact about ISISEMD services are that they will support the everyday life of persons with 
cognitive decline or mild dementia who in some cases are not able to take legal decision by 
themselves. Therefore, in these cases they have a legal representative. Because of these circumstances, 
the applicable national laws will be fully respected. The principles of the Mental Capacity Act of 2005 
include supporting people to make decisions for themselves wherever possible, and making decisions 
in the best interests of people who cannot decide for themselves. The Code of Practice which 
accompanies the Act outlines how health professionals should support the person and/or include carers 
in the decision making process. The social services department of the local authority has a duty of care 
for vulnerable adults living in its area. It has to assess the needs of these adults and provide services 
and/or equipment to meet any assessed needs. Social services also employ Occupational Therapists 
(OT), who are specialists in assessing the living environment. 
The Data Protection Act of 1998 covers medical records, and medical professionals often quote it 
when families ask to see a person's medical notes or ask to be kept informed about their care. 
However, it could be argued that it is in the patient's best interests for the information to be made 
available so that the people who are involved in their care are well informed and able to act in the 
person's best interests. 
 
5.1.3 National acts 
 
Frederikshavn 
 
In order to carry out the ISISEMD pilot in Denmark, the project will be certified by the Local 
Scientific Ethnics Committee for North Jutland Region and will follow the rules set by the National 
Scientific Committee (and the Helsinki declaration):  
http://www.cvk.sum.dk/CVK/Home/English.aspx and  
http://www.efgcp.be/Downloads/EFGCPReportFiles/Flow%20Chart%20Denmark%20(revised)%200
8-03-01.pdf. 
The project has already been approved by the Bureau for Control of Personal Data, July 2009 and data 
will be administrated by their rules: http://www.datatilsynet.dk/english/the-act-on-processing-of-
personal-data/ 
Other applicable law in Denmark is “Magtanvendelseloven” (law for preventing use of force). This 
law will be respected when ISISEMD services are being integrated, deployed and used.  
 
Some more relevant information is summarised from the book “Håndbog om demens. Til 
myndighedsniveau: ledere, politikere og forvaltningsmedarbejdere” published by Servicestyrelsen in 
Denmark: 
 
The legal right of the dementia persons 
Use of force over persons with dementia is only something, with some exceptions, that can be applied 
as a last resort; after all possible means are tried and failed. The use of force is considered an “attack” 
over the personal freedom of the person. Applying these rules is, to a high degree, to strengthen the 
legal right of the person with dementia so that unnecessary interventions do not take place and to 
ensure openness and reflection about the situation of the person with dementia 
 
Personal rights 
The Danish society is a democratic society and the human rights are written in Grundloven. Two of 
these fundamental rights are the right to self-decision and integrity. Self-decision means that the single 
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person has the right to decide over their own life both in personal and economical respect. Integrity 
means actual and real wholeness or inviolableness: however, one can go further and define integrity as 
respect for the single person in physiological, physical or personal aspects. Integrity is therefore 
further understanding of self-decision. Interference in one person’s self-decision can only take place 
with a law and only when the person himself, other people or the society behaves for this.  
 
Use of alarms, technical care systems, door openers  
If the person with dementia leaves their home and poses a risk for damage to themselves or others, the 
care personnel can search for permission to use personal alarms or technical care systems. It must be 
documented that the person with dementia leaves the home and cannot care for themselves and the 
personnel has utilized different social, pedagogical approaches without success to avoid the person 
leaving the home. Only after this situation should the use of alarms or technical care systems be 
considered.  
If all other approaches have been tried without success and there is high risk for personal damages if 
the person leaves their home, an exception could be given for the use of special door-openers in a 
limited period.  
Decision for use of personal alarms, special door-openers or technical care systems is taken by the 
care personnel in the municipality in a limited period.  
 
More information for the topic “use of force” and the use of technical means for care for dementia can 
be found in: 
- Guide for alarm- and care systems for persons with dementia, Styrelsen for Specialrådgivning 
og Social Service, 2007 
- Vejledning om magtanvendelses m.v. efter lov om social service nr. 16 af 31/03/2008. 
 
In general, more information about patients with dementia, their relatives, and conditions for all 
aspects of everyday care can be obtained from Servicestyrelsen website 
www.servicestyrelsen.dk/demens. 
 
Lappeenranta  
 
There are two acts concerning the ISISEMD application: 
• Personal Data Act 22.4.1999/523: 
http://www.finlex.fi/fi/laki/kaannokset/1999/en19990523.pdf 
• Act on the Protection of Privacy in Electronic Communications 516/2004: 
http://www.finlex.fi/fi/laki/kaannokset/2004/en20040516.pdf 
This Act entered into force on 1 September, 2004. 
 
Trikala 
 
The collection, processing and management of sensitive personal data holds threats to the patients who 
have the legal right to be protected according to the 9th Article of the Greek Constitution. In Greece, 
these people’s rights are safeguarded by the Independent Authority of Personal Data Protection. 
 
European and Greek Legal Context  
The legal context of personal data protection determines: 
1) The Greek Law 2472/1997 which constitutes a full legal system to protect the subject from the 
processing of personal data. 
2) The Greek Law 3471/2006 which mainly concerns the protection of personal data and privacy 
in the field of telecommunications. With this law there have been major amendments to the 
aforementioned law and Greece complied with the 2002/58/EK of the European Union, 
incorporating amendments that the Authority of Personal Data Protection suggested as an 
outcome of its experience, abolishing law 2774/1999, in which the already applying directive 
97/66ΕΚ had been incorporated. 
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3) The Greek Law 3625/2007 through which the field of application and jurisdiction of the 
Authority of Personal Protection Data is determined. 
4) The Directive 95/46/EK which is still applying concerning the protection of natural subjects 
against the processing of personal data and the free circulation of these data. 
5) The Directive 2002/58/EK which is still applying about the processing of personal data and 
the protection of privacy in the field of telecommunications. 
6) Article 9 of the Greek Constitution 
7) Article 8 of the European Agreement on Human Rights 
8) The Greek Law 2071/1992 about the National Health System, article 47 
9) Bearing in mind the arrangements of article 22 of the Greek Law 2472/1997, as it was 
amended, it is currently applying and the arrangements of the Penal Code about trespassing of 
confidential data, articles 370 and the following ones, specifically article 371 of the Penal 
Code concerning professional confidentiality and the arrangements concerning crimes against 
the subject’s value (articles 361 and the following of the Penal Code) which determine the 
penal repercussions of the offenders. 
10) Different arrangements of the Greek Civil Code, especially those which concern the rights of 
the self, article 57 of the Greek Civil Code, and the arrangements 914,919 and 932 of the 
Greek Civil Code, which determine the civil outcomes. 
11) The regulatory acts, directives and decisions of the Authority of Personal Data Protection, 
which constitute the result of this institution’s function until the present day and the in 
concrete application of the relative legislation. 
11) The decisions of the Greek Courts of Law, Administrative, Civil, Penal. 
12) The relative European Legislation, Regulation (European Union), no 460/2004 of the 
European Parliament and the 10th of March Commission about the creation of the European 
Organization about the Network and Information Security (F375KB), Security of Networks 
and Information: European policy proposition, Index (com/2001/0298), 18th February 2003 
Commission’s Resolution about the European perspective concerning the networks’ and data 
security, 28th January 2002 Commission’s Resolution about a joint approach and special 
actions in the field of data and network protection(2002/C43/02) 
 
Belfast 
 
Two pieces of legislation are of particular relevance to people with dementia and housing, the Mental 
Capacity Act (MCA) of 2005 and the Disability Discrimination Acts (DDA) of 1995 and 2005. The 
MCA clarifies the legal position of those providing help or services to people who may lack the 
capacity to take certain actions or decisions for themselves. The DDA prohibits discrimination against 
a disabled person. People with dementia would fall into this category, along with those with a learning 
disability or mental illness. The Mental Capacity Act 2005 provides a statutory framework to 
strengthen the position of - yet also protect - adults who may lack capacity to make some decisions for 
themselves. It enables capacitated people to plan for a time when they may lack capacity and clarifies 
who can take decisions, in what situations and how to go about it. The Act is relevant to everyone who 
supports or cares for – whether formally or informally – people who may lack capacity to make 
decisions for themselves. 
 
The UK laws that will concern the ISISEMD application will also involve the Data Protection Act of 
1998 and the protection of Personal Information. 
 
5.2 Trial Objectives  
 
This section presents overview of the main objectives which ISISEMD partners aim to achieve with 
testing ISISEMD services with end-users.   
 
One of the main objectives of ISISEMD project is to trial the integrated services in a real life, for 12 
months, involving all relevant main end-user groups.  
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A major potential for big impact in improving quality of life for elderly with mild dementia in Europe 
is that on first place, some type of technology assistive services in their homes will be offered to them 
and their closest relatives. Currently such type of “home” services does not at all exist in the care-
provider organisations of the regional partners for these specific groups of clients.  
 
On the second place, with the help of the ISISEMD platform and demand-driven services, the senior 
citizens will be able to live independently in their homes safely and longer, their quality of life will be 
improved and the burden of taking care for them which their closest relatives feel will be reduced.    
Of course, after the end of the 12-month trial period, technical assessment of the ISISEMD services 
will be done. The outcomes of it will be presented in D-3.3.4 “Report on validated common functional 
specifications building on the pilot experience”. On the other hand, it is of a crucial importance to 
assess to what extent the ISISEMD services fulfil the user expectations, what the user acceptance and 
satisfaction is after the 12-month trial. These are aspects related to the human factor and in many 
situations directly linked with subjective evaluation and perceived individual quality.  
The main topic of this report is exactly this – to discuss the acceptance from the point of view of the 
human subjects. This report could also serve as a handbook for caring out the trial. Therefore, as a 
starting point, the trials objectives must be clearly defined. They are mapped to the overall project 
objectives.  
Table 10 below is based partially on a table from Description of Work presenting the project 
objectives and their respective Quantifiable Success Indicators. It must be noted, that only the project 
objectives relevant to the testing with human subjects, are discussed in this table.  
 
Table 10: Mapping of Project Objective and Trial Objectives 
Project objective Quantifiable Success 
Indicators for each Project 
objective 
Trial objectives 
O1 - Improve care of elderly 
with cognitive problems by 
offering them ICT services for 
self-care 
Satisfaction of elderly using 
ISISEMD services  
• Measure improvements in 
quality of life of elderly  
• Measure acceptability of the 
services by elderly 
• Measure satisfaction from the 
use of the services by the 
elderly 
O2 - Improve care of elderly 
with cognitive problems by 
offering the care-givers ICT 
services 
Satisfaction of the care-givers 
using ISISEMD services 
• Measure acceptability of the 
services by informal and 
formal caregivers 
• Measure satisfaction from the 
use of the services by the 
informal and formal caregivers 
• Measure improvements in 
quality of life of informal 
caregivers and reduction in 
their burden  
• Measure efficiency of 
ISISEMD services for the 
formal caregivers  
O4 - Evaluate the pilot set of 
scalable ISISEMD services 
under realistic conditions and 
for adequate time period 
Run the pilot service for a 
certain period (12 months)  
• Carry out the trials in the 
clients homes for 12 months  
 
O6 - ISISEMD services to be 
demand-driven 
Involve all main stakeholders in 
the pilot service  
• Carry out the trials with the 
three main user groups  
 
As seen from the table above, the key words for the trial objectives are User Acceptance, 
Satisfaction, QoL and Efficiency. 
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More specifically, the trials will try to give answers to a number of hypotheses which ISISEMD 
partners have formulated, based on the objectives of ISISEMD project.  
In the following lines, the hypothesis and the research questions are presented.  
 
Main hypothesis:  
• - ICT services will have a positive effect on Quality of Life for the elderly with mild 
dementia and their caregivers 
 
• Supporting Hypotheses: 
o Quality of Life 
 ICT services will increase QOL for 50% of EPs in the test group 
 ICT services will increase QOL for 70% of ICGs in the test group 
o Burden of care for the informal caregivers  
 ICT services will reduce the burden of care by 60%  
o Feeling of Safety 
 Test group EPs and ICGs will report a higher feeling of safety (30% 
higher) in their daily life than the control group. 
o Social Benefits (Effectiveness and Economic Impact/Costs) 
 ICT services will allow for the transfer of care giving tasks from FCGs to 
ICGs (more efficient for FCG daily tasks, time, and travel) 
 Test group ICGs can remain employed outside the home longer due to 
reduced need in time spent in the care giving role  
o Accessibility (to care/services offered by the care provider) 
 There will be a 25% increase in access to care offered to the public in test 
group participants  
o Acceptability/Satisfaction 
 Test group participants will report 75% higher acceptance of ICT systems 
for home care than the control group 
 75% of participants in the test group will use the ICT services regularly 
 75% of ICGs in the test group will report acceptance of ICT services as 
support in their care for EP (desire to continue utilizing ICT services) 
 75% of test group participants will report satisfaction of ICT services   
 
Answers will be sought to the following SCIENTIFIC (RESEARCH) QUESTIONS   
 
• What effect will ICT-services have on the quality of life of the end-users?  
• How is the user accept and satisfaction with use of ICT-services?  
 
• Could ICT-services help EP to live longer in their home?  
 
• The need for care will be stable (will not increase) for EP who uses ICT-services while there is 
increasing need for a lot of care with the progressing of the disease with elderly who do not 
use ICT-services.  
 
• How is user satisfaction correlated with a certain user group characteristics?  
o Age 
o Gender 
o Living alone or with an informal caregiver  
o Dementia stage  
 
• Which of the ICT services have maximum/minimum accept by the test persons?  
 
• Which of the ICT services is maximum/minimum satisfactory for the test persons?  
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• Which parameters of the ICT-services are the most important for the user-satisfaction and 
accept?  
o That ICT-services are easy to use?  
o The look of the service  
o The functionality of the service  
o Support/Training for the users and maintenance of the service  
 
5.3 Test Methodology  
 
Shortly speaking, in the evaluation process, the selection of appropriate evaluation method to be used 
is very important in order to avoid subjective evaluation, be most suitable for the client and the care 
staff. This section describes test methodologies to be used in the evaluation process, namely which 
methods will be used in assessing Quality of Life (QOL), user acceptance, user satisfaction and 
cognitive functioning.  
 
For assessing for Quality of Life (QOL), some standard questionnaires will be used, which have been 
explained in Section 5.3.4. It is important to underline though that in order to make accurate and 
objective comparisons, the first round of evaluations (such as functioning status, user acceptance and 
QOL) will be conducted before intervention implementation. Another round of evaluations will be 
administered before the clinical trials are completed and again after the interventions have concluded. 
In this way we hope to have as clear picture of the status as possible in the very begging of the 12-
month trial period. After that, the initial results will be compared with the results in the end of the 
evaluation period. 
 
For assessing user acceptance and user satisfaction, ISISEMD partners will use their own explorative 
approach, presented in the next subsection.  
 
Additionally, initial assessment of cognitive functioning of the primary end-users will be carried out, 
but this is considered as part of the selection process and selection criteria. The rating scales for 
assessment of cognitive functioning have been described in Section 3.1.2. For this reason they will not 
be presented here again. Assessment of cognitive functioning is seen as a secondary testing during the 
pilot trials since the main objective of the ISISEMD services is to improve the quality of life. 
However, since small number of the ISISEMD services is targeting cognitive stimulation, they might 
have a positive effect on the speed of cognitive decline in terms of delaying the time when the person 
has severe dementia. Such positive influence could be caught by administering MoCA/MMSE 
questioners and comparing the tests scores of the test group and the control group before and after end 
of the trial period. 
 
Note: The instruments, rating scales and questionnaires that are described in this report are presented 
in the Appendix section. 
 
5.3.1 Triangulation of the three methods 
 
Due to the specifics of dementia, many of the primary users do not see themselves as impaired; either 
they do not see their difficulties in their daily life or they are embarrassed and try to hide them. Having 
dementia, and the difficulties derived from that condition are often tabooed, so getting into the issue 
can be difficult both to the demented person but also to the data collector. Due to different 
understandings and views on one’s own condition, one method will have different applicability on 
different demented persons. Therefore, it is necessary to approach the trial participants from different 
angles to gain the best understanding of the actual situation. The philosophy is that each of the 
methods will reveal different aspects of the same reality. Thus, by applying them all to the same 
participant, they will piece together an image closer to the objective reality.  
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At the same time, the selection of appropriate evaluation methods to be used is important in order to 
avoid invalid measurements. Considering the pathology (cognitive impairments), intervention 
(technological), care setting (community dwelling) and desired outcomes (user acceptance and 
increased QOL), evaluations need to be situation appropriate for the end users and caregivers. We 
consider the following methods for evaluation and validation to be appropriate: 
• Questionnaires for EP, FCG and ICG 
• Participation observations  
• Qualitative and quantitative interviews 
To answer the above mentioned challenge, in the project we will use an explorative approach in the 
evaluation of user acceptance, satisfaction and quality of life – before, during and after the pilot trail 
for the EP. Besides questionnaires, we will apply two quantitative methodologies in the analytical 
work for the EP: semi-structured interviews and participation observations. Finally, we will use a 
triangulation of the three methods to approach the EP of the system from different angles. This is 
similar to the method we used in collection of user requirements – the method of triangulation of 
data collection techniques.  
 
In the pre-analysis phase, when determining the user requirements, the two qualitative methodologies 
were taken into use. By applying the two methods simultaneously on the same user, they were found 
to supply each other well. The Table 11 below lists some of the strengths and weaknesses seen from 
that approach to the users. 
 
Table 11: Comparison of the data-collection methods  
Method Participation observation Semi-structured interviews 
Strengths  • Visualizes the physical problems in 
daily life (for example decor of the 
house) 
• Easily reveals difficulties in the daily 
day life upon the acts of the observed 
person 
• Fast to conduct 
• A structured way of getting the 
interesting information  
Weaknesses • Time consuming 
• Demands that the observed person is 
acting 
• Demands that the observant is a natural 
part of the situation 
• It is easy for the interviewed person 
to hide difficulties that he don’t 
want to talk about 
 
In the first phase of the project ISISEMD partners were seeking to identify difficulties and insecure 
situations from the daily life of the persons with dementia. Difficulties and insecure situations were 
the two key-words in the interviews and observations to help us gain knowledge of how technology 
could give the users an easier life with less dependency to ICG and FCG and feel safer. In the same 
manner, we will find keywords for User Acceptance, User Satisfaction and Quality of Life and create 
interview and observation guides to be carried out on these topics. 
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5.3.2 User Acceptance  
 
In the evaluation of the ISISEMD services we will discuss user acceptance from all three main end-
user groups point of view – EP, ICG and FCG. 
 
User Acceptance by elderly subjects and their relatives  
Acceptance of remote support and monitoring by elderly and their relatives is by far one of the most 
important parameters in ISISEMD evaluation. If clients and their relatives are not comfortable with 
the technology, or feel that they do not have control over the system, they may avoid using it, thereby 
precluding other benefits of self-care and remote monitoring. 
 
User Acceptance by Professional Caregivers 
Acceptance of homecare services by caregivers and other healthcare professionals is important in 
homecare evaluation. If care professionals are not comfortable with the technology or judge that the 
technology decreases their control over clients, they may avoid using it, thereby precluding other 
benefits of homecare. Clinical acceptance of a homecare application may depend on the degree of 
confidence which the caregivers and medical staff have in their work tasks from using the application 
as well as the caregiver's satisfaction with the encounter in the absence of proximate interaction with 
the client.  
 
We distinguish by user acceptance from a technology perspective and from a human perspective. 
 
User Acceptance from a technology perspective 
Dillon and Morris [Dillon, 1996] define user acceptance in trials such as this as “the demonstratable 
willingness within a user group to employ information technology for the tasks it is designed to 
support.”  
Innovation diffusion theory is a paramount theoretical perspective on technology acceptance and it 
aims to provide a description of the mode in which technological innovation moves from invention to 
pervasive utilization. It applies five characteristics of innovations that affect their diffusion: 
1. Relative advantage (the extent to which a technology offers improvements over currently 
available tools) 
2. Compatibility (its consistency with social practices and norms among its users) 
3. Complexity (its ease of use and learning) 
4. Trialability (the the opportunity to try an innovation before committing to use it) 
5. Observability (the extent to which the technology’s outputs and gains are clear to see) 
 
User Acceptance from a human perspective 
Acceptance has also been conceptualized as an outcome variable in psychological processes that users 
go through in making decisions about technology [Dillon, 1996]. Theory of Planned Behaviour, or 
TPB, [Ajzen, 1991] holds that attitudes, subjective standards and perceived behavioural control are 
immediate determinants of objectives, which in turn influence behaviour. The Technology Acceptance 
Model (TAM), developed by Davis [Davis, 1989] predicts user acceptance of technology is influenced 
by perceived value and perceived ease of use. Theoretical work in social and cognitive psychology and 
sociology also study user acceptance, and this is particularly applicable for ISISEMD use where 
acceptance will be subjectively evaluated and empirically measured. Relationships between beliefs, 
attitudes, norms, intentions and behaviour shape subjective norms, and all are of great significance in 
shaping human behaviour in exercising choice. The field of human-computer interaction (HCI) and 
Man-Machine-Interaction (MMI) calls for user-cantered technology and current textbooks cover basic 
psychology and social impact, associating social science and engineering research to develop more 
useable and acceptable systems.  
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Training to increase User Acceptance/Satisfaction 
In order to facilitate the best possible conditions for user acceptance, a reasonable amount of time 
must be spent on training. The amount of time and type of training caregivers and primary participants 
require for them to feel competent and confident with using the technologies, will be different for each 
situation. Face-to-face training at the time of installation and extensive print material with specific 
instructions and demonstrative pictures (such as how to provide a feedback to a prompt for example or 
set up an appointment) will be vital in influencing user acceptance. More technologically experienced 
relatives and caregivers will require more advanced materials to allow them to modify the initial 
system settings to meet their personal needs, such as disabling door sensor alarms during high volume 
use.   
Training for the three main user groups is foreseen and will be carried out by technical partners before 
the start of the trials. More details about the training activities are presented in Section 4 of this report 
and will be provided in the upcoming deliverable from WP 2 D-2.2.2 “Service adaptation and 
customisation”.  
 
Method for assessing user acceptance for the ISISEMD services 
Acceptance and use of the technological intervention by elderly and their caregivers is an important 
parameter in ISISEMD evaluation. Clinical acceptance of a home care intervention will depend on, at 
least, the degree of confidence which the ICG and FCG have in their work tasks using the application 
and performance satisfaction. If trial participants are not comfortable with the technology, or if the 
service does not work as they expect from the very first times, they are more likely to avoid using it. 
Additional risk factor for user acceptance from EP aspect is that sometimes they might forget which 
the purpose of the special box installed in their home is and thus feel confused about its presence. 
Another risk factor is that in the early stages of the illness, the patients sometimes does not confess 
their cognitive or memory decline and thus may resist (in general) that they need ICT support for their 
independent daily living.  
 
User acceptance can be assessed by utilizing Choice Modelling methodology. Choice modelling is 
held to be the most accurate and general purpose tool currently available for making probabilistic 
predictions about human decision making behaviour in a particular situation. As opposed to utilizing a 
poll or survey, Choice Modelling predictions are applicable over large numbers of scenarios within a 
context and it is considered the most appropriate method for assessing consumer willingness to pay for 
quality enhancements in multiple dimensions. 
 
For assessing user acceptance, we will make questionnaires and interviews with the users to determine 
their acceptance with the ISISEMD-services. Care givers (CGs) can be asked to determine how much 
they would be willing to sacrifice, pay or exchange to use a particular service/intervention. For 
example, an ICG may be asked to estimate how much they are willing to pay for an intervention or a 
FCG may be asked how much work time they would exchange for a service. 
 
5.3.3 User Satisfaction 
 
As the primary user group of elderly demented people shows a general resistance to technology, User 
Satisfaction is considered as one of the central measurements of the ISISEMD success. If the user is 
comfortable with a service, its aiding abilities are higher. 
 
In the ISISEMD project, user satisfaction can be defined as a user’s critical evaluation of several 
aspects of the service.  
This evaluation is believed to be influenced by the user’s expectations, perceptions, attitudes and 
personal values. Accordingly, satisfaction is considered as a multidimensional concept where 
different aspects should be considered and tuned to fulfil the user expectations and needs and thereby 
heighten the impact of the service. Therefore, user satisfaction will also be a central parameter in the 
improvement of the services during the pilot trail. 
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Method for assessing user satisfaction from the use of ISISEMD services 
Similarly to assessing user acceptance, we will make questionnaires, interviews and perform 
observations with the users to determine their satisfaction with the ISISEMD-services. The Quebec 
User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0) can be inspiring to this 
action [Demers 2001, Demers 2002]. 
QUEST is a method to assess how satisfied a person is with the use of an Assistive Technological 
Device (ATD) without considering how well the aid device is performing. To make a QUEST-analysis 
12 items are evaluated; 8 items on the physical device or service and 4 on the service that is provided 
for the maintenance of the device or service. Below the 12 items are listed: 
 
Device parameters: 
Comfort Physical and psychological well-being associated with use of ATD 
Dimensions Convenience of the device’s size (height, width, length) 
Simplicity of use Ease in using the ATD 
Effectiveness Goal achievement with the ATD 
Durability Robustness and sturdiness of the ATD 
Adjustments Simplicity in setting/fixing the components of ATD 
Safety Degree to which the ATD is safe, secure and harmless 
Weight Ease in lifting and/or moving the ATD 
 
Service parameters: 
Service delivery Ease in acquiring the ATD including length of time 
Repairs and servicing Ease in having the ATD repaired and serviced 
Follow-up services Ongoing support services for ATD 
Professional services Quality of information on ATD provided, accessibility and competence of 
professionals 
 
For each of the parameters, QUEST provides evaluation questions. There are 5 possible answers for 
the questions.  
1 – very unsatisfied  
2- unsatisfied 
3- somehow satisfied 
4- satisfied 
5 – very satisfied  
 
Even though ISISEMD services cannot be fully considered as a single ATD, our evaluation will be 
based on QUEST as a method to evaluate user satisfaction. Relevant updates and additions will be 
made in the parameters to be evaluated. It will be further decided if the ISISEMD platform and 
services will be only evaluated as a whole or there will be also a separate evaluation per service or per 
service bundle. 
 
Aspects of the value added services from ISISEMD platform to be assessed are: 
• Easily managed, transparent and comprehensive user interaction 
• Feelings of safety and security in the home 
• Satisfaction in the ability to self-care and extend independence 
• Enhanced social interaction 
• Ability to locate EP in- and outdoors 
• Ability to communicate remotely with EP 
• Reduction in care burden for ICG 
• Memory support 
 
Another questionnaire that evaluates how people with dementia use technology in their everyday tasks 
is ETUQ - Everyday Technology Use Questionnaire [Nygård, 2002] and [Rosenberg, 2009]. The 
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ETUQ is developed to map out perceived relevance and competence in the use of everyday technology 
among older adults with MCI or mild dementia. However, it evaluates commonly used technology 
devices for personal care, household, data and telecommunications, shopping and transportation 
[Rosenberg, 2009]:    
 
Household devices – iron, microwave  
Activities in the home – TV, video/DVD player, computer 
Personal care – electric toothbrush  
Power tools – unspecified  
Accessibility – levitator, code-operated door lock  
Data and telecommunications – cell phone, email, internet  
Economy and shopping – credit card, internet banking 
Transportation – automated check-in at airport  
 
It uses a four-category scale: 4= use without difficulty, 3=use independently with difficulty, 2=use 
with help from someone else, 1 = does not use anymore.  
 
The ISISEMD interview guides for user satisfaction and acceptance by primary end-users and the 
questionnaires for the informal caregivers have been based on these two evaluations (QUEST 2.0 and 
ETUQ).  
Interview guide for evaluation of user satisfaction from the ISISEMD platform by the primary end-
user is included in Appendix D1. 
 
Important note:  
User acceptance and satisfaction are so very important in the process of introducing ICT services to 
elderly and also people with cognitive problems that these aspects will be two of the crucial factors 
which will define the susses of ISISEMD services. Therefore, in the evaluation of user acceptance and 
satisfaction, iterative process will be followed. The first evaluation will take place already after the 
first two months of the pilot trials, during the small-scale testing. There will be after that midterm and 
final evaluations. The drawback identified from them will be immediately provided to the technical 
partners to improve the services customisation. 
 
 
5.3.4 Evaluation of Quality of Life of Primary End User  
 
The World Health Organization [WHOQOL, 1995] defines quality of life as one’s perception about 
their current status in the perspective of their culture, mores and concerning their aspirations, 
opportunities and interests.   
It is a broad, multidimensional construct involving physical health, psychological status, 
environmental factors, social relationships, level of independence and individual convictions. The 
most common thread connecting quality of life (with dementia) assessment tools is that they are 
modelled after Lawton’s constructs. He stresses that QOL has temporal dimensions, including 
reflection on the past and expectation of the future, as well as appraisal of the present and the need for 
cues to reinforce identity.  Lawton identified four overarching dimensions that contribute to QOL 
[Lawton, 1969, 1983; 1991]:   
1. Psychological Well Being (positive and negative affect)  
2. Behavioural Competence (cognitive and functional abilities, weighted by third party 
assessment)  
3. Objective Environment (caregivers and living situation)  
4. Perceived QOL (paralleling behavioural competence but weighted by primary party 
assessment)  
 
Going further in assessing QOL of patients with dementia, according to Scholzel-Dorenbos et al., 
[Scholzel-Dorenbos, 2007], the domains important for QOL according to patients with dementia are: 
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affect, self-esteem/self-image, social contact, attachment, physical and mental health, enjoyment of 
activities, sense of aesthetics, financial situation, security and privacy, self-determination and freedom, 
being useful/giving meaning to life and spirituality. 
 
When assessing QOL, two perspectives come into play: the first is the subjective experience by the 
individual to be assessed; the second is the subjective perception by the proxy individual (usually a 
caregiver or physician or a closest relative). Because quality is a subjective term and different people 
perceive different levels of quality on the same subject, the problematic nature of measuring QOL 
becomes even more confounded when dealing with cognitive impairments. In standard rating scales 
for assessing QOL, it is very common that both the patient and her/his care-givers fill in the 
questionnaires. Very often, the scores of the care-givers or the relatives are lower than the patients 
themselves. This is due to the fact that they compare the current status of the patient with his/her best 
performance before the illness. 
 
ISISEMD will utilize the Quality of Life – Alzheimer’s disease, or QOL-AD, [Logsdon, 2002] 
measurement tool to assess EP QOL. It is designed for patients with mild to severe dementia, living in 
the home care setting. QOL-AD measures domains of: physical health, energy, mood, living situation, 
memory, family, marriage, friends, self as a whole, ability to do activities around the house, ability to 
do activities for fun, financial and a global “life as a whole” question. Comparing with Scholzel-
Dorenbos domains, in the context of our study, we will focus on social contact, physical and mental 
health, enjoyment of activities, finances, security, self-determination and being useful. 
 
Methods 
The method to be used in assessing QOL will be a combination of approaches for the assessment of 
QOL in patients with dementia. These include self-reports by the individual with dementia, proxy 
reports by a family member or caregiver, and participation observation of behaviours assumed to be 
related to QOL. Each of these approaches has strengths and weaknesses. 
Self-report directly involves the individual in the assessment, taking into account his or her subjective 
experiences, and places value on the perspective of the person who has the most to gain or lose from 
using the services. This respect for the autonomy of the individual is very important from a clinical 
and ethical standpoint. 
Proxy reports are usually obtained from a close relative or caregiver of the affected person. They 
circumvent the cognitive limitations that are problematic for the person with dementia and can be used 
throughout the course of the disease. 
Participation observation of behaviours believed to be associated with QOL has the advantage of 
being more “objective” in that ratings can be based on predefined behaviours and consistently rated 
over time. Limitations of this approach include uncertainty about whether what is being observed is 
what the individual considers to be important to his or her QOL. Direct observations may also be 
subject to many of the biases associated with proxy ratings. In addition, some raters are very alert and 
attuned to subtle nuances of affect and behaviour; others are not [Logsdon, 2002]. 
 
Brief presentation of QOL-AD 
QOL-AD includes patient and proxy report of patient’s quality of life, it is reliable and valid for 
individuals with MMSE greater than 10. It is 13-item questionnaire with 4-pt responses which could 
be completed as interview for primary user (Table 12 below). It takes usually 10 minutes. Answers are 
structured on a four-choice scale and items are rated according to current status. Patients complete the 
QOL-AD in an interview format and ICG complete a questionnaire, both taking less than fifteen 
minutes. Answers are recorded and EP response scores are doubled, added to ICG scores and the total 
is divided by three to give more weight to the primary subjective evaluation; higher scores indicating 
higher reported quality of life. Interviewers will use a set of explicit instructions in order to avoid 
influencing participant responses. Participants will also follow along on their own copy of the 
measurement and can either respond verbally or mark their own response. If an EP is unable to 
comprehend/respond to more than two items, the interview will be discontinued and that EP will be 
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considered “unable or unwilling to complete the assessment.” The participant version of the 
instrument could be seen in Appendix C4.   
 
It must be noted, that similar to MoCA rating scale, QOL-AD should exist in corresponding versions 
in Finish, Greek and Danish in order to be used by ISISEMD regional partners. QOL-AD has been 
already in use by AA in Athens and they have Greek version. Currently Finish version does not exist. 
To amend this, a leading authority in quality of life studies in Finland (Professor Olli-Pekka Ryynänen 
from University of Kuopio) has been contacted to help translate and adapt version of QOL-AD in 
Finish.  
 
5.3.5 Evaluation of Quality of Life of Informal Caregiver (ICG) 
 
It is well known that a chronically disabled person may often disorganize the life of the entire family 
and disrupt the existing balance among them. Patients in advanced stages of the disease become 
dependent upon family members and require permanent help from the care-givers, resulting in a 
declining former professional life, abilities to manage the household and to perform self-care. The 
need for permanent care and help to the chronically disabled person leads to a decrease in the quality 
of life of care-givers [Ellgring, 1993], [Gallo, 1990]. 
Quality of life means “the perception and evaluation by the patient (her- or himself) of the impact that 
the disease and its consequences have produced in her/his life” [Martínez, 1997]. 
 
It is also well documented that caregivers of persons with dementia experience substantial stress from 
the care giving tasks they perform. The concept of the burden of care was defined by Zarit [Zarit, 
1980], an American gerontologist, as the discomfort encountered by the primary caregiver of an older 
family member, including the caregiver's health, psychological well-being, finances and social life. 
Since, there have been numerous studies showing the negative impact of increased caregiver stress on 
the person with dementia as well as caregiver overall health.  
 
Assessing caregiver burden is a measure of how straining the caregiver experiences the care giving 
task to be, involving objective burden (e.g. number of tasks, time per task) and care giving capacity, 
among others.  
 
To measure burden and, thusly, effects from interventions aimed at reducing burden, the Zarit Burden 
Interview (ZBI) full revised version [Zarit, 1985] could be used. It consists of 22 items and reporting 
excellent internal consistency [0.89; Zarit , 1987]. ZBI measures emotional strain, level of frustration, 
fulfilment, relational, caregiver uncertainty, mental, social, financial, support and physical domains of 
informal care-giving. It consists of a list of statements, which reflect how people sometimes feel 
when taking care of another person. After each statement, ICG indicates how often they feel that 
way - never, rarely, sometimes, quite frequently, or nearly always.  
The whole rating scale could be seen in Appendix C5.  
 
Another, more recent and advanced assessing tool for measuring QOL of informal caregivers, 
specifically designed for carers of patients with cognitive problems, is Glozman rating scale 
[Glozman, 1998]. This is the Scale of Quality of Life of Care-Givers (SQLC). It analyses the quality 
of life of parkinsonian patients’ caregivers and additionally some factors determining their social dis-
adaptation. It is a comprehensive questionnaire covering the persons’ activities from different aspects: 
professional, family related, social and others. It evaluates both qualitatively and quantitatively the 
principal levels of the subject’s activities: (a) professional activity of the care-giver, (b) social and 
leisure activities, (c) responsibilities of the care-giver to help the patient in everyday living. It is in 
total of 16 questions, divided in three sections.  
 
The partners from ISISEMD consortium, based on own experience and on the consultation with 
specialists from the national Alzheimer Associations, find SQLC rating scale very suitable for the 
purpose of the project evaluation. Additionally, the formulation of the questions is neither positive nor 
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negative which gives a very good basis of objective evaluation. SQLC is already in use in Athens 
Alzheimer Association. Instructions how to administer the instrument are available in [Salec, 2004].  
 
Another instrument which is focusing on evaluating how much time the informal caregivers spend for 
caring for a patient, is the Caregiver Activity survey (CAS), presented in [Davis, 1997]. The activities 
measured are in relation to the daily activities in the home that must be performed by the patient.  
The framework of evaluation is spanning off the last 24-housrs and the instrument is self-
administering by the informal caregiver and takes approx. 5 min.  
This rating scale is designed to be used as a means of evaluation of the economical implications of the 
Alzheimer disease on the informal caregiver and also the potential effect of therapy means in the 
treatment and care of Alzheimer patients. It requires initial training session.  
The whole CAS instrument could be seen in Appendix E2.  
 
5.3.6 Instrumental Activities of Daily Living (IADL) 
 
Quality of life for the ageing population is associated with the ability of the elderly people living 
independently and with dignity without having the need to be attached to their children, grand-children 
or any other person whose help would they need for their daily life and social behaviour. The dementia 
is one of the problems that hinder these people’s ability to have such an independent life, making 
necessary the presence and monitoring of their daily activities by care-givers.  
 
Activities of daily living (ADL) for old population in general are divided in Basic ADLs and 
Instrumental ADLs. 
1. Basic ADLs 
The basic activities of daily living consist of these self-care tasks: Bathing, Dressing and 
undressing, Eating, Transferring from bed to chair, and back; Voluntarily control urinary and 
faecal discharge; Using the toilet, Walking (not bedridden).  
2. Instrumental ADLs (IADL) 
Instrumental activities of daily living are not necessary for fundamental functioning, but 
enable the individual to live independently within a community: Light housework, Preparing 
meals, Taking medications, Shopping for groceries or clothes, Using the telephone, Managing 
money. 
 
ISISEMD services focus on partially supporting instrumental ADLs mainly related to meals intake, 
Taking medications and Using the telephone tasks, safety procedures and emergency responses.  
 
ADLs and IADLs have statistically been proven to be correlated with reported caregiver burden. In 
order to better equip the trial home with appropriate intervention services, an accurate account of 
physical functional abilities is also needed. Rather than using only observations or self-reports, ICGs 
will be presented list of IADLs and asked to report which they assist with and approximate time spent 
assisting the care receiver. In the initial home interview, an Occupational Therapist (OT) will assist 
ICG in answering for daily activities as OTs are specially trained in assessing patient functional 
abilities.  
 
Important consideration: 
Assessment of basic ADL and IADL provide the care team with an assessment of physical functional 
abilities. These results will serve to help ISISEMD accurately to fine-tune the services to the end users 
specific needs. It should be emphasized that although both parameters of physical functioning 
are measured, ISISEMD is mainly providing services and solutions to aid IADLs (secondary 
effects may aid ADLs, but it is not the purposed goal). 
 
IADLs will be evaluated using Lawton and Brody’s IADL Scale [Lawton, 1969]. The exact 
parameters which will be measured with Lawton and Brody’s IADL Scale could be seen in Section 
5.4.5.  
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As an optional choice for the regional partners who are the care providers, ADLs could also be 
assessed. In this case, Katz’s ADL Scale [Katz, 1970] will be used. The exact parameters which will 
be measured with Katz’s ADL Scale could be seen in Section 5.4.5.  
 
5.3.7 Cost Utility Analysis 
 
Finally, using data from the outcomes of QOL and IADLs assessments for the primary end-users and 
the informal caregivers, Cost Utility Analysis (CUA) of ISISEMD services will be done. This will be 
carried out after the end of trial period.  
 
Cost-utility analysis (CUA) is a form of economic analysis used to guide procurement decisions. The 
most common and well-known application of this analysis is in pharmaco-economics, especially 
health technology assessment (HTA). 
In health economics, the purpose of CUA is to estimate the ratio between the cost of a health-related 
intervention and the benefit it produces in terms of the number of years lived in full health by the 
beneficiaries. Hence it can be considered a special case of cost-effectiveness analysis, and the two 
terms are often used interchangeably. 
Cost is measured in monetary units. Benefit needs to be expressed in a way that allows health states 
that are considered less preferable to full health to be given quantitative values. However, unlike cost-
benefit analysis, the benefits do not have to be expressed in monetary terms. In HTAs it is usually 
expressed in quality-adjusted life years (QALYs). 
A complete compilation of cost-utility analyses in the peer reviewed medical literature is available at 
the CEA Registry Website 
On the plus side, CUA allows comparison across different health programs and policies by using a 
common unit of measure (money/QALYs gained). CUA provides a more complete analysis of total 
benefits than simple cost-benefit analysis does. This is because CUA takes into account the quality of 
life that an individual has, while CBA does not. 
 
Health Technology Assessment (HTA) is a multi-disciplinary field of policy analysis that examines 
the medical, economic, social and ethical implications of the incremental value, diffusion and use of a 
medical technology in health care. [INAHTA, 2009]  
It is intended to provide a bridge between the world of research and the world of decision-making 
[Battista, 1996]. Health technology assessment is an active field internationally and has seen continued 
growth fostered by the need to support management, clinical, and policy decisions. It has also been 
advanced by the evolution of evaluative methods in the social and applied sciences, including clinical 
epidemiology and health economics. Health policy decisions are becoming increasingly important as 
the opportunity costs from making wrong decisions continue to grow. [Menon, 1996] 
 
Cost utility analysis will be part of the overall assessment methodology of ISISEMD services.  
 
5.3.8 Important points to be considered  
 
Carrying out the interviews  
The intention is to carry out the interviews separately with primary subjects from relatives/partners 
because the care for a person with dementia puts a lot of burden and psychological stress on the 
informal caregiver which is documented as affecting their evaluation. It is expected that the ICG could 
express more sincere opinion when interviewed alone.  
In addition, when EP lives with a partner, in the everyday tasks the partners compensates for the 
declined functions of the EP and in many cases EP does not realise that he/she a decline.  
 
A note for the international rating scales 
It must be underlined though that all these international rating scales which have been talked about in 
the previous sections (MMSE, MoCA, QOL-AD and SQLC, CAS) are initially published in English. 
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As explained in the previous sections, they need not only to be translated to the local language but also 
to be adapted. This is to avoid different understandings in the formulations leading to inaccurate 
results, coming from some cultural difference in different countries. For the tests for which 
translations already existed in Greek, Danish and Finish, they were obtained from MAPI Institute in 
France, specialised in rating scale translations. For the tests that do not have translation, the regional 
partners are in contact with their scientific dementia advisors who help them with the translations.  
In addition to that, there could be small differences in the range of the scores in the countries. 
Therefore, the need for their validation and standardisation. However, validation of these tests requires 
running of the tests in each country with many subjects, usually more than 100 patients per country. 
This is a process which cannot be done in the framework of the project and usually is done by some 
authorised organisation.  
 
Moreover, in order to be used for research purposes by the project partners, who are the care provider 
organisations, permissions for use were obtained by all the authors by each regional partner. In the 
same way, instructions how t carry out the tests were also obtained by the authors.  
 
Conclusions for Section 5.3 
Evaluation of ISISEMD services from human point of view is quite complex task, which has many 
aspects. The services will be evaluated with all three main user groups for user acceptance, user 
satisfaction, and quality of life improvements. With evaluation of these aspects, ISISEMD partners 
aim to be able to assess the introducing this new technology in the everyday life of senior citizens with 
mild dementia and their closest relatives from different angles and revealing different layers of factors 
influencing the process. In the evaluation process, some standard rating scales will be used, together 
with tailor made questionnaires and quantative interview.  
The following Table 13 presents summary of the test methods/tools and to which group of test 
participants they will be applied: 
 
Table 12: Matrix of the evaluation methods and instruments 
 
Evaluation aspect Assessment tool End user 
involved 
Time demand  Assessment method 
Assessing QOL of 
primary end-user 
QOL-AD EP 3x  
10 minutes 
Questionnaire with 
support 
Assessing care 
burden of informal 
caregiver 
ZBI ICG 3x 
15 minutes 
Questionnaire self 
administered 
Assessing QOL of 
informal caregiver 
SQLC and CAS ICG 3x 
10-15 minutes 
each  
Questionnaire self 
administered 
Assessing cognitive 
decline for primary 
end-user 
MoCA EP 3x  
10-15 minutes 
Questionnaire with 
professional  
(Certified for MoCA) 
Assessing cognitive 
decline for primary 
end-user 
MMSE EP 3x  
30 minutes 
Questionnaire with 
professional  
(Certified for MMSE) 
Assessing activity 
of daily living 
ADL/IADL EP 3x  
15 minutes 
Questionnaire with 
occupational therapist 
User acceptance of 
assistive technology 
or service and User 
satisfaction 
User Satisfaction/ 
Acceptance 
EP, ICG, FCG 3x 
30 minutes 
Structured interviews 
with ISISEMD personnel 
from the care providers  
 
The next section presents overview of the parameters which will be evaluated using these methods and 
tools.  
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5.4 Parameters to be evaluated  
 
This subsection discusses which parameters will be evaluated during the tests and the evaluation 
process and how they will be evaluated.  
 
5.4.1 Parameters for Stage of Cognitive decline  
 
The Montreal Cognitive Assessment (MoCA) assesses the cognitive domains of: 
• Executive function,  
• Visio-spatial function,  
• New learning,  
• Attention and concentration,  
• Abstraction,  
• Memory,  
• Language,  
• Conceptual thinking,  
• Calculations and  
• Orientation. 
 
5.4.2 Parameters for Quality of Life of primary end-user  
 
According to Schölzel-Dorenbos et al. [Schölzel-Dorenbos, 2007], domains of life important to 
persons with dementia are: 
• Affect 
• Self-esteem/self-image 
• Social contact 
• Attachment 
• Physical and mental health 
• Enjoyment of activities 
• Sense of aesthetics 
• Financial situation 
• Security and privacy 
• Being useful/giving meaning to life 
• Spirituality 
 
Of these, Quality of Life – Alzheimer’s disease (QOL-AD) directly evaluates the person with 
dementia: 
• social contact (family, friends) 
• attachment (marriage)  
• physical and mental health (physical health, energy, mood, memory)  
• enjoyment of activities (leisure)  
• financial situation (finances) 
• being useful (ability to contribute) 
 
QOL-AD will additionally evaluate living situation, self as a whole and life as a whole of the person 
with dementia.  
 
5.4.3 Parameters for informal caregiver burden and Quality of Life  
 
The Zarit Burden Interview (ZBI) full revised version [Zarit, 1985] measures the following domains of 
informal caregiver burden: 
• emotional strain,  
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• level of frustration,  
• fulfilment,  
• relational,  
• caregiver uncertainty,  
• mental,  
• social,  
• financial,  
• support and  
• physical domains. 
 
The Glozman rating scale (SQLC) measures the following domains for QOL for informal caregivers: 
• Professional activity 
• Social and leisure activities 
• Responsibilities of the care-giver to help the patient in his everyday living 
 
 
5.4.4 Parameters for caregiver activities survey (CAS) 
 
Davis [Davis, 1997] use parameters for time spent for carrying for a patient with dementia (including 
time for reminding him) related to:   
• Communicating with the person 
• Using transportation 
• Dressing 
• Eating 
• Looking after one’s appearance 
• Supervising the person 
 
 
5.4.5 Parameters for Activities of Daily Living of primary end-users 
 
Katz’s ADL Scale [Katz, 1970] assesses: 
• Bathing 
• Dressing and undressing 
• Eating 
• Transferring from bed to chair, and back 
• Voluntarily control urinary and faecal discharge 
• Using the toilet 
• Walking (not bedridden) 
 
Lawton and Brody’s IADL Scale [Lawton, 1969] measures: 
• Light housework 
• Taking medications 
• Shopping for groceries or clothes 
• Using the telephone 
• Care of others (including selecting and supervising caregivers) 
• Care of pets 
• Child rearing 
• Communication device use 
• Community mobility 
• Financial management 
• Health management and maintenance 
• Meal preparation and cleanup 
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• Safety procedures and emergency responses 
 
5.4.6 Parameters for user acceptance and satisfaction 
 
User acceptance will be measured for the following domains: 
• Relative advantage (the extent to which a technology offers improvements over currently 
available tools) 
• Compatibility (its consistency with social practices and norms among its users) 
• Complexity (its ease of use and learning) 
• Trialability (the the opportunity to try an innovation before committing to use it) 
• Observability (the extent to which the technology’s outputs and gains are clear to see) 
 
User satisfaction will be measured for the following domains:  
• User interaction with the platform 
• Feelings of safety and security in the home 
• The ability to self-care and extend independence 
• Enhanced social interaction 
• Ability to locate EP in- and outdoors 
• Ability to communicate remotely with EP 
• Reduction in care burden for ICG 
• Memory support 
 
5.4.7 Other relevant factors   
 
Objective parameters: 
• Factors related to the person with dementia (education, profession, ethnicity, diagnosis and 
severity, other health issues, functioning abilities, acceptance of problem, ADLs and IADLs, 
etc.) 
• Factors related to the caregiver (relationship to the person with dementia, the nature of the care 
giving role, living arrangement, employment status, perceptions of EP, expected outcomes of 
non-pharmaceutical intervention, etc.) 
• Factors related to the environment (nature and extent of services provided, EP’s home 
environment, etc.) 
• Factors related to the assistive devices (design, function, reliability, etc.) 
• Factors related to the researchers (their opinions, problems the assistive device is meant to 
address and opinions about potential usefulness) 
 
Subjective parameters 
• If assistive technologies are useful to people with mild dementia and their caregivers. 
• Potential outcomes depending on the type of problem addressed (e.g. falls at night, leaving the 
stove turned on, and better social interaction). 
• Importance of the problem to EP, caregivers and society and how the(se) problem(s) affect 
them. 
 
 
Also very relevant for the overall assessment of ISISEMD services are the societal benefits expected 
to be achieved and to be evaluated:   
• Saving of personnel, time and travel for FCG, leading to reduced overall health and social care 
costs 
• Possibility of reallocating responsibilities and tasks among FCGs in such a way that personnel 
with lower education levels can perform tasks when supported by ISISEMD 
• Possibility to increase the number of patients one FCG is responsible for 
• New business opportunities for European industries and SMEs 
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However, their evaluation will be part of the overall assessment methodology and will be presented in 
Del 3.3.1 “Assessment Methodology on ISISEMD platform” due in M13.  
 
5.5 Success criteria for the ISISEMD platform  
 
In the end, based on the overall evaluation of the ISISEMD platform, achievement of success criteria 
will be reported. The following Table 14 presents examples of evaluation questions and such success 
criteria (as presented in ISISEMD description of Work).  
 
Table 13: Examples of success criteria 
Parameters Example of questions Examples of Success 
Criteria 
Elderly Perceptions - Were elderly satisfied with the homecare service 
compared to the alternative(s)? 
70-75% of the elderly 
feel satisfied using the 
system 
Caregiver Perceptions - Were attending and/or consulting caregivers satisfied 
with the homecare application compared to the 
alternative(s)? 
75% of the caregivers 
feel satisfied using the 
system 
Relatives perceptions  - Were relatives satisfied with the homecare service 
compared to the alternative(s)? 
75% of the relatives 
feel satisfied using the 
system 
Quality of Care and 
Health Outcomes 
- What were the effects of the homecare application on 
the care process of care compared to the alternative 
care options?  
- What were the effects of the homecare application on 
immediate, intermediate, or long-term health outcomes 
compared to the alternative(s)? 
70-75% of the test 
subjects feel positive 
effects  
Access to Care - Did homecare affect the use of services or the level or 
appropriateness of care compared to the alternative(s)?  
- Did the services affect the timeliness of care or the 
burden of obtaining care compared to the 
alternative(s)? 
Increase of access to 
care with 20-30% 
Home Care Costs and 
Cost-Effectiveness 
- What were the costs of the homecare application for 
participating care providers or compared to the 
alternative(s)? 
- What were the costs of the homecare application for 
elderly and families compared to the alternative(s)?  
- What were the costs for society overall compared to 
the alternative(s)?  
- How did the cost of the system relate to the benefits 
of the homecare application compared to the 
alternative(s)? 
10-20 % decrease in 
costs for elderly and 
families 
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5.6 Specific Key Performance Indicators (KPIs) 
 
Additionally, a set of specific KPIs (Key Performance Indicators) related to the specific project 
objectives and expected impact of the project has been initially drafted. They are presented below: 
 
Table 14: Set of specific Key Performance Indicators (KPIs) 
Specific KPI Target per region 
Number of elderly people actually recruited for the 
Test and Control Groups 
The target is 20 elderly people from each region 
to be involved in the evaluation of the ISISEMD 
services 
Number of relatives actually recruited for the Test 
and Control Groups 
The target is 20 relatives from each region to be 
involved in the evaluation of the ISISEMD 
services 
Number of official care-givers actually recruited 
for the Test and Control Groups 
The target is 10 official care-givers from each 
region to be involved in the evaluation of the 
ISISEMD services; 
Number of elderly people actually recruited for the 
Test and Control Groups.  
The target is 20 
Use of the ISISEMD platform by elderly with mild 
dementia. During the trials the elderly will be 
asked to use the ISISEMD services to keep in 
touch with their formal and informal care-givers. 
The target is that at least 90% of the members of 
the Test Group use the ISISEMD services till the 
end of the project 
Use of the ISISEMD platform by relatives. During 
the trials the relatives will be asked to use the 
ISISEMD services to care for their relatives with 
mild dementia 
The target is that at least 90% of the members of 
the Test Group use the ISISEMD services till the 
end of the project 
Number of prevented risks for the health of the 
elderly test persons in their own home. The system 
is designed to prevent risks coming from improper 
use of home/kitchen electrical equipment. 
Target is zero such risks during the trial period 
 
Outcome and statistics for these KPIs will be done after the end of the trial period, together with the 
overall assessment of the ISISEMD services.  
 
5.7 Quantifiable Success Indicators for the pilot sites  
 
High level ISISEMD project objectives have been defined in Description of Work. Following these 
objectives, the consortium has defined a numbered list of operational objectives following the SMART 
principle (Specific, Measurable, Accurate, Realistic and Timed) in order for the consortium and for the 
European Commission to assess the project partial or full success. For each of these objectives, 
Quantifiable Success Indicators (QSI) has been also defined. 
They are presented in the table below. From these objectives and QSIs, all but O3 are not related to the 
testing of ISISEMD services with human subjects. Outcome and statistics for these QSIs will be done 
after the end of the trial period, together with the overall assessment of the ISISEMD services 
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Table 15: Quantifiable Success Indicators for the project objectives 
Project objective Quantifiable Success 
Indicators for each Project 
objective 
Measurement unit 
O1 - Improve care of elderly with cognitive 
problems by offering them ICT services for 
self-care 
Satisfaction of elderly using 
ISISEMD services  
% of end-users 
O2 - Improve care of elderly with cognitive 
problems by offering the care-givers ICT 
services 
Satisfaction of the care-givers 
using ISISEMD services 
% of care-givers 
O3 - Integrate existing partial services and 
solutions from the partners  
Operation of ISISEMD 
integrated prototype  
Integrated 
prototype working  
O4 - Evaluate the pilot set of scalable 
ISISEMD services under realistic conditions 
and for adequate time period 
Run the pilot service for a 
certain period  
Number of months  
O5 - Demonstrate European acceptance of 
ISISEMD service  
To be tested in a number of 
European member states 
Number of regions 
O6 - ISISEMD services to be demand-driven Involve all stakeholders in the 
pilot service  
Number of user 
groups  
O7 - Prove cost-efficiency of the services  Reduction in the number of 
hours spent per end-user 
% reduction of 
hours spent 
 
5.8 Important point to be considered during the tests 
 
One important point which needs the attention of the partners for the evaluation of the trials is: How to 
ensure that the test persons provide their honest feedback on the questionnaires and during the 
interviews? It sometimes happens that during trials with human subjects, they tend to answer more 
positively then they really feel. 
 
This is actually a general aspect when usability evolutions are carried out. The partners will apply a 
number of measures to prevent this: 
One measure for this is the selected approach for triangulation of methods aiming to avoid insincere 
answers. Other measure is that the interviews for use satisfaction and acceptance will be administered 
by persons from the care-giver organisations that are specially trained for the techniques for objective 
interviews. Also for the questionnaires for the rating scales (MoCA, MMSE, QOL-AD, SQLC, CAS, 
ZBI, IADL) will be administered by staff trained to perform such questionnaires.  
 
5.9 Overall work plan for the pilot sites  
 
The first task in WP3, namely installation of the pilots for the small scale study, will take place in M12 
in all four regions. This will ensure that in the very first month of the operation of the pilot services, 
the systems are working properly in the users’ homes.  
The inclusion and exclusion criteria for the user test groups are identified in this document. With these 
criteria in mind, the regional partners would have been identified a group of 22-23 POTENTIAL trial 
participants (who will be split after that to test and control groups) in the period M11. This group of 
22-23 POTENTIAL trail participants would have been found via the channels, explained in Section 
3.1.5.1.  
During 12 months (M13-M24), the pilots will be used by the test users under realistic conditions – 
older adults in their homes; the professional caregivers in their work tasks, performing their daily work 
to care for the elderly; the informal caregivers/family, also in their everyday activities to care for the 
seniors. The services will be first tested in a smaller scale, with a few end-users at each site for 2 
months (M13-M14), in order to identify if some major problems exist before the large scale testing 
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with all users during the rest of the testing period until M24. The pilot sites will be maintained and 
serviced during this second phase by the technical partners. 
Before the start of the test period in M13, a few persons from the care-provider organisations will be 
trained to use the system as expert users with the aim to provide support and guidance to the test 
participants during the 12-month test period. This training will take place in each pilot site, in the form 
of a small workshop, by the technical partner who is doing the installation. Such training workshops, if 
possible, will be also done for the relatives who live in the area where the pilot services will be tested. 
For this purpose, demo-rooms will be used as explained in Sect. 3.1.5.2. 
As mentioned in Section 3.1, in some cases, the illness may progress fast; therefore the process of 
cognitive assessment for the stage of dementia (test MoCA/MMSE) will be done immediately before 
starting the test period – in M12. For the same reason, MoCA/MMSE tests will be again carried out 
after 6 month period. This is also necessary, because if during the first 6-month period, more cognitive 
problems appeared for the elderly person, they may need advanced service level. This testing of the 
cognitive decline in the middle of the 12-moith test period will ensure that the correct service level is 
provided to the client. At last, in the end of the testing period, MoCA/MMSE test will be carried out 
again. This will be done because part of the test participants, who have been in dementia stage 4 
during the test period, may have progressed to dementia stage 5, thus making the use of some of the 
services inappropriate for them. A very specific example is the Outdoor Guard Service from service 
bundle C (C1) for providing help for the person to find the way to home in case they become lost. As 
soon as the dementia stage is progressed and the client is not safe to go alone in the streets because of 
risks for traffic accidents, this service will not be offered any longer to them since at this stage they 
may need to be admitted to dementia care home anyway.    
Another important aspect of the work plan for the test pilots is the evaluation of the quality of life 
(QOL) for the primary user group and the informal care-givers. The types of QOL test was described 
in Section 5.3.4. QOL evaluation will be carried out in the beginning (M13) and the end (M24) of the 
test period using standard questionnaires. Similarly, assessing IADL will be carried out at the same 
time. QOL-AD will be administered for the test group of EP, while SQLC, ZBI and CAS will be 
administered to their relatives, in order to measure the baseline for their quality of life and care 
burden. These tests will be carried out also in the middle of the pilot period, in order to access the level 
to which EP and ICG rely on the assistive services after the initial months when they are not very used 
to use the services.  
As described in Sections 5.3.2 and 5.3.3, to evaluate the user acceptance and satisfaction from using 
ISISEMD services, iterative process of periodically receiving user feedback will be applied with 
overall goal of constantly improving the services in the life time of the project. The first evaluation for 
this aspect will be carried out in the second half of M14, after the smaller scale testing with a few test 
participants. The main goal of this will be to identify some major flaws in the design of the services 
which will be avoided with the full scale testing. 
Then, mid-term and final evaluation for user acceptance and satisfaction will be done in M18 and M24 
respectively. Test materials are described in the Appendix section of this report.   
At the end, based on feedback of this evaluation, identification of possible weaknesses in the design 
will be presented to the technical partners and recommendations for improvements will be given.  
The following Figure 1 depicts the work plan for the pilots.  
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Figure 2: Work plan of the pilots and instruments to be administered 
 
5.10 Selecting and organising tasks to test  
 
The test tasks will aim at evaluation of the functionality of the ISISEMD platform with all the services 
and for validation of the usability of the assistive technology. Both the ISISEMD portal and the client 
CareBox will be evaluated by the respective user groups.  
Below examples of the main test tasks are listed: 
 
For ISISEMD portal: 
• Task A: creation of three formal caregivers and update of information for them 
• Task B: create three elderly persons and assign caregivers to them 
• Task C: find EP1 information and assign home safety services and outdoor positioning service 
to EP1.0 
• Task D: Assign the Service for daily reminders for EP2 
• Task E: login as FCG1 and open the assigned services for EP1. 
• Task F: login as FCG2 and find EP2 and access the service for reminders for daily activities 
for EP2 
• Task G: find EP1 and remove service Smoke detector-Fire Alarm from his services; delete 
EP1  
 
For ISISEMD CareBox (client site):  
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• Task A: (from the portal) - login as region, find EP1 and assign the service for daily 
reminders, brain games, memory lane for EP1; 
• Task B: (As a care-giver) - login as CG1 and create different reminders for EP1 with the 
necessary settings  
• Task C: (as a patient EP1 – from CareBox)  
• Log-in as EP1 and see the information shown on the GUI and hear the upcoming reminders  
• Task D: (As a care-giver from the portal) - Log-in as CG1 and update/remove reminders for 
EP1    
• Repeat Task C: (as a patient EP1 – from GUI EP) – to see the changes of the settings in the 
reminders on the CareBox screen  
• Task E: (As a care-giver from the portal) Log-in as CG1 and add/remove two more pictures 
for EP1 in the service “Memory Lane”   
• Task F: (As a patient EP1) from CareBox – see the changes in the CareBox in the list of the 
pictures for “Memory Lane” 
• Task G: (As a patient EP1) from CareBox – play Brain Game  
 
Similar test tasks will be carried out for all the services.  
 
5.11 Description of test scenarios 
 
Based on the above listed tasks to be tested, step by step test scenarios will be prepared. Some 
examples of test scenarios are presented in Appendix F.  
 
5.12 Preparing the testing environment  
 
The test environment will be carefully prepared. Already in M12 demo rooms in the regions will be 
organised, with one of the aims – to help the regional partners to get hands-on experience on installing 
the systems in home environment. 
To help in this process, the technical partners are preparing installation manual and installation video. 
Additionally, help line for the technicians will be established by the technical partners. In order to 
reduce installation costs, the list of equipment has been prepared in such a way, that it is not necessary 
authorised electrician to make the installations. Also, in the beginning of M12, physical meeting will 
be held with all partners, where installation demonstration will be done.  
After making the installations in each of the homes, the floor plans of the homes will be drawn and the 
place of the sensors will be noted on them. These maps of the equipment of each home will then be 
uploaded on ISISEMD portal, to facilitate the everyday use of the home safety services.  
 
5.13 Forming the test teams   
 
The test teams will be formed depending on the type of the data collection methods to be administered.  
Overview of who will administered what type of questionnaire to which group of end user, is 
presented in Table 12: Matrix of the evaluation methods and instruments.  
 
Conclusions for section 5 
This section presented one of the major contributions in this report and very important aspects of 
measuring the success of ISISEMD services – namely, the trial objectives, parameters to be evaluated, 
the methods which will be used in the evaluations, etc. Additionally, all relevant ethical and legal 
aspects will be considered during the trials, as explained in the beginning of the section in ethical and 
legal framework for the ISISEMD trials. It was also explained which will be test tasks, the test 
scenarios, how the test teams will be formed and how the testing environments will be prepared.  
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Section 6 -  Conclusions and Further work  
 
The main user group of ISISEMD services will be not only old citizens but even those having mild 
cognitive impairments or mild dementia. This poses a number of challenges not only in the process of 
adaptation and customization of the services, but also in the evaluation and validation process via the 
trials in real-life settings.  
In this respect, the goal of a controlled study will be to get from the trail participants the maximum 
amount of feedback about the usability, accessibility, acceptance, motivation of use, if they like or not 
and how do they like the services. The question is also to know the characteristic of the primary end-
user in order to have the appropriate strategies in the evaluation. Since elderly people are not experts 
in communicating technical information, one of the most critical issues is how to define the indicators 
to be measured and how to measure them during the evaluation. In addition, partners and closest 
family play a key role in the level of independence of old people with cognitive impairments or mild 
dementia. Certainly, they act as informal caregivers and support elderly dependent people. A system 
like ISISEMD platform is complementary to the daily support provided by them and the relative itself 
is considered a user of the system. Their opinion for the user-friendliness of the system matters too, it 
must be also evaluated. All these crucial aspects for the trial planning have been discussed in this 
report. 
Initially, the specifics of dementia as illness and the general profile of the main end-user groups of 
ISISEMD services were described. The main end-user groups of ISISEMD services are defined as 
follows: the elderly persons (EP), the informal caregivers (ICG) and the formal caregivers (FCG). Due 
to dementia, EP have decline in memory or in other cognitive ability. Depending on the stage 
progressing of the disease, they have difficulties to live independently or it is very dangerous for them 
to live independently. It is expected that they have very limited knowledge about using new 
technology and it will be difficult for them to learn to use it if the illness has progressed. ICG are 
further split in two subgroups - the ICG-partners and ICG-children. ICG-partners are statically females 
and do not have very good knowledge for the new technology either. For them, the burden to care for 
their ill partner causes a lot of stress and social isolation. ICG-children are usually middle-aged and 
statistically females too, who is expected to be able to use technology on a daily basis. FCG are 
generally females with formal education in care for seniors or in care for dementia patient. It is 
expected that they use PC, mobile phone, etc in their professional tasks.  
In order to have the correct sample of users to test the ISISEMD services during the trial period, it is 
important to find the right trial participants. This will be based on strictly defined main and secondary 
inclusion and excision criteria. The main inclusion criterion will be adults over 60 years of age, 
diagnosed with dementia stage two (Age Associated Memory Impairment) to four (Mild Dementia). 
The World Health Organization (2007) International Classification of Diseases (ICD-10) will be used 
to classify dementia as disease. The classification standard for dementia stages which will be used is 
The Global Deterioration Scale (GDS), developed by Dr. Barry Reisberg. To assess the level of 
cognitive decline, international rating scales will be utilized.  
As a primary rating scale, Montreal Cognitive Assessment (MoCA) will be used. MoCA is useful for 
assessing milder stages of cognitive impairment, including Mild Cognitive Impairment (MCI) and 
mild Alzheimer Disease (AD) where there are currently no other screening tools as quick and accurate 
to distinguish MCI from healthy controls. Due to its high specificity and sensitivity in detecting MCI, 
MoCA will be used as the primary cognitive assessment tool in determining level of cognitive 
functioning and changes over the course of the clinical trials. As a secondary option – Mini Mental 
State Exam (MMSE) is selected. The scores for inclusion will be 19-26. 
The sample of trail participants from the primary group will be a total of 80 persons. There will be 20 
primary end-users per region, with a back up of 2-3 persons to allow for substituting some drop out. 
These 20 primary end-users will be randomly split in a test and a control group, 50% division. For the 
caregivers - the aim is to have a trail group of 80 persons from ICG and 40 persons from the FCG in 
total, equally split per region and in test and control groups. However, their selection will depend on 
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the primary end user and will not be random. Potential participants (adults with mild dementia and 
their informal caregivers) will be recruited with the help of general and nurse practitioners, aging and 
cognition specialists, memory and dementia clinics and local organizations for aging programs and 
services.  
During the trial period, all ethical rights of the citizens will be respected and the trial will be carried 
out according to the national regulations and the privacy of the trial participants and all data related to 
this will be ensured. All applicable national and international laws and acts will be respected too. The 
trial participants will be recruited only after approval from Ethical Committees is granted for each 
region (if such approval is required). Very important activity in preparation for the trails will be 
preparation of the trail protocols – a set of materials, necessary for these applications and for carrying 
out the trials. The protocol will include a number of short documents providing information about 
guidelines for oral information for the trial participants, guidelines for information interview, written 
information for participants, list of equipment, informed consent form, description of the services, user 
guides, etc. By M11, the applications to the Ethical Committees in all regions where required have 
been sent. For the time being, approval has been granted for the pilot site in Finland and provisionally 
approved in Belfast site.  
Evaluation of ISISEMD services from human point of view is a quite complex task, which has many 
aspects. The services will be evaluated with all three main user groups for user acceptance, user 
satisfaction, and quality of life improvements. With evaluation of these aspects, ISISEMD partners 
aim to be able to assess the introducing this new assistive technology in the everyday life of senior 
citizens with mild dementia and their closest relatives from different angles and revealing different 
layers of factors influencing the process. The major trial objectives will be:  
• Measure improvements in quality of life for EP and ICG  
• Measure acceptability of the services by all three groups  
• Measure satisfaction from the use of the services by all three groups 
• Measure efficiency of ISISEMD services for the formal caregivers 
For assessing user acceptance and user satisfaction, ISISEMD partners will use their own explorative 
approach. In the core of this approach is “Triangulation of the three methods”. The test methodology 
will include questionnaires, participation observations, qualitative and quantitative interviews, use 
case description and analysis. To assess the user acceptance and satisfaction with the use assistive 
technology, specially designed ISISEMD questioner will be used, inspired by QUEST 2.0 and ETUQ 
instruments, which have specific focus on daily use of assistive technology and for adults with mild 
dementia. To measure quality of life improvements in primary user group, ISISEMD will utilize 
Logsdon rating scale - the Quality of Life – Alzheimer’s disease (QOL-AD). It is designed for patients 
with mild to severe dementia, living in the home care setting. To measure quality of life improvements 
in ICG group, Glozman rating scale will be administered. This is the Scale of Quality of Life of Care-
Givers (SQLC). To measure reducing the burden of care, Zarit Burden interview (ZBI) will be 
administered for relatives. Since one of the expected impacts for relatives of introducing ISISEMD 
system is reducing the time spent by them in the everyday care, Caregiver Activity Survey (CAS) has 
been found as relevant for ISISEMD trials and will be used too.  
Chronologically, the trials will run in a period of 12 months (March 2010-February 2011). There will 
be two stages – small-scale and large-scale validation. The services will be first tested in a smaller 
scale, with a few end-users at each site for 2 months, in order to identify if major problems exist 
before the large scale testing with all users during the rest of the testing period. Evaluation and 
refinement from the small-scale trial will lead to second iteration of customization. Mid-term 
evaluation will follow in the middle of the trial period. The final assessment will be carried out after 
the end of the trial.  
To help the users during the trials, fist and second level support will be provided. The first level 
support will be provided by personnel who are trained and responsible to receive the requests from the 
end-users. The second level of support will be more technical to professional care-giving services - on 
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how to upgrade specific versions of the software installed, for example. There will be also help desk 
assisted by a hot line to allow for a phone communication channel. Training to all user groups is 
foreseen too. The activities will involve training of super-users in each region and educational and 
training workshops in each region. User guides have been also prepared.  
This final version of the report provided information for aspects which could not be explained in M06 
when the initial version of the report was submitted. Namely, final integrated set of services, selection 
of the services to be tested, list of equipment, definition of test tasks and test scenarios, supporting 
material for the trial protocol, etc. 
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Appendix A1 - Propose to Written Material for Trail Participants 
 
This proposal of structure to the written material for trial participants is an edit of the appendix of 
“Guidelines about Notification etc. of a Biomedical Research Project to the Committee System on 
Biomedical Research Ethics”  
[http://www.cvk.sum.dk/English/guidelinesaboutnotification.aspx] 
This material must been only as an example what type of generic material was prepared and 
sent as application to Ethical Committees. Each region prepared their own version based on the 
more specific national templates and on their language.  
 
The written material should respect Section 5.1.1.4 – “Written information for participants”. 
 
Contents of the information for participants 
1. Front page/heading 
2. Introduction 
3. Purpose of the trial 
4. Benefits of the trial 
5. Side effects, stress, risks, complications and inconveniences  - preferably listed in a box 
6. Other possible treatments 
7. Exclusion from and discontinuation of trials 
8. Trial plan 
9. Contact person 
10. Information about financial matters 
11. Access to trial results 
12. Conclusion that requests the person to decide on participation in the trial.  
 
Appendices: 
• “The rights of a trial subject in a biomedical research project”  
• The pre-printed consent form issued by the Danish National Committee on Biomedical 
Research Ethics 
 
Structure and contents 
 
Front Page/Heading 
• Title: for instance “Information for participants about participation in a scientific trial 
involving individuals with dementia”. The heading should be as readable and as inviting as 
possible. 
• It must be clearly stated that it is a scientific trial and not a routine examination, a diagnostic 
examination or a treatment.  
• The target group for the trial must be stated on the front page, e.g. healthy people or patients – 
including which patients. 
• The formal name of the protocol. If an abbreviated title is used on the information and not the 
title stated on the notification form, the original title must be stated as well. 
• The name of the relevant department and hospital. 
• Footer with issue no., date and protocol number. 
• To the extent possible questions should be avoided in headlines as such questions presume 
views on the part of the reader that may be non-existing. E.g. ‘What side-effects occur?’ 
(Presumes that there are always side-effects). Rather use ‘Side-effects of the trial’ or ‘The 
trial’s side-effects’. 
 
Introduction 
• Neutral terms such as “request for participation”, “ask for” and the like should be used. 
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• I must be clear who the sender of the text is and who conducts the trial. E.g. ‘The trial is 
collaboration between XX, XX and XX and we request whether you are prepared to 
participate’. Remember to maintain consistent clarity on these issues throughout the text. 
• It is a good idea to explain the significance of research and of trials so that the person 
understands why his or her participation is requested. 
• Explain that a refusal to participate in the trial or any later discontinuation of participation will 
not influence the person’s right to present or future treatment. 
• When describing the principle of voluntaries, it may be explained that the researchers benefit 
from knowing why a participant decides to leave the trial as this may influence results, but 
that individuals of course are free not to provide this information. 
 
Purpose of the Trial 
• The purpose and method must be explained to the trial subject in plain language and without 
unnecessary medical terms. When medical terms are nevertheless required, these should 
always be translated into everyday language in a parenthesis and translation should be 
provided consistently throughout the text. The description must be objective and not create 
expectations of unrealistic results. It should be pointed out that it is not known whether the 
trial may benefit the participants – and that this is the reason for conducting the trial. 
• Information about the use of and the names of approved and non-approved medicinal 
products. 
• The use of randomisation, blind preparations and treatment-free period must be described. In 
this connection terms from other semantic fields should be avoided, e.g. ‘drawing lots’. 
• The general procedure, including the use of invasive examination methods, must be described. 
Reduce any use of the passive voice, e.g. ‘10 blood samples are drawn’.  
• It must be clear how many trial subjects are involved. 
 
 
Benefits of the Trial 
• The information must include whether the trial subject may or may not expect to benefit 
directly from the trial. This does not mean the direct benefit that the trial subject may gain 
through participation in the trial in terms of additional care or remuneration for his or her 
participation. 
• Furthermore, it should be stated whether the trial will be of general benefit for instance to 
future patients or to science. 
 
Side Effects, Risks, Complications and Inconveniences 
• Any known and predictable side effects, risks, complications and inconveniences in 
connection with the trial must be disclosed. Information about side effects must be provided 
regardless of whether they are temporary, long-term, frequent or rare.  
• In addition, it must be stated that there could be unforeseeable side effects or risks in 
connection with participation in the trial, including any control treatment. This is often the 
case when testing of non-approved medicinal products. 
• Information must be provided about inconveniences, which are the practical difficulties and 
discomforts suffered by trial subjects, such as absence from work due to visits for check-ups, 
blood tests or the like. 
• Side effects, risks and complications should preferably be listed in a box so that decoding is 
easier for the reader.  
• Side effects, risks and complications should preferably be listed as ‘frequent/not serious’ and 
‘seldom/serious’. 
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Other Possible Treatments 
• The trial subject must be informed of any other possible treatments in cases where the aim of 
the trial is both scientific and therapeutic. 
 
Exclusion from and discontinuation of trials 
• Trial subjects must be informed of any circumstances that may result in their involuntary 
exclusion from the trial and any circumstances under which the trial as a whole may be 
discontinued.  
 
Project Plan 
• How long will the trial take? 
• How many visits? 
• How will the treatment be given? And by whom? 
• Which examinations will be involved? 
 
It may be useful to tabulate the project plan if it involves many visits. This will provide a quick 
overview. Avoid using both a table and plain text to explain the same thing. 
 
Reduce any use of the passive voice (is given, is taken) in the text. Use e.g. ‘The nurse draws the 
blood samples’ rather than ‘blood samples are drawn’ so that the reader knows whom he or she is 
going to meet. 
 
Never use words from other semantic fields in the text. E.g. drawing lots, a cup of blood, and a 
spoonful of blood. Such words are associated with matters that in the patient’s mind are far from the 
world of health care. Rather use more neutral words such as e.g. ‘random distribution’, ‘decilitre’ and 
‘millilitre’. 
 
When medical terms are used these should always be translated into everyday language in a 
parenthesis – and translations should be consistently provided throughout the text. E.g. 
‘electrocardiogram (measuring of the heart’s impulses)’ 
 
Contact Person 
• The information must contain the name, address and telephone number of the chief 
investigator and at least one contact person associated with the trial. If the contact person can 
only be contacted at certain times, these should be stated. 
• It is recommended that the chief investigator or another professionally competent person is the 
contact person. 
• Introduce the contact person at the beginning of the text and make the identity of this person 
clear throughout the text in order not to create a distance vis-à-vis the reader. 
 
Information about Financial Matters 
• If the researcher receives any funding from private enterprises, foundations etc. in connection 
with the trial, this should be stated. The names of any sponsors and the amounts from each 
sponsor must be stated. The application of the financial aid shall be stated, showing which part 
of the aid goes to the researcher as e.g. a personal fee and which part of the amount is 
allocated to payment of salary to assisting staff, laboratory tests or other examinations, 
respectively. The reason for this is that it is up to the committee to assess whether the amount 
of the fee is reason-able in relation to the researcher’s expenses for implementing the trial. 
• It must be made clear whether the financial support is given as a fixed amount per trial subject 
(perhaps within a specified number) or as a lump sum for the entire project, and whether the 
money is paid to the researcher, to his/her department/institute, to a joint research fund or 
other recipients. It must also be stated how any excess financial support is to be used. 
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• Information about whether the chief investigator has any financial connection with the 
enterprises or foundations interested in the scientific trial in question. (It may also be stated 
whether other researchers in the group have such affiliations). 
 
Access to Trial Results 
• It must be explained where, when and how the trial subject will be able to obtain information 
about the trial results, negative as well as positive. This could for instance be in the form of a 
telephone number, a website or the like where the trial subject may obtain the information. 
• If a trial subject after completion of the trial is allowed to receive information of which 
treatment he or she has been given, it would be appropriate to write in the information for 
participants that “completion of the trial” means that tests of all the trial subjects included 
should be completed and the data processed. In this way, the misconception that trial subjects 
can obtain information as soon as they have completed their participation in the trial is 
avoided. It may be explained that it could take some time before information on results can be 
provided (preferably further specified if possible). 
 
Conclusion 
Always provide a summary by way of conclusion of the text. Request that the person takes a decision 
and preferably let the person know that any further questions are welcome. E.g.’ We hope that this 
information has given you sufficient understanding of what it means to take part in this trial and that 
you  feel that you have a basis for taking a decision on your possible participation. If you would like to 
get more information please contact “name”. Kind regards, name 
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Appendix A2 – The rights of a trial subject in a biomedical research project  
 
As a participant in a biomedical research project you should know that: 
• your participation in the research project is completely voluntary and can only take place after 
you have received both written and oral information about the research project and signed the 
consent form; 
• you may at any time orally, in writing or by any other clear notification withdraw your 
consent to participation and withdraw from the research project. If you withdraw your 
consent, this will not affect your right to any current or future treatment or any other right you 
may have; 
• you are entitled to bring a member of your family, a friend or an acquaintance with you to the 
informative interview; 
• you are entitled to time to think it through before you sign the consent form; 
• strict confidentiality is observed with regard to information about your health, other purely 
private matters and other confidential information about you disclosed in connection with the 
research project; 
• information about you, including information about tissue and blood samples from you, will 
be stored according to the provisions specified in the Danish Act on Processing of Personal 
Data and the Health Act ; 
• you will be able to get access to research protocols according to the provisions of the Danish 
Open Administration Act. This means that you can gain access to all documents concerning 
your participation in the project apart from the parts containing business secrets or 
confidential information about others. 
• you have the right to complain and compensation can be paid pursuant to the Act on the Right 
to Complain and Receive Compensation within the Health Service. 
 
(The above Appendix is published by the Danish National Committee on Biomedical Research Ethics 
and must be attached to the written information about the biomedical research project) 
From: http://www.cvk.sum.dk/English/rightstrialsubject.aspx  
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Appendix A3 – Information to primary user (example from Belfast site) 
 
Research and Innovation Project 
 
 
Intelligent System for Independent living and SElfcare of seniors with 
cognitive problems or Mild Dementia 
ISISEMD Project 
 
 
 
 
Participant Information on Participation in a Scientific  
Trial at Municipality of Belfast  
 
 
PILOT TRIAL 
 
 
 
 
 
 
Audience  
 
Citizens with the diagnosis of mild 
dementia associated Municipality of Belfast 
 
 
The research and innovation project was approved on the XX of XXX 2009 by the Science Ethics 
Committee, and by The Danish Data Protection Agency, 1st of July 2009. 
 
 
Introduction  
We will ask you if you want to participate in the pilot study of a scientific project. The project aims to 
test a system to support people with dementia in maintaining independent living in their own homes. 
The system consists of a series of assistive technologies that together will help you to an easier day 
with more security and less dependencies to health professional. System is tailored to suit your needs, 
which practically says that you will have installed assistive technologies that fit to you and your home.  
The pilot project will last for one year.  
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The target group for this study are people diagnosed with mild dementia, which is connected to:  
Municipality of Belfast. The [title] Jill Harpur from Belfast Health and Social Care Trust is 
responsible for the study.  
 
The project is supported by the EU and conducted in 4 countries with collaborative partners from the 5 
EU countries: Finland, Denmark, Great Britain, Greece and Italy 
 
What is the purpose of the project? 
The project aims at the ideals "healthy aging" and "independent lives at home" for older citizens. This 
will be achieved by:  
1. Supporting people with dementia to perform an independent daily life without the need for 
health professional, by addressing difficult situations and insecurity  
2. Improve citizen's ability to contact relatives and carers  
3. etc. 
 
 
How are people with dementia selected and how many will participate? 
Before starting the pilot 20 people with mild dementia linked to Municipality of Belfast are asked, 
whether they will participate in the pilot study. 
 
In the pilot study, the 20 citizens will be divided into a control group and a test group by drawing lots. 
The Test Group are the people with dementia, offered to use the assistive technologies at home in 
addition to the regular home care if such are received. The control group is people with dementia, 
which follows the usual care by home nursing, Municipality of Belfast. The purpose of having a 
control group and a test group is to decide whether it makes a difference for people with dementia to 
use technology to support them in everyday life at home. The study involves a total of 20 people with 
dementia divided by 10 individuals in each group. 
 
What assistive technology is included in the experiment? 
You will have installed one or more assistive technology in your home. It can for example be an 
electronic calendar, light sensors, alarm monitoring of catering equipment, video telephone, etc. In 
collaboration with Health personnel we will find, means there may be relevant to you and give you a 
detailed instruction in how to use them. Health staff will also conduct a continuous follow-up of your 
use of your tools and help you as needed. 
 
Technical issues about the system configuration and components  
This section should say something about which equipment will be installed in the home and how it 
keeps the user connected to the health professional. There must also describe who will install it and 
how it would be configured.  
 
The use of the system  
How to use the system and by whom? 
 
 
How is the test carried out? 
1. Staff from Municipality of Belfast will carry out a conversation with you in your home to 
inform you of the tools and adapt the system to your needs  
 
2. A home carer will then contact you and arrange a time for the system to be installed in your 
home.  
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3. Your home carer and a technician will deliver the technology and put it your home. The 
equipment will remain in your home as long as you participate in the study.  
 
4.  The home carer will educate you and your relatives in the use of the equipment. You will 
simultaneously receive a written guide for instructions of how to use the equipment.  
 
5.  Nursing home staff will contract with you, about the ongoing contact, and decide whether you 
need weekly visits by a home carer.  
 
6.  When you are finished using the equipment, a home carer will uninstall it. 
 
 
Who can benefit from the research? 
In the project, we will identify to which extent it is advantageous to use assistive technology to support 
people with dementia and their caregivers. This knowledge will be used for development of new care 
and treatment and support tomorrow's citizens with dementia and their caregivers. 
 
 
What side effects, risks and complications may occur?  
There are estimated to be no risks associated with your participation in the test, as medically approved 
equipment are being used. However, when you participate in the pilot study, you must expect that 
there may be minor technical problems and the agreed workflows must be adjusted. That is why we 
need your help to focus on how we can improve communication and collaboration between health 
professionals or guides for the assistive technologies.  
 
If you feel uncomfortable with the system or you need immediate assistance please contact the 
following:  
• Weekdays at. 8AM-4PM:  
o Belfast Health and Social Care Trust tel: xx xx xx xx  
 
• Weekdays after 4PM, evenings and weekends:  
o ISISEMD hotline tel: xx xx xx xx 
 
Setting up the system in your home 
The system must be plugged in at all times while it is in your home. In order to cover power and 
dispatch of your measured values, you will receive a total of DKK xx, which will be transferred to 
your bank account. 
 
Exclusion and suspension of the trial 
You can drag out of the study at any time if you wish if you later on regret your participation. This 
will be respected and not have any impact on your connection to the health system. You may be 
excluded from the study if you move from your residence. 
 
How are data collected? 
To gather knowledge about the need for and experiences with use of the system for people with 
dementia and their caregivers, we have scheduled the following data:  
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  PILOT PHASE 
20 citizen with dementia, that uses ISISEMD system 
Pilot start Questionnaires which are about your satisfaction in life and your 
attitude towards technology. 
While the system 
is in use  
Citizens with dementia and their caregivers are asked if they will attend 
the following: 
 
• Visits from researchers in the home  
• Interview with citizen with dementia  
• Interview with citizen with dementia and their caregivers  
 
Home visits and interviews is expected to last a few hours total 
 
After the 
finalization of the 
pilot 
Questionnaire, which is about your satisfaction with the system and 
your life satisfaction in general. 
 
 
Contact persons 
 
Responsible for the study: 
Jill Harpur 
Title 
Belfast Health and Social Care Trust 
Address 
Zip code 
Tlf: xx xx xx xx 
E-mail: jill.harpur@belfasttrust.hscni.net 
 
 
Home carer Belfast Health and Social Care Trust 
Contact person(s): __________________ 
Tlf: xx xx xx xx 
 
Other persons from the project 
 
xxxxxx 
 
When and how research will be available? 
Results from the study will be available when the study is completed. In practice this means that once 
included all subjects have been completed and data is made up. The first results are expected in 
autumn 2011 and will be published in newspapers, journals and international scientific journals. By 
contacting Jill Harpur from Belfast Health and Social Care Trust you will be able to obtain copies of 
the articles. 
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Facts about the project 
 
FACTS ABOUT THE ISISEMD-PROJECT 
 
The project is running from 1st of March 2009 to 30th of June 2011. The project is funded by 
the EU of € 2,750,000 (approximately £ XXXXXX) and an equal amount from all partners in 
the project (project budget totalling approximately £ XXXXXX).  
 
The parties involved in the project:  
Denmark: North Denmark EU-Office, University of Aalborg, Frederikshavn Municipality, 
Eltronic A / S  
United Kingdom: Belfast Social and health care  
Greece: Trikala Municipality, National Technical University of Athens, converge ICT 
Solutions & Services SA  
Finland: Lappeenranta Municipality  
Italy: Alcatel-Lucent Italia SpA, Hewlett Packard Italiana Spa, Socrates Medical Srl  
Read more at: www.eu-norddanmark.dk/dk/nyheder/isisemd.htm 
 
 
 
Appendix 
 
• ”Your rights as a trial subject” 
• Consent Statement 
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Appendix B1 - ISISEMD Informed Consent Statement – overall for the trial  
 
Informed consent statement for participation in research project 
 
Research project title: ISISEMD  
 
Declaration from the trial participant: 
 
I have read this consent form. I have had the opportunity to discuss this research study with name of 
Investigator and or his/her study staff. I have received written and oral information and I know enough 
for the objectives, the methods, the advantages and disadvantages. I have had my questions answered 
by them in language I understand. The risks and benefits have been explained to me. I believe that I 
have not been unduly influenced by any study team member to participate in the research study by any 
statement or implied statements. Any relationship (such as employee, student or family member) I 
may have with the study team has not affected my decision to participate.  
 
I understand that my participation in this Pilot is voluntary and that I may choose to withdraw at any 
time. I freely agree to participate in this research study. 
 
I understand that information regarding my personal identity will be kept confidential, but that 
confidentiality is not guaranteed. I authorize the inspection of my data by (list of entities with access to 
data).  
 
By signing this consent form, I have not waived any of the legal rights that I have as a participant in a 
trial study. 
 
I understand that, ISISEMD consortium intends to offer services to Elderly Persons (EP) and Informal 
Care Givers (ICG) in such a way that:  
EP and ICGs are aware that ISISEMD system intends to offer a set of pilot services, which should not 
be considered as life critical in any manner. ISISEMD pilot system and pilot services do not substitute 
the required supervision of the EP and no one should rely on the existence of ISISEMD pilot services 
for anything that might occur to the EP. 
EP and ICGs will hold ISISEMD harmless from and against any claims, costs, damage or injury or to 
third persons, or property arising directly or indirectly out of, or the use of ISISEMD pilot system and 
pilot services. 
 
I give my agreement to participate in the research project ISISEMD and have received a copy of the 
written information for the project for my personal use. I understand that I will be given a copy of this 
consent statement after signing it.  
 
Participant’s name:  …………………………………………….. 
 
 
Date:   ……………………  Signature: ………………………….. 
 
 
Do you with to be informed about the result of the research project, together with eventual 
consequences from them? 
 
Yes   ………….. (set X)   No   ……………. (set X) 
 
Declaration from the responsible person for the trail: 
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I declare that the trial participant has received written and oral information about the trial and has had 
possibility to ask questions to me. 
 
I am convinced that it is provided sufficient information in order decision to be taken for participation 
on the trail and the project. 
 
Name of the responsible person for the trail:  ……………………………………………………. 
 
 
Date:   ……………………  Signature: ………………………….. 
 
Project Identification:  
ISISEMD project is partially funded by the European Commission under the ICT PSP Programme.  
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Appendix B2 - ISISEMD Informed Consent Statement for the service “Outdoor guard” 
 
Informed consent statement for the service “Outdoor guard” from the project ISISEMD 
 
Research project title: ISISEMD – the service “Outdoor guard” 
 
Declaration from the trial participant for using the service “Outdoor guard”: 
 
I have read this consent form. I have had the opportunity to discuss this service “Outdoor guard” 
from ISISEMD trial with (name of Investigator) and or his/her study staff. I have received written and 
oral information and I know enough for the objectives, the methods, the advantages and disadvantages 
of the project and this specific service. I have had my questions answered by them in language I 
understand. The risks and benefits have been explained to me.  
 
I believe that I have not been unduly influenced by any study team member to participate in the 
research study by any statement or implied statements. Any relationship (such as employee, student or 
family member) I may have with the study team has not affected my decision to participate.  
 
I understand that my participation in the evaluation of the service “Outdoor guard” under the 
framework of ISISEMD trial is voluntary and that I may choose to withdraw at any time. I freely agree 
to participate in this research study. 
 
I understand that information regarding my personal identity and regarding my outdoor location will 
be kept confidential, but that confidentiality is not guaranteed. I authorise the inspection of my data by 
(list of entities with access to data).  
 
By signing this consent form, I have not waived any of the legal rights that I have as a participant in a 
trial study. 
 
I understand that, ISISEMD consortium intends to offer services to Elderly Persons (EP) and Informal 
Care Givers (ICG) in such a way that:  
EP and ICGs are aware that ISISEMD system intends to offer a set of pilot services, which should not 
be considered as life critical in any manner. ISISEMD pilot system and pilot services do not substitute 
the required supervision of the EP and no one should rely on the existence of ISISEMD pilot services 
for anything that might occur to the EP. 
EP and ICGs will hold ISISEMD harmless from and against any claims, costs, damage or injury or to 
third persons, or property arising directly or indirectly out of, or the use of ISISEMD pilot system and 
pilot services. 
 
I give my agreement to participate in the trial for the service “Outdoor guard” under the framework 
of ISISEMD trial and have received a copy of the written information for the project and this service 
for my personal use. I understand that I will be given a copy of this consent statement after signing it.  
 
Participant’s name:  …………………………………………….. 
 
 
Date:   ……………………  Signature: ………………………….. 
 
 
Do you wish to be informed about the result of the research project and the service “Outdoor guard”, 
together with eventual consequences from them? 
 
Yes   ………….. (set X)   No   ……………. (set X) 
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Declaration from the responsible person for the trail for using the service “Outdoor guard”: 
 
I declare that the trial participant has received written and oral information about the trial of the 
ISISEMD service “Outdoor guard” and has had possibility to ask questions to me. 
 
I am convinced that it is provided sufficient information in order decision to be taken for participation 
on the trail of this specific service and the project. 
 
Name of the responsible person for the trail:  ……………………………………………………. 
 
 
Date:   ……………………  Signature: ………………………….. 
 
Project Identification:  
ISISEMD project is partially funded by the European Commission under the ICT PSP Programme.  
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Appendix C1 – MoCA test – for primary end-user 
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Appendix C2 – MMSE test – for primary end-user 
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Appendix C3 – ADL/IADLs Questionnaire – for primary end-user  
 
This questionnaire is based on the  
KATZ BASIC ACTIVITIES OF DAILY LIVING (ADL) SCALE. 
 
 
Questions  Independent  
 YES NO 
1. Bathing (sponge bath, tub bath, or shower) 
Receives either no assistance or assistance in bathing only one 
part of body 
  
2. Dressing - Gets clothes and dresses without any assistance 
except for tying shoes. 
  
3. Toileting - Goes to toilet room, uses toilet, arranges clothes, 
and returns without any assistance (may use cane or walker for 
support and may use bedpan/urinal at night). 
  
4. Transferring - Moves in and out of bed and chair without 
assistance (may use can or walker).  
  
5. Continence – Controls bowel and bladder completely by self 
(without occasional "accidents").   
  
6. Feeding - Feeds self without assistance (except for help with 
cutting meat or buttering bread). 
  
 
This questionnaire is based on the  
LAWTON - BRODY 
INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE (I.A.D.L.) 
 
 
LAWTON - BRODY 
INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE (I.A.D.L.) 
 
A. Ability to Use Telephone  E. Laundry  
1. Operates telephone on own initiative-
looks 
up and dials numbers, etc. 
1 1. Does personal laundry completely 1 
2. Dials a few well-known numbers 1 2. Launders small items-rinses stockings, 
etc. 
1 
3. Answers telephone but does not dial 1 3. All laundry must be done by others 0 
4. Does not use telephone at all 0   
B. Shopping  F. Mode of Transportation  
1. Takes care of all shopping needs 
independently 
1 1. Travels independently on public 
transportation or drives own car 
1 
2. Shops independently for small purchases 0 2. Arranges own travel via taxi, but does not 
otherwise use public transportation 
1 
3. Needs to be accompanied on any 
shopping trip 
0 3. Travels on public transportation when 
accompanied by another 
1 
4. Completely unable to shop 0 4. Travel limited to taxi or automobile with 
assistance of another 
0 
  5. Does not travel at all 0 
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C. Food Preparation  G. Responsibility for Own 
Medications 
 
1. Plans, prepares and serves adequate 
meals independently 
1 1. Is responsible for taking medication in 
correct dosages at correct time 
1 
2. Prepares adequate meals if supplied with 
ingredients 
0 2. Takes responsibility if medication is 
prepared in advance in separate dosage 
0 
3. Heats, serves and prepares meals, or 
prepares meals, or prepares meals but does 
not maintain adequate diet 
0 3. Is not capable of dispensing own 
medication 
0 
4. Needs to have meals prepared and served 0   
D. Housekeeping  H. Ability to Handle Finances  
1. Maintains house alone or with occasional 
assistance (e.g. "heavy work domestic 
help") 
1 1. Manages financial matters independently 
(budgets, writes checks, pays rent, bills, goes 
to bank), collects and keeps track of income 
1 
2. Performs light daily tasks such as dish 
washing, bed making 
1 2. Manages day-to-day purchases, but needs 
help with banking, major purchases, etc. 
1 
3. Performs light daily tasks but cannot 
maintain acceptable level of cleanliness 
1 3. Incapable of handling money 0 
4. Needs help with all home maintenance 
tasks 
1   
5. Does not participate in any housekeeping 
tasks 
0   
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Appendix C4 – QOL-AD rating scale - for primary end-user  
 
 
The QOL-AD (Participant Version) 
 
Instructions: Interviewer administers according to standard instructions. Circle participant 
responses. 
 
1. Physical health   Poor Fair Good Excellent 
2. Energy     Poor Fair Good Excellent 
3. Mood Poor Fair Good Excellent 
4. Living situation Poor Fair Good Excellent 
5. Memory Poor Fair Good Excellent 
6. Family Poor Fair Good Excellent 
7. Marriage Poor Fair Good Excellent 
8. Friends Poor Fair Good Excellent 
9. Self as a whole Poor Fair Good Excellent 
10. Ability to do chores around 
the house 
Poor Fair Good Excellent 
11. Ability to do things for fun Poor Fair Good Excellent 
12. Money Poor Fair Good Excellent 
13. Life as a whole Poor Fair Good Excellent 
 
 
Comments: 
Permission to use the scale -  
© 1996 R. G. Logsdon, University of Washington, Seattle, WA. 
Administration instructions available on request. 
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Appendix C5 – Zarit Burden Interview (ZBI) – for informal caregivers 
 
This questionnaire is based on the ZARIT BURDEN INTERVIEW 
 
 
 
 
ISISEMD/WP 3/Del 3.3.2-update/Task 3.3                          CIP-ICT-PSP 238914 ISISEMD
 
 
ID: C:\Documents and 
Settings\kjeld\Dokumenter\ISISEMD\Deliverables\ISISEMD_D3.3.2_NDEU_v.2.doc 
Date:  Sunday, 31 January 2010  
Revision: v 1.3 Security: Confidential 
Last saved by AIM Page 93 of 119 
 
 
 
Appendix D - Interview Guidelines for User Satisfaction, Acceptance and QoL 
 
Appendix D1 - Interview Guide for Collection of User Satisfaction and Acceptance for 
Primary Users  
 
 
Interview guide for User satisfaction for ISISEMD system for EP 
 
Goals of the interview: 
• Measure to what extent the user is satisfied with the service and the importance to have it 
• Identify the source of satisfaction or dissatisfaction with the use of the service 
 
Scales: Based on 4-category scale; the higher the score, the more positive the rating of the system 
 
For ease of use:  
3 No difficulty 
2 Some difficulty 
1 Significant difficulty 
0 Too much difficulty to use 
 
Importance to have it  
3 Most important 
2 Quite important 
1 Somewhat important 
0 Not important for in this situation 
 
Overall satisfaction: 
3 – full satisfaction  
2- partial satisfaction 
1 – no opinion 
0 – not satisfied  
 
Services and Devices Easy / 
difficult to 
use 
Importance 
to have in 
home 
Overall 
Satisfaction 
Home safety  
Cooking monitor     
Smoke detector / fire alarm     
water reminder in kitchen    
water reminder in bathroom    
Key reminder when leaving home    
Front door alarm    
Refrigerator door alarm    
Reminders  
Reminder for daily events    
Reminder for date and time, day or 
night. 
   
Reminder for the season and type of 
weather 
   
Reminder for medicine    
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Locating personal belongings  
Can find items when looking for 
them 
   
Videophone   
Video call with relatives and/or 
caregivers  
   
Memory Lane   
Memory training with family photos     
Brain Games   
Use and strengthen mental ability 
and performance 
   
Portable outdoor guard   
Help to find way to home    
Panic button    
Fall alarm     
TOTAL:    
 
Comments and remarks from EP:  
 
 
 
 
 
 
 
Interview guide for User Acceptance and Independent Use for ISISEMD system for EP 
 
Goals of the interview: 
• Measure to what extent the user accepts ISISEMD system and the different technologies 
• Identify the source of acceptance or non- acceptance with the use of the system 
• Measure how difficult is for the elderly person to use the system independently  
 
Scale for independent use – Based on 4-category scale; the higher the score, the more positive the 
rating of the system  
3 - Use without difficulty;  
2- Use independently with difficulty;  
1- use with help from someone else;  
0 – Do not use  
 
Scale for acceptance - Based on 4-category scale; the higher the score, the more positive the rating of 
the system 
3 – Full acceptance 
2- Partial acceptance  
1 – without opinion 
0 – Do not accept  
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Services and Devices Independent 
use 
Acceptance 
Home safety 
Sensor for cooking monitor  N/A  
Smoke detector / fire alarm  N/A  
Sensor for water reminder in kitchen N/A  
Sensor for water reminder in bathroom N/A  
Key reminder when leaving home N/A  
Front door alarm N/A  
Refrigerator door alarm N/A  
Reminders 
Reminders on the touch screen for daily events   
Locating personal belongings 
Device to find personal items    
Videophone  
Video call on the touch screen    
Memory Lane  
Slide show for family photos on the touch 
screen 
  
Brain Games  
Brain games on the touch screen   
Portable outdoor guard  
Lommy device    
TOTAL:   
 
Comments and remarks from EP:  
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Appendix D2 – Questionnaires for user acceptance and satisfaction – for caregivers  
 
 
Informal Caregiver Satisfaction 
Based on 4-category scale; the higher the score, the more positive the rating of the system 
 
Activity Area Examples of 
Devices 
Easy to use Important for care 
(fulfils a need, 
increases quality of 
care) 
Flexibility (for 
making individual 
settings) 
Automatic 
functions (system 
functions in an 
intelligent way) 
Easy to integrate 
into care routine 
Important for care 
giving (fulfils a 
need, increases 
quality of care) 
Overall experience 
with the system 
(please share your 
thoughts) 
  3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
3 Very satisfied 
2 Somewhat 
satisfied 
1Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
 
Reminders Reminder for date, 
time, meals, 
medication, 
appointments, etc. 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Medication 
assistant 
Medicine reminders  3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Alert if medicine 
dose is skipped 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Lifestyle 
pattern 
report 
Detect changes in the 
normal patterns 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Bed detector Tells how long they 
have been in bed  
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Tells if they are 
leaving the bed at 
night frequently /  for 
long time 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Remote 
consultation 
Conference with 
nurses or doctors  
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Transfer of 
information through 
the Internet 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
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Videophone Videophone for 
communication with 
family and 
caregivers 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
PDA/wireless 
phone 
Phone to receive 
alerts, reminders, 
and messages 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Phone to contact 
loved one 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Multimedia Memory stimulation 
with digital photos 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Training for mental 
ability and 
performance 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Positioning Using the system to 
find belongings 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Intelligent 
front door 
Notification if person 
is leaving the home  
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Alarm if person has 
left home for long 
time  
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Home safety Stove/oven monitor  3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Smoke detector / fire 
alarm in emergency 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Automatic water stop 
if water is left 
running (kitchen) 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Automatic water stop 
if water is left 
running(bathroom) 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Key reminder when 
leaving home 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Front door and lock 
alarm 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Refrigerator door 
alarm 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Outdoor 
safety 
Can locate the 
person outdoors 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 Panic button with 
tracker if the person 
becomes lost 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
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 Fall alarm if the 
person should fall 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
Transfer of 
tasks 
Tasks are less 
demanding with 
support from the 
system 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 More tasks can be 
accomplished in the 
home with less 
intervention from the 
professional care 
team 
3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0 3    2    1    0  
 
 
Overall feeling of safety about the home environment 
3 I feel significantly safer  
2 I feel safer 
1 I do not feel safer  
0 I feel less safe 
 
 
 
Overall feeling of satisfaction about the system 
3 I am more satisfied than I thought I would be  
2 I am satisfied 
1 I am not satisfied  
0 I am disappointed 
 
 
Would you want to use a system like this one after this study? 
3 I definitely would use a system like this  
2 I would consider using a system like this 
1 I would not consider using a system like this  
0 I would not use a system like this 
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Formal Caregiver Satisfaction 
Based on 4-category scale; the higher the score, the more positive the rating of the system 
 
Activity 
Area 
Examples of 
Service 
Ease of use Important for 
care (fulfils a 
need, 
increases 
quality of 
care) 
Automatic 
functions 
(system 
functions in an 
intelligent 
way) 
Easy to 
integrate into 
care routine 
Important for 
care giving 
(fulfils a need, 
increases 
quality of 
care) 
Flexibility 
(for making 
individual 
settings) 
Overall 
experience 
with the 
system (please 
share your 
thoughts) 
Videophon
e 
Communication 
with family and 
caregivers 
3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very satisfied 
2 Somewhat 
satisfied 
1 Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
 
Remote 
consultatio
n 
Conferences 
with family, 
care personnel, 
or other 
medical 
professionals  
3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very satisfied 
2 Somewhat 
satisfied 
1 Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
 
 Transfer of 
patient 
information 
through Internet 
3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very satisfied 
2 Somewhat 
satisfied 
1 Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
 
Lifestyle 
pattern 
report 
Detect changes 
in the normal 
patterns for 
update of 
patient status 
3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very satisfied 
2 Somewhat 
satisfied 
1 Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
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Transfer 
of tasks 
Tasks are less 
demanding with 
support from 
the system 
3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very satisfied 
2 Somewhat 
satisfied 
1 Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
 
 More tasks can 
be 
accomplished in 
the home with 
less intervention 
from the 
professional 
care team 
3 No difficulty 
2 Some difficulty 
1 Significant 
difficulty 
0 Too much 
difficulty to use 
3 Most important 
2 Quite important 
1 Somewhat 
important 
0 Not important for 
in this situation 
3 Very satisfied 
2 Somewhat 
satisfied 
1 Dissatisfied 
0 Not satisfied at all 
3 Very easy to 
integrate 
2 Easy to integrate 
1 Difficult to 
integrate 
0 Did not integrate 
3 Makes significant 
difference 
2 Makes positive 
contribution 
1 Not important to 
regular routine 
0 Negatively affects 
regular routine 
3 Very flexible 
2 Quite flexible 
1 Inflexible 
0 Not flexible at all 
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Appendix E1 – Scale of Quality of Life of Informal Care-Givers - SQLC  
 
From article - J. M. Glozman, K. G. Bicheva, N. V. Fedorova, Scale of Quality of Life of Care-Givers (SQLC), J 
Neurol (1998) 245 [Suppl 1] :S39–S41, © Springer-Verlag 1998  
 
I. Professional activity  
 
1. Have you continued at your former place of work after your relative fell ill?  Yes (5)  No (0) 
 
Full-time, for full working day       5  0 
Part-time with incomplete working day       3  0 
Had to start working (if hadn’t worked before)      0  5 
Didn’t work before either        5  0 
 
2. Do you manage to perform your duties while now being occupied with the patient’s care?  Yes (5)  No (0) 
 
As well as previously         5  0 
With difficulty          3  0 
Partly manage          1  0 
Not at all           0  0 
 
3. Did you change your work because of your relative’s disease?    Yes (0)  No (4) 
 
If yes, your job is now: 
The same as previously        3  0 
Close to previous type        2  0 
In another branch         1  0 
Changed the job for other reasons not related to the relative’s disease    4  0 
 
4. Are you obliged to perform any complementary job for extra money?    Yes (0)   No (5) 
 
As frequently as before                            5 
Rarely                              4 
Somewhat less                              3 
Often                               2 
Very frequently                               1 
Never                               0 
Perform other job for reasons unconnected to the relative’s disease                          3 
 
II. Social and leisure activities 
 
5. Do you have time for different kinds of leisure activities in spite of your involvement into the patient’s care?  Yes (3)  No (0) 
 
As frequently as before                                    3 
Somewhat more than before                                   4 
Somewhat less than before                                    2 
Rarely                                      1 
Never                                          0 
Never did                                     3 
 
6. Does care of the patient allow you run the household?     Yes (3)  No (0) 
 
 
 
 
 
 
 
 
Buying food                      2            3                      2                    1                  0               3 
Making laundry              2             3                     2                    1                   0              3 
Cleaning house              2             3                   2                      1                   0              3 
Cooking               2             3                   2                      1                  0               3 
Other (indicate)              2             3                   2                      1                  0                3 
 
Now I 
have 
more 
to d 
As 
much, 
as 
previo
usly 
Somewhat 
less 
Very 
rarely 
Never Never 
did 
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7. Does care of patient allow you to give a hand to you parents and other relatives?  Yes (3)   No (0) 
 
More frequently than before as I have now stopped work                           4 
As frequently than before                             3 
Somewhat less frequently                              2 
Very rarely                              1 
Never                               0 
Never did                              3 
More frequently than before as now it is my responsibility                          2 
 
8. Do you continue to discuss family plans and problems with your ill relative?   Yes (3)   No (0) 
 
More often than before                            4 
As often as before                              3 
A little less often than before                            2 
Very rarely                            1 
Never                              0 
Never did before                               3 
 
9. Does the care of our relative let you to continue to attend to the needs of your children or the grandchildren as well as you did 
before? 
Yes (3)  No (0) 
 
 
 
 
 
 
 
 
 
To control and help children in scholarship            4         3            2                          1                 0                 3              2 
To take children to school,  
to sport activities or for a walk                   4        3            2                          1                 0                3               2 
To take children to theatres, museums, etc.                  4        3            2                          1                 0                3                2 
Other (indicate)              4       3            2                          1                 0               3                 2 
 
III. Responsibilities of the care-giver to help the patient in his everyday living 
 
10. Does the regular everyday care and attention to the chronically disabled person make you depressed?  Yes (0)  No (3) 
 
The mood is the same as before                          5 
Continuous depression (a week or more)                           3 
Stable depression with weight loss and insomnia                          0 
Depression for reasons unconnected with relative’s disease                         5 
 
11. Can the patient stay at home by himself while the family members are out or away?   Yes (3)  No (0) 
 
Without assistance he is able to:     Always  Sometimes  Never 
Dress       2  1   0 
Make the bed      2  1   0 
Warm up food      2 1   0 
Take food left for him     2  1   0 
(wrapped up or in container) 
 
12. Does your patient need assistance when using public transport or car-driving?   Yes (0)   No (3) 
 
Never needs assistance                               3 
Somewhat more often than before                              2 
Very often                               1 
Always needs assistance                              0 
Needed assistance before disease started                             3 
 
 
More 
freque
ntly 
than 
before 
as I 
have 
now 
stoppe
d work 
As 
frequen
tly than 
before 
 
Somewhat 
less 
frequently 
 
Very rarely 
 
Never 
 
Never 
did 
 
More 
frequentl
y than 
before as 
now it is 
my 
responsib
ility 
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13. Can your patient regularly take the prescribed medicine by himself?    Yes (3)   No (2) 
 
Always                                2 
Sometimes                                1 
Never                                 0 
 
14. Can your relative take a bath without assistance?     Yes (3)   No (0) 
 
Always                                 2 
Sometimes                                1 
Never                                 0 
 
 
15. Can your patient move around without assistance?     Yes (3)   No (0) 
 
Without assistance he is able to:    Always  Sometimes  Never 
Visit his therapist      2  1   0 
Go for a walk or shopping     2  1   0 
Move around inside the whole house   2  1   0 
Go to the lavatory      2  1   0 
Get seated on the bed     2  1   0 
 
16. Can your relative call for a physician by himself?     Yes (3)   No (0) 
 
Always                            2 
Sometimes                           1 
Never                             0 
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Appendix E2 – Questionnaire for CAREGIVER ACTIVITY SURVEY (CAS) - for 
informal caregivers 
 
Source: KENNETH L. DAVIS, DEBORAH B. MARIN, ROBERT KANE, DONALD PATRICK, 
ELAINE R. PESKIND, MURRAY A. RASKIND AND KATHERINE L. PUDER 
THE CAREGIVER ACTIVITY SURVEY (CAS): DEVELOPMENT AND VALIDATION OF A 
NEW MEASURE FOR CAREGIVERS OF PERSONS WITH ALZHEIMER'S DISEASE, 
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, VOL. 12: 978±988 (1997)  
 
1. Communicating with the person 
Please consider the following examples of activities: 
• . answering the same question again and again 
• . trying to make sense of what the person says 
• . leaving reminders for the person 
 
Thinking back over the past day, how much time did you and others spend in the last 24 hours (day 
and night) doing these types of activities? 
  __  hours              __   minutes 
 
2. Using transportation 
Please consider the following examples of activities: 
• . reminding the person about means of transportation 
• . taking the person to various places (other than shopping) by car or public transportation or 
taxi 
 
Thinking back over the past day, how much time did you and others spend in the last 24 hours (day 
and night) doing these types of activities? 
   __  hours           __ minutes 
3. Dressing 
Please consider the following examples of activities: 
• . reminding the person to dress 
• . choosing what to wear 
• . laying out clothes 
• . helping the person to dress or undress 
• . supervising the person dressing 
• . keeping the person from undressing at the wrong time 
 
Thinking back over the past day, how much time did you and others spend in the last 24 hours (day 
and night) doing these types of activities? 
  __ hours     __ minutes 
 
4. Eating 
Please consider the following examples of activities: 
• . reminding the person to eat 
• . setting up utensils and food 
• . cutting or arranging food on the plate 
• . supervising or encouraging the person to eat 
• . cleaning the person after eating 
 
Thinking back over the past day, how much time did you and others spend in the last 24 hours (day 
and night) doing these types of activities? 
   __ hours    __ minutes 
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5. Looking after one's appearance 
Please consider the following examples of activities: 
• . reminding the person to brush their teeth, brush their hair, apply cosmetics, shave or care for 
nails 
• . helping the person to groom 
• . setting out items for grooming activities 
• . supervising grooming activities 
• . maintaining the person's appearance over the course of the day 
 
Thinking back over the past day, how much time did you and others spend in the last 24 hours (day 
and night) doing these types of activities? 
  __ hours   __  minutes 
 
6. Supervising the person 
Please consider the following examples of activities: 
• . keeping an eye on the person to be sure that they do not wander or get into some kind of 
difficulty 
• . looking out for the person 
• . preventing the person from getting lost 
• . finding the person if they get lost 
 
Thinking back over the past day, how much time did you and others spend in the last 24 hours (day 
and night) doing these types of activities? 
  __  hours     __ minutes 
 
About you 
Please answer the following questions about yourself and your situation if you are filling out these 
forms for the first time. 
1. What is your relationship to the person you provided care for? 
(Please circle one number) 
 
1 Spouse 
2 Daughter, son, or other relative 
3 Friend or neighbour 
4 Other (please specify) 
 
2. Do you live in the same household as the person you provided care for? 
(Please circle one number) 
1 Yes 
2 No 
 
3. In what year were you born? 
 
4. What is your sex? 
(Please circle one number) 
1 Male 
2 Female 
 
Permission to use the test and correspondence to:  
Dr. K. L. Davis, Department of Psychiatry, Mount Sinai School of Medicine, New York, One Gustave 
Levy Place, New York, NY 100978.  
Email: kenneth.davis@mssm.edu    
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Appendix F– Examples for test tasks and test scenarios  
 
Below some step by step examples of tests tasks are shown. 
 
It is assumed that each region has created a new CG1 and EP1 and assigned client EP1 to CG1.  
 
Task A: (from the portal) - login as region, find EP1 and assign the service for daily reminders, brain 
games, memory lane for EP1; 
 
Nb. Test description Expected test result Observation 
Tester 
dd-mm-
yyyy/ 
Init 
1. Log-in as region 
See list with patients 
assigned to FCG1 
  
2. Find <id>_EP1 
Information for EP1 is 
found 
  
3. 
Assign <id>_EP1 to service for 
daily reminders, brain games, 
memory lane 
EP1 is successfully 
assigned to the A2 services, 
brain games, memory lane 
  
4. Logout region user from portal  
The user is successful 
logged out 
  
 
 
Task B: (As a care-giver) - login as CG1 and create different reminders for EP1 with the necessary 
settings  
Note – please allow around 30 min interval among different reminders to avoid overlapping.  
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Nb. Test description Expected test result Observation 
Tester 
dd-mm-
yyyy/ 
Init 
1. Log-in to the portal as <id>_CG 1  
The user is logged in with the 
right attributes  
  
2. 
Find reminder services for 
<id>_EP1  
The reminder services for EP1 
is successfully found  
There is no active reminders 
for EP1 
  
3. 
Create reminders for every day - 
breakfast, lunch, dinner, afternoon 
breakfast to <id>_EP1 as events for 
every day, with sounds and audio 
messages and with dismiss time 3 
min, interval of repetitions of 5min 
and two times to repeat. The 
speaker must be on. Pls select the 
time to be in the period of the 
following 2-3 hours so you can see 
the reminders.  
Three reminders are 
successfully created – you can 
see them in the list of active 
reminders  
  
4. 
Create reminders for one time - for 
guest at home and dress to go out as 
reminders for today (pls note you 
should mark for one day duration). 
Assign sound and audio, with 
dismiss time 3 min, interval of 
repetitions of 5min and two times to 
repeat.  The speaker must be on. Pls 
select the time to be in the period of 
the following 2-3 hours so you can 
see the reminders. 
   
5. 
Create reminders for one time with 
free text “Call friend”.  Assign 
sound and audio, with dismiss time 
3 min, interval of repetitions of 
5min and two times to repeat.  The 
speaker must be on. Pls select the 
time to be in the period of the 
following 2-3 hours so you can see 
the reminders. 
   
6. 
Press the link on the portal for 
returning from the selected service. 
The portal is directed to the 
expected url. Verify that it 
works as expected and looks 
like expected. 
  
7. 
Logout the <id>_CG1 User from 
the portal: 
 
The user is successful logged 
out 
  
 
 
ISISEMD/WP 3/Del 3.3.2-update/Task 3.3                          CIP-ICT-PSP 238914 ISISEMD
 
 
ID: C:\Documents and 
Settings\kjeld\Dokumenter\ISISEMD\Deliverables\ISISEMD_D3.3.2_NDEU_v.2.doc 
Date:  Sunday, 31 January 2010  
Revision: v 1.3 Security: Confidential 
Last saved by AIM Page 108 of 119 
 
Task C: (as a patient EP1 – from CareBox)  
 
Log-in as EP1 and see the information shown on the GUI and hear the upcoming reminders  
 
Nb. Test description Expected test result Observation 
1. On GUI EP – log-in as EP1 
You can see the reminders list 
with the next two reminders on 
the left and the picture slide 
show on the right.  
 
2. 
Observe and hear how the 
reminders appear on GUI EP    
3. Close CareBox   
 
 
Task D: (As a care-giver from the portal) - Log-in as CG1 and update/remove reminders for EP1    
 
Nb. Test description Expected test result Observation 
Tester 
dd-mm-
yyyy/ 
Init 
1. 
Find <id>_EP1 and the 
reminders services for EP1 
Information for EP1 and 
active reminders are found   
2. 
Update the reminder “guest at 
home” to be in the evening 
hours and save the changes  
 
 
  
3. 
Find reminder for afternoon 
breakfast and delete it  
The reminder afternoon 
breakfast should not appear 
on the list of active 
reminders  
  
4. 
Logout the <id>_CG1 User 
from the portal: 
 
The user is successful 
logged out 
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Repeat Task C: (as a patient EP1 – from GUI EP) – to see the changes of the settings in the reminders on 
the CareBox screen  
 
Task E: (As a care-giver from the portal) Log-in as CG1 and add/remove two more pictures for EP1 in 
the service “Memory Lane”   
 
Nb. Test description Expected test result Observation 
Tester 
dd-mm-
yyyy/ 
Init 
5. Find <id>_EP1 Information for EP1 is 
found 
  
6. 
Find the service for “Memory 
lane” and add two new pictures   
 
Two new pictures are added 
  
7. 
Find and delete one old picture 
from the list  
One picture is deleted from 
the folder with pictures  
  
8. 
Logout the <id>_CG1 User 
from the portal: 
 
The user is successful 
logged out 
  
 
 
Task F: (As a patient EP1) from CareBox – see the changes in the CareBox in the list of the pictures for 
“Memory Lane” 
 
Nb. Test description Expected test result Observation 
Tester 
dd-mm-
yyyy/ 
Init 
4. On GUI EP – log-in as EP1 
You can see the reminders 
list on the left and the 
picture slide show on the 
right  
  
5.  
See changes in the pictures 
from task E 
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Task G: (As a patient EP1) from CareBox – play Brain Game  
 
Nb. Test description Expected test result Observation 
Tester 
dd-mm-
yyyy/ 
Init 
1. On GUI EP – log-in as EP1 
You can see the reminders 
list on the left and the 
picture slide show on the 
right  
  
2. 
Find button Brain Game on the 
right side of GUI EP and start 
the game 
Game starts in the down 
right corner of GUI EP 
  
3. Play the brain game by clicking   
You can see a penguin  
  
  
4. Close/Finish the brain game  
The brain game is no longer 
shown on GUI EP   
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Appendix G– Screen shots from User Guides   
 
Service assignment for EP: 
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Setting for reminder service  
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CareBox GUI 
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Abbreviations 
 
 
GDS Global Deterioration Scale  
FAST Functional Assessment Staging Test 
MMSE Mini Mental State Exam 
EP Primary end-user group 
ICG Informal care giver  
FCG Formal care giver 
CG Care givers 
MoCA The Montreal Cognitive Assessment  
ADL Activities of Daily living  
IADL Instrumental Activities of Daily living 
QOL Quality of Life 
QOL-AD Quality of Life - Alzheimer Disease 
ZBI Zerit burden interview 
CAS Caregiver activity survey  
SQLC Scale of Quality of Life of Care-Givers 
ITIL IT Infrastructure Library paradigm 
SLA Service Level Agreement 
ATD Assistive Technological Device  
AD Alzheimer Disease 
AA Alzheimer Association  
MCI  Mild Cognitive impairment  
OT Occupational Therapist  
DoW Description of work 
HTA Health Technology Assessment 
CUA Cost-utility analysis 
QALYs Quality-adjusted life years 
HCI Human-computer interaction 
MMI Man-Machine-Interaction 
 
 
